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                         Abstract 
 
RASSF7 protein localises to the centrosome and plays a key role in mitosis. Its 
expression is also increased in a range of tumour types. How ever, little is 
know n about the molecular basis of RASSF7’s function and it is not clear if  it 
acts as an oncogene in the cancers w here its levels are elevated. This thesis 
carries out the f irst analysis of the domains of rassf7, focusing on w hich of them 
are responsible for its localisation.  
Constructs w ere generated to allow  the expression of a series of truncated 
versions of rassf7 and the localisation of these proteins w ere analysed. This 
w as carried out in Xenopus embryos and my data show s that the coiled-coil 
domain of rassf7 is required and suff icient to direct its centrosomal localisation. 
Surprisingly, removal of  the extreme C-terminus of the protein caused rassf7 to 
accumulate at the centrosome and drive centrosome and mitotic defects, and 
ultimately cell death. Interestingly, analysis of a database of tumour sequences 
identif ied a mutation in RASSF7, w hich w ould cause a similar C-terminal 
truncation of the protein. Based on my data, this truncated protein might drive 
centrosomal defects and w e propose the hypothesis that truncated RASSF7 
could act as an oncogene in a small subset of tumours w ith such mutations.  
Finally, studies in Xenopus show ed the f irst evidence that RASSF7 can localise 
at the tight junctions. The coiled-coil domain w as found to be required for 
driving the tight junctional localisation of rassf7. This data suggests a new  
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Mitosis is a spectacular part of  the cell cycle and it is over one hundred years 
since errors in this process w ere f irst linked to the origin of some cancers 
(Boveri, 1902). This thesis w ill test the hypothesis that the centrosomal protein 
RASSF7 is a new  mitotic regulator w ith a potential role in promoting cancer 
formation. Therefore, this introduction w ill focus on three areas: mitosis, the role 
and structure of the centrosome and the RASSF family of proteins. 
 
1.1 A general overview of the cell cycle and mitosis  
 
That ‘Cells originate from cells’ is a basic principle of cell biology, w hich w as 
coined by Rudolf  Virchow  in 1858 (Virchow  1858). He determined that all cells 
originate from pre-existing cells and that cell division is the w ay multicellular 
organisms increase in size and complexity. How ever, the mechanisms 
controlling normal cell division are still not completely understood and even less 
is know n about how  uncontrolled cell division can lead to cancer. The cell cycle 
is the process by which mother cells divide to give tw o daughter cells, it consists 
of a series of events that ensure correct transmission of the genetic material 
f rom one generation of cells to the next (Salaun et al., 2008). 
. 
In eukaryotes, the cell cycle consists of tw o separate phases: interphase and 
mitosis (Zucca and Nigg, 1995). Interphase is further divided into three phases: 
S-phase for DNA Synthesis during w hich centrosome duplication occurs is 
bracketed by tw o Gap-phases, G1 and G2 (Vermeulen et al., 2003) (Figure 
1.1). The cell cycle contains three cell cycle checkpoints: G1-S, G2-M and the 
 18 
spindle assembly (Lukas et al., 2004). These checkpoints consist of  regulatory 
pathw ays that control the order and timing of cell cycle transitions and regulate 
crucial events such as DNA replication and chromosome segregation  (Elledge, 
1996). Additionally, DNA damage causes checkpoints to arrest the cell cycle 
thereby providing time for repair including transcription of DNA repair (Kastan 
and Bartek, 2004). This section w ill focus on the mitosis phase of the cell cycle 














Figure 1.1: Schematic diagram of the mammalian cell cycle. During G1 (Gap phase 
1) metabolic changes prepare the cell for division; cellular contents, excluding the 
chromosomes are duplicated. During S phase (stands for DNA synthesis) genetic 
material is duplicated. At G2 (Gap Phase 2) the cell double checks the duplicated 
chromosomes for errors and makes any necessary repairs. During M phase (division 









Mitosis is the fundamental biological process that generates tw o genetically 
identical daughter cells from a single mother cell. More specif ically, it is the 
stage in the cell cycle w hereby duplicated copies of the chromosomal genetic 
material (condensed as sister chromatids) are equally segregated into tw o 
dividing cells. This phase comprises reorganization of cellular architecture, 
including the assembly of the mitotic spindle and the formation of an 
actomyosin-based contractile ring. The orchestration of events in M phase in 
time and space require accurate regulation since in mammals for example the 
failure of faithful chromosome segregation could cause severe defects such as 
spontaneous abortions, birth defects and cancer (Barr et al., 2004). Thus, 
mitosis is crucial for the proliferation, propagation and development of uni-
cellular and multi-cellular organisms. 
 
1.1.1 Mitotic stages 
 
Due to the fundamental requirement of mitosis, cells segregate their 
chromosomes w ith incredibly high f idelity (Kops, 2009). This segregation occurs 
in a specif ic order in stages classif ied as prophase, prometaphase, metaphase, 
anaphase, telophase and cytokinesis. These mitotic stages are show n 
schematically in Figure 1.2A and in confocal images in Figure 1.2B.  
During prophase, the chromatin starts to condense to form w ell-def ined-
chromosomes, in a process termed condensation, through the action of 
condensins (Strunnikov, 2003). Chromosomes, w hich consist of  a pair of  sister 
chromatids, are held together through the action of  cohesins in a structure 
know n as the centromere (Belmont, 2006; Michaelis et al., 1997). Cohesins are 
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added to chromosomes in S phase and resolved in tw o steps: f irst they are 
removed from chromosome arms during prophase, w hen the centrosomes are 
already duplicated, and subsequently removed from the centromere at the 
metaphase-to-anaphase transition (Waizenegger et al., 2000).  
Centrosome maturation occurs during prophase and duplicated centrosomes 
then separate and begin to migrate w ithin the nucleus to form tw o groups at 
opposite poles (Salaun et al., 2008). Another important event during prophase 
is the start of  the formation of the mitotic spindle. This event is concomitant w ith 
the movement of the centrosomes, also referred to as spindle poles, to opposite 
ends of the cell. During prophase the mitotic spindle forms and by its conclusion 


















































Figure 1.2. The different phases of mitosis. (A) An overview of the events that occur 
during mitosis. Following DNA and centrosome replication at interphase, the dividing 
cell progresses into prophase where the nuclear chromatin condenses to form 
chromosomes, each consisting of two sister chromatids bound at their centromeres. 
Simultaneously, centrosomes, duplicated during interphase, mature and migrate to 
opposite poles of the nucleus, producing a bipolar mitotic spindle. At prometaphase, 
the nuclear envelop breaks down, allowing sister chromatids to interact and attach to 
opposite spindle poles via centromeric structures called kinetochores. Subsequent re-
arrangement of the mitotic spindle allows chromosomes to align or congress in a linear 
fashion at metaphase. This is followed by the segregation of sister chromatids towards 
each centrosome during anaphase, resulting in two copies of the karyotype at opposite 
sides of the cell. Following contraction at the cell equator and subsequent cytokinesis, 
the result yields two genetically identical daughter cells, each with a centrosome. 
Illustration was adapted from (Salaun et al., 2008). (B) Immunoflouorescent images of 
mitosis in rat kangaroo epithelial kidney cells, representing five different mitotic stages 
as well as the interphase. The DNA is shown in blue, mitochondria is shown in red and 
microtubules are shown in green. Micrographs from micro.magnet.fsu.edu.  
 
 
In prometaphase, the nuclear membrane is broken dow n, the microtubules 
originating from centrosomes reach the chromosomes, the chromosomes, led 
by their centromeres become thicker and migrate to the equatorial plane that 
bisects the cell and lies perpendicular to the axis specif ied by the centrosomes 
(Sikirzhytski et al., 2014). This arrangement of the mitotic spindle forms w hat is 
called the ‘metaphase plate’. The kinetochore, a structure associated w ith the 
centromere of each chromosome, provides an anchor for the binding of spindle 
f ibres.  
Microtubules are highly dynamic polymers and they probe the cytoplasm w ith 
their plus-ends to capture chromosomes (Hayden et al., 1990; Holy and Leibler, 
1994; Jemseena and Gopalakrishnan, 2013). Centrosomes nucleate asters of 
microtubules that search for and attach to the chromosomes. Further 
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microtubules, similarly nucleated by the chromosomes, assist assembly of a 
bipolar spindle. The centromeres and their associated kinetochores are 
therefore important for microtubule nucleation, in a process regulated by the 
metaphase spindle assembly checkpoint. 
During metaphase, chromosomes reach their maximum condensation state to 
form the metaphase plate. Each chromosome consists of tw o sister chromatids 
held together by specialised proteins know n as cohesins. There are several 
necessary preconditions for the subsequent correct segregation of the 
duplicated DNA into each daughter cell. Firs t, each pair of  chromatid 
kinetochores must attach one kinetochore to a centrosomally nucleated 
microtubule array; the same process occurs at the other pole of the cell.   (Inoue 
and Salmon, 1995). Secondly, the dynamic instability of  the microtubules 
regulates the formation of a bipolar spindle such that at the completion of 
metaphase, the spindle is subject to tension and every chromosomes 
kinetochore is aligned on the metaphase plate and attached to both 
centrosomes. Metaphase continues until each of the conditions described 
above are fully complete resulting in exit f rom spindle assembly checkpoint 
(Salaun et al., 2008). 
Anaphase is initiated follow ing this check point exit  (de Gramont and Cohen-
Fix, 2005). Anaphase comprises an initial phase during w hich sister chromatids 
are pulled in opposite directions tow ards their respective mitotic poles 
(Anaphase A), and a subsequent stage (Anaphase B) w hen further separation 
of the sister chromatids occurs. To allow  this to occur, the cohesins that 
remained associated w ith the sister chromatids are degraded, enabling the 
tension w ithin the spindle to pull each sister chromatid tow ard the poles, 
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resulting in the division of the genetic information betw een tw o identical sets of 
chromosomes.  
While the chromosomes are undergoing their spindle-mediated movement to 
the poles, numerous kinetochore associated proteins detach, remain at the 
centre of cell, and participate in the assembly of the central spindle. 
Subsequently, a structure know n as a ‘contractile actin ring’ forms below  the 
plasma membrane in close proximity to the central spindle. These produce tw o 
cells attached at the midbody by contraction of the plasma membrane tow ard 
the equator of the cell (Barr and Gruneberg, 2007). This stage is know n as 
telophase, and is follow ed by cytokinesis, w hich completes cell division. 
Cytokinesis (division of cytoplasm) the f inal cellular division to form tw o new  
cells is arguably the least w ell understood event of mitosis . To separate the tw o 
daughter cells, the midbody breaks and the cleavage furrow  appears at the cell 
surface, and completely divides the cell in tw o by progressively becoming 
deeper and spreading around the circumference of the cell. To avoid the cell 
leaking its contents, the plasma membrane is rapidly repaired by recruiting 
Golgi-derived membrane vesicles that also contain proteins essential for 
cytokinesis (Salaun et al., 2008). 
 
1.1.2 Mitotic proteins 
 
One remaining and key question is w hat regulates the cell cycle? The transition 
betw een dif ferent phases of the cell cycle depends on various regulatory 
proteins including ubiquitins, kinases, phosphatases and scaffolding proteins.  
Dynamic control of  protein phosphorylation plays a crucial role for the regulation 
of multiple cellular processes including mitosis and cytokinesis. Recent studies 
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have also emphasised the importance of protein phosphatases in spatial and 
temporal control of  protein activity (Barr et al., 2011; Chen et al., 2007; Gharbi-
Ayachi et al., 2010; Kitajima et al., 2006; Mochida et al., 2009; Mochida et al., 
2010; Riedel et al., 2006; Zeng et al., 2010). It is this balance of kinase and 
phosphatase activity that orchestrates the changes seen during cell division 
(Figure 1.3) Interference w ith either type of activity w ill alter the amount and 
half -life of substrate phosphorylation (Heinrich et al., 2002), and thus disturb 
orderly mitotic progression (Figure 1.4). 
 
 
Figure 1.3: Localisation and activation of mitotic kinases and phosphatases 
during the cell cycle. The green bar indicates high activity of kinases or 
phosphatases during specific phases of the cell cycle and where applicable, subcellular 
localisation of kinase/phosphatase is shown. The yellow bars indicate inactive forms of 
the kinase/phosphatases during cell cycle stages. The white bar indicates unknown 








Figure 1.4: Kinase-phosphatase cycle. Simultaneous activity of a kinase and a 
phosphatase. A protein kinase adds a phosphate group (P) to the protein, known as 
phosphorylation. Adding the P (phosphorylation) alters the biological properties of the 
protein. A protein phosphatase removes P from the protein. The relative balance of 
kinase/phosphatase activity determines the amount of phosphorylated protein, which is 
present. Figure adapted from (Fisher et al., 2012). 
 
This section w ill focus on kinases, as they are w ell studied and linked to 
subsequent experiments. The protein kinases described below  are all involved 
in the regulation of multiple events during mitotic progression and cytokinesis. 
Protein phosphorylation is carried out by a series of conserved serine/threonine 
protein kinases of the Cdk, Polo, Aurora and Nek families. These protein 
kinases have w ell-established roles in phosphorylating key mitotic substrates 
(Barr et al., 2004; Lindqvist et al., 2009; Nigg, 2001; O'Farrell, 2001; Ruchaud et 
al., 2007; Salaun et al., 2008). Therefore, w ithout the dynamic control of  protein 







1.1.2.1 The cyclin-dependent kinases 
 
In mammalian cells, protein kinases such as Cdk, Plk, Aurora and Nek play a 
key role in driving cell division.  
Cyclin-dependent kinases (Cdks) w ere f irst discovered by combining the results 
of genetic and biochemical studies. For example, a seminal study of the yeast 
cell cycle by Nurse (1975)  identif ied genes responsible of the regulation of cell 
size during nuclear division (Nurse, 1975). Similarly, biochemical experiments 
conducted on amphibian oocytes (Masui and Markert, 1971; Smith and Ecker, 
1971) led to the identif ication of maturating-promoting factor (MPF), a factor 
facilitating entry into mitosis. Lohka and co-w orkers used Xenopus oocytes to 
purify MPF from a structure know n as the centromere (Lohka et al., 1988), 
w hich w as subsequently found to be composed of Cdk1 (Arion et al., 1988; 
Dunphy et al., 1988; Gautier et al., 1988; Labbe et al., 1988). 
Cdks regulate key events including commitment to the cell cycle, DNA synthesis 
and the triggering of mitosis (Malumbres, 2011). Cdks are a family of 
serine/threonine kinases that promote progression through the cell cycle by 
phosphorylating many target proteins (Chee and Haase, 2010). Cdk activity is 
controlled by protein-protein interactions and reversible phosphorylation 
(Morgan, 1995). Cdks need to bind cyclins to become active (Nigg, 1995). 
Approximately tw elve human Cdks have been described; the f irst, Cdk1 (or 
cdc2), w as considered responsible for all cell cycle transitions and w as 
therefore termed the ‘cell cycle master kinase’ (Fisher and Nurse, 1996). 
How ever, this w as only true for yeast w here Cdk1 kinase activity w as 
demonstrated essential for transition betw een G1/S and G2/M (Durkacz et al., 
1986). In contrast, in mammalian cells Cdk1 activity is only required for G2/M 
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transition (Draetta and Beach, 1988). Cdk1 activation is dependent of binding 
both cyclin A and cyclin B (Draetta et al., 1989; Karaiskou et al., 2001). Cdk1 is 
the only CDK essential for cell cycle in mammals (Santamaria et al., 2007), 
w hereas both Cdk2 and Cdk3 are dispensable (Malumbres and Barbacid, 2005; 
Ortega et al., 2003). Cdk7, Cdk8, Cdk9, Cdk11 and Cdc20 are know n as a 
transcriptional subfamily and are not associated w ith the cell cycle in mammals 
(Malumbres, 2014).  
Signif icantly, misregulation of Cdks is one of the most common changes 
associated w ith human cancer (Malumbres and Barbacid, 2007). Furthermore, 
the Cdks do not function alone; a number of additional kinases are required to 
regulate mitotic events. These are kinases of the Polo, Aurora and Nek families 
that are involved in the centrosome cycle and the regulation of spindle function 
(w hich will be discussed in the next section w hich focuses on centrosomes); the 
spindle assembly checkpoint is regulated by Bub1, BubR1 and Mps1 










Figure 1.5: An overview of mammalian cell cycle kinases during mitosis. 
Drawings represent a normal cell entering mitosis and growing in size. The genome is 
represented in red, the microtubules are in black and centrosomes as purple small 
cylinders. As the cell receives the mitotic signal, Cdk3, 4 and 6 start cell cycle specific 
transcription Cdk2 and Cdk1 controls DNA replication and repair, respectively. Cdk1, 
Cdk11, Nek2, Aurora A, Plk1 and Plk4 are involved in centrosome duplication and 
separation. Nuclear membrane and cytoplasmic changes including microtubule 
nucleation and spindle formation require Cdk1, Cdk11 Aurora B and Plk1 activity 
whereas chromosomal changes (condensation and segregation) are controlled by 
Cdk1, Aurora B, Bub1, BubR1 and Mps1. Aurora A, Aurora B and Plk1 are involved in 
cytokinesis. Image adapted from (Malumbres, 2011). 
 
1.1.2.2 The Polo-like kinases 
 
The Polo-like Kinases (Plks) w ere f irst identif ied in a Drosophila-based screen 
to isolate mutants affecting spindle pole behaviour (Sunkel and Glover, 1988).  
Mammalian Plks are a family of four dif ferent proteins that regulate dif ferent 
aspects of the cell cycle and have dif ferent subcellular localization (Nigg, 1998), 
Xenopus expresses three Plks (Plx1-3) w hereas in other species, such as 
Drosophila and yeast, have only one member (Takai et al., 2005; Takaki et al., 
2008; van de Weerdt and Medema, 2006).  
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Plk1 is the most extensively studied mitotic kinase, w hereas Plk2, Plk3 and Plk4 
are more likely involved only in interphase (Nigg, 1998; van de Weerdt and 
Medema, 2006) although Plk4 activity is required for both centriole duplication 
and assembly of the mitotic spindle (Habedanck et al., 2005).  
The activity and localisation of Plk1 are subject to dynamic regulation during the 
cell cycle, w ith high expression from late S-phase to G2 (Golsteyn et al., 1995; 
Hamanaka et al., 1995; Lee et al., 1995). Plk1 localises to both the cytoplasm 
and nucleus during G2 and is subject to centrosome specif ic targeting (Golsteyn 
et al., 1995; Taniguchi et al., 2002). Plk1 is found at the centrosomes and 
kinetochores during early mitosis (Golsteyn et al., 1995); how ever at the onset 
of anaphase Plk1 also accumulates at the spindle midzone and midbody via a 
carboxly-terminal domain (Polo-box domain PBD) (Takaki et al., 2008). The 
regulation of Plk1 kinase activity is achieved by binding of the kinase domain to 
the PBD domain (Archambault and Carmena, 2012; Bruinsma et al., 2012; Park 
et al., 2010b). New  insights into this mechanism w ere provided by the crystal 
structure of the zebraf ish kinase domain–PBD complex w hen this w as bound to 
a PB-binding motif  of  Drosophila microtubule-associated protein 205 
(Archambault et al., 2008; Xu et al., 2013). Inhibition of the kinase domain is 
achieved in three w ays. First by reduced f lexibility of  the kinase domain hinge 
region mediated by the PBD (the site of Ser137 localisation). Second, by an 
interdomain linker that connects the kinase domain w ith the PBD and captures 
the T-loop (the site of Thr210 localisation). Third, autoinhibition is stabilised by 
binding of the PBD to Map205 w hich also separates the kinase from its 
substrates (Zitouni et al., 2014). 
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In vertebrate cells, various cellular processes are controlled by Plk1 and are 
summarised in Figure 1.6 (Petronczki et al., 2008; van de Weerdt and Medema, 
2006). When Plk1 is absent, animal cells are not able to form a bipolar spindle 
or attach kinetochores to microtubules (van de Weerdt and Medema, 2006). 
Instead, cells form a monopolar spindle that is surrounded by radially arranged 
chromosomes (Kumagai and Dunphy, 1996; Toyoshima-Morimoto et al., 2001) 
causing the trapping of cells in mitosis due to activation of the spindle assembly 
checkpoint (Takaki et al., 2008).  
 
 
Figure 1.6: Localisation and roles of Polo-like kinase 1 during the cell cycle. 
Roles of Plk1 are represented in pink boxes and localisation is shown by dotted lines. 
Cell cycle stages are represented by immunofluorescence of cultured human cells.  
Microtubules are shown in red and genetic material in blue. Figure adapted and 
micrographs are taken from (Takaki et al., 2008). 
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Related to its role in cell division regulation, Plk1 also contributes to the 
formation and proliferation of human cancers. Overexpression Plk1 is observed 
in many human tumours including lymphomas, melanomas and carcinomas 
(Eckerdt et al., 2005; Strebhardt and Ullrich, 2006; Winkles and Alberts, 2005) . 
Overexpression of Plk in mouse f ibroblasts resulted in a block in contact 
inhibition enabling the formation of tumours in nude mice (Smith et al., 1997). 
These data suggest that Plk1 contributes to tumorigenesis. This also leads to 
the argument that if  Plk1 enhances tumour formation, then selective inhibition of 
Plk1 may promote tumour regression (Archambault et al., 2015). One specif ic 
Plk1 inhibitor called BI2536 show s promise as a cytotoxic drug for the treatment 
of several cancers; in non-small cell lung cancer (NSCLC) this causes mitotic 
catastrophe due to  activation of spindle assembly checkpoint (Choi et al., 
2015). Therefore, Plk1 has attracted the attention as a potential target for anti-
cancer therapy. 
  
1.1.2.3 Aurora kinases 
 
Aurora kinases are a family of serine/threonine protein kinases that regulate 
various cell division processes (Carmena and Earnshaw , 2003). Aurora kinase 
hasbeen studied in S. cerevisae (Chan and Botstein, 1993); how ever,  the f irst 
aurora allele w as identif ied among Drosophila mutants displaying defects in 
spindle-pole behaviour (Glover et al., 1995). Yeast possesses only one Aurora 
kinase, w hilst tw o (A and B) are found in invertebrates such as Drosophila and 
C. elegans, and vertebrates, including mammals have three Aurora isoforms  
(A, B and C) (Adams et al., 2001a; Adams et al., 2001b; Nigg, 2001) that are 
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very similar in sequence (Giet and Prigent, 1999) but have district localisations 
and functions. Aurora A, B and C w ill be discussed individually below . 
 
1.1.2.3.1 Aurora A 
 
The def ining feature of the Aurora-A subfamily is its association w ith both 
centrosomes and regions of microtubules located adjacent to the centrosome 
(Bettencourt-Dias et al., 2004; Glover et al., 1995; Schumacher et al., 1998).  
Aurora A localises to the centrosomes. The centrosomal localisation of Aurora A 
is dynamic and is subject to continuous exchange w ith a cytoplasmic pool 
(Berdnik and Knoblich, 2002). This w as show n by photobleaching (FRAP) 
studies in mitotic HeLa cells w hich revealed that the level of  Aurora A w as 
reduced in G1 cells, by prophase it w as concentrated around the centrosomes, 
w hilst in metaphase it became associated w ith the microtubules near the 
spindle poles, had a similar distribution in anaphase before f inally becoming 
concentrated at the midbody in cytokinesis (Carmena and Earnshaw , 2003). 
Activation of Aurora A is mediated by binding to its substrates such as the 
microtubule-associated protein TPX2 (Tsai et al., 2003). Both 
phosphorylation/dephosphorylation and degradation is required for the 
regulation of Aurora A (Carmena and Earnshaw , 2003). Phosphorylation 
stimulates kinase activity and Xenopus Aurora A contains three important 
phosphorylation sites for the kinase activity (Littlepage and Ruderman, 2002; 
Littlepage et al., 2002). Phosphorylation of Thr295 (Thr288 in human Aurora A), 
w hich resides in the activation loop and is required for kinase activity (Walter et 
al., 2000). The target residue is located in a protein kinase A (PKA) consensus 
motif  ((R/K)X(T/S)(I/L/V)) (Cheeseman et al., 2002) and PKA can both 
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phosphorylate and activate Aurora A in vitro (Walter et al., 2000). 
Phosphorylation of Ser53 occurs during M phase and has a putative role in the 
regulation of Aurora A degradation (Castro et al., 2002a; Castro et al., 2002b; 
Honda et al., 2000). The third phosphorylation site, Ser349 is not essential for 
catalytic activity (Littlepage and Ruderman, 2002; Littlepage et al., 2002). In 
addition, the phosphatase PP1 negatively regulates the Aurora A kinase activity 
by regulating TPX2 activity (Eyers et al., 2003; Eyers and Maller, 2003; Tsai et 
al., 2003).  
Aurora A phosphorylates CDC25B (cell division cycle protein 25B) and this 
phosphorylation contributes to G2/M transition (Dutertre et al., 2004). Aurora A 
activity is required for centrosome separation and maturation and requires 
recruitment of proteins associated w ith microtubule nucleation (this w ill be 
discussed in more detail in the centrosome section) (Berdnik and Knoblich, 
2002; Salaun et al., 2008). The Aurora A kinase phosphorylates both motor 
proteins (Giet and Prigent, 1999; Giet et al., 1999) and proteins required for 
astral microtubule nucleation (Giet et al., 2002)(Giet et al., 2002). Aurora A 
plays an important role in spindle assembly in association w ith Ran-GTP that 
regulates TPX2 activity (and other centrosome associated proteins such as 
Numa) (Carmena and Earnshaw , 2003; Salaun et al., 2008; Tsai et al., 2003). 
The Aurora A gene is located on chromosome 20q13 in a region frequently 
amplif ied in human cancers and associated w ith over-expression of Aurora A 
(Sen et al., 2002). This Aurora A over-expression/amplif ication is present in 
many cancers including breast, pancreatic, colon, ovarian, prostate, bladder 
and neurablastomas (Bischoff  et al., 1998; Fry et al., 1998a; Tanaka et al., 
1999; Zhou et al., 1998).  
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In vitro (in primary colorectal cancer cells and mouse NIH 3T3 cells) over -
expression of Aurora A kinase causes aneuploidy and centrosome amplif ication 
that can lead to transformation of cells (Bischoff  et al., 1998; Zhou et al., 1998). 
In summary, Aurora A is a centrosome protein w hose activation is mainly 
regulated by phosphorylation and has a potential oncogenic role in tumours .  
 
 
1.1.2.3.2 Aurora B 
 
Human Aurora B kinase w as f irst identif ied in a screen designed to detect  
kinases displaying over-expression in cancers (Bischoff  et al., 1998). Aurora B 
kinases are one of the chromosomal passenger proteins required for various 
process during mitosis (Carmena and Earnshaw , 2003). Aurora B associates 
w ith INCENP (inner centromere protein) and INCENP/survivin/Borealin (Giet et 
al., 2005) w hich form the chromosome passenger family complex (CPC). The 
localisation of CPC changes during dif ferent phases of the cell cyle. In early 
mitosis it localises to chromosome arms, then it is detected at the inner 
centromeres until metaphase-anaphase transition occurs. (Adams et al., 2000). 
CPC proteins then relocate to the spindle midzone and to the cell cortex (Cooke 
et al., 1987). Aurora B and INCENP w ere f irst know n to be part of  the CPC 
complex w hen co-immunoprecipitated from dif ferent model systems and the 
study of the phenotypes derived from their knockdow n show ed similar defects, 
such as failure of chromosome segregation (Adams et al., 2000).  
Activation/regulation of Aurora B is similar to Aurora A; w hich requires binding 
to some of its substrates and also phosphorylation plays an essential role for 
kinase activity.  
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Aurora B has three clear functions during mitosis. Firstly, Aurora B 
phosphorylates serines 10 and 28 on histone H3 and serine 7 in the centromere 
via histone variant CENP-A (Giet and Glover, 2001; Hsu et al., 2000; Zeitlin et 
al., 2001). There have been various debates about the function of these 
phosphorylations.  One possible function for Aurora B phosphorylation is to 
promote chromosome condensation and cohesion (Adams et al., 2000; Goto et 
al., 1999; Goto et al., 2002). Another possibility is to load proteins onto the 
chromosomes and/or signalling in mitosis (Prigent and Dimitrov, 2003). 
The second know n function in mitosis for Aurora B is re-organisation of 
incorrect microtubule-kinetochore attachments via the spindle assembly 
checkpoint (SAC)(Honda et al., 2000). This is achieved via phosphorylation of 
mitotic centromere-associated kinesin (MCAK) by Aurora B, w hich then 
inactivates its microtubule depolymerase catalytic activity and its targeting to the 
kinetochores (Ohi et al., 2004). MACK also corrects the mis-attachment of the 
microtubules to kinetochores (Ohi et al., 2004). Aurora B has been also involved 
in the regulation of Ndc80/Hec1, w hich contributes the formation of stable 
kinetochore-microtubule attachments at the outer kinetochore (Nezi and 
Musacchio, 2009), In fact, the interaction of Ndc/Hec1 w ith microtubules may be 
affected by the phosphorylation of NDC/HEc1 by Aurora B, therefore leading to 
microtubule release (Cheeseman et al., 2002) Aurora B role has also been 
linked to the recruitment of checkpoint proteins such as Mad2 and BubR1 to 
kinetochores (Ditchf ield et al., 2003). Besides, Aurora B can modulate BubR1 
activity via phosphorylation upon entry mitosis (Ditchf ield et al., 2003), therefore 
regulating the activity of the spindle checkpoint.  
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Aurora B is essential for cytokinesis, w hich is the third know n function for the 
kinase. Over-expression of a catalytically inactive form of rat Aurora B leads to 
cytokinesis  failure in a number of cell lines (Terada et al., 1998). Aurora B 
phosphorylates vimentin, a kinesin (ZEN-4/MKLP1) and MgcRacGAP, w hich 
are components of the cleavage furrow that are required for cytokinesis (Goto et 
al., 2003; Guse et al., 2005; Minoshima et al., 2003). Inactivation of Aurora B is 
associated w ith delocalization of the kinesin-like protein 
Pavarotti/CHO1/MKLP1/ZEN4, that is part of  central spindle complex, w hich 
contributes to  formation of the central spindle (Giet and Glover, 2001; Kaitna et 
al., 2000; Severson et al., 2000).  
Aurora B has been found overexpressed in many cancers including colorectal 
(Katayama et al., 1999; Takahashi et al., 2000), thyroid carcinoma (Adams et 
al., 2000) and prostate cancer (Chieff i et al., 2006). How ever, amplif ication of 
the Aurora B gene has not been found in cancer and is therefore not considered 
an oncogene. How ever its over-expression does induce metastasis (Salaun et 








Figure 1.7: Localisation and functions of Aurora kinases. (A) Functions of Aurora 
kinases during mitosis are shown in the pink boxes below the illustration of the mitotic 
cell. Centrosomes are shown as purple circles, MTs in black and chromatids in yellow. 
(B) Localisation of Aurora kinases are shown in HeLa cells; Aurora A localises to the 
centrosomes whereas Aurora B localisation is centromeric. Figure adapted and 
micrographs are taken from (Hochegger et al., 2013). 
 
 
1.1.2.3.3 Aurora C 
 
There is little know n about Aurora C Expression of Aurora C w as reported in 
testis (Hu et al., 2000) and some human cancer cell lines (Kimura et al., 1999; 
Ulisse et al., 2006) w ith the highest level detected in the G2/M phase. 
Endogenous Aurora C in meiotic mouse oocytes w as observed at the 
centromeres and the chromosome arms during prometaphase I and metaphase 
I; it relocalized to the midbody at telophase I and then migrated to the 
centromeres again in metaphase II.  
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As little is know n about the kinase, the function and regulation of Aurora C 
remains unclear. It w as first show n as an anaphase centrosome protein (Kimura 
et al., 1999), but w hen over-expressed, Aurora C acted like Aurora A in 
interphase and like Aurora B in mitosis (Dutertre et al., 2005; Sasai et al., 2004). 
Activation of Aurora C appears similar to other family members - it is activated 
by binding its substrates, especially an Aurora B substrate, INCENP (Sasai et 
al., 2004) suggesting that Aurora C could substitute for Aurora B. The same 
study also show ed that in mitosis, Aurora C mimics Aurora B and rescues 




NIMA (Never in mitosis A) is a serine/threonine-specif ic protein kinase that has 
been implicated in controlling entry into mitosis (Doonan, 1992; Morris et al., 
1988; Osmani et al., 1991). Mutations in Aspergillus nidulans that inactivate 
NIMA caused a late G2 arrest w ith cells containing duplicated but unseparated 
centrosomes (Morris et al., 1988; Osmani et al., 1991). Nek2 (NIMA related 
kinase-2) is the closest NIMA relative among the thirteen mammalian Nek 
kinases and Nek2 activity is required for mitosis (Schultz et al., 1994). Nek2 
phosphorylates C-Nap1 (centrosomal Nek2-associated protein 1) and C-Nap1 
phosphorylation by Nek2 is essential for centrosome separation/bipolar spindle 
formation (Fry, 2002; Fry et al., 1998a; Fry et al., 1998b). In Drosophila, Nek2 
over-expression led to cytokinesis defects (Prigent et al., 2005). Related to its 
functions, Nek2 localises to the centrosome throughout the cell cycle as show n 
in HeLA cells (Andersen et al., 2003; Fry et al., 1998b; Hames and Fry, 2002). 
Centrosomal localisations of Nek2 homologues have been described in mouse, 
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Xenopus and Drosophila (Fry et al., 2000; Graf, 2002; Ha Kim et al., 2002; 
Prigent et al., 2005). Centrosomal localisation of Nek2 is associated w ith a motif  
in its C-terminal domain. This motif  is also required for microtubule binding 
(Hames et al., 2005). In addition to centrosomal localisation, Nek2 has seen at 
nucleoli during interphase (Noguchi et al., 2004), on condensed chromatin in 
meiotic and mitoticcells  (Fujioka et al., 2000; Rhee and Wolgemuth, 1997) (Ha 
Kim et al., 2002), and at the kinetochores (Lou et al., 2004a; Lou et al., 2004b) 
and midbodies (Ha Kim et al., 2002; Prigent et al., 2005) of dividing cells. Nek2 
activation is promoted by trans-autophosphorylation and Nek2 inhibition is 
mediated by dephosphorylation by the phosphatase PP1 (Helps et al., 2000). 
There is no clear evidence for Nek2 acting as an oncogene although its over-
expression induces errors in centrosome organization and function (Hayw ard 
and Fry, 2006; Lingle et al., 2002).  
Other members of Nek family also play roles during mitosis including Nek6, 
w hich is required for mitosis progression (show n in HeLa cells) (Belham et al., 
2003; Yin et al., 2003), and Nek9 that phosphorylates and activates Nek6 and is 
required for spindle assembly (Roig et al., 2005). 
The best-studied mitotic protein kinases have been described above; how ever, 
as demonstrated by various screens many more kinases w ith potential roles 
mitosis remain to be identif ied and/or characterised (Bettencourt-Dias et al., 






1.2 The centrosome 
 
Centrosomes play a key role in regulating mitosis and are central to the w ork 
reported in this thesis so w ill be considered in detail in this section. 
Centrosomes w ere f irst discovered in 1887 by Theodor Boveri and Édouard 
Joseph Louis Marie Van Beneden w hile w orking on cell division in the egg of 
the roundw orm Ascaris, w hich they called 'polar corpuscles' or centrosomes. 
Centrosomes w ere suspected to have a role in cell symmetry, breaking the 
maintenance of cell polarity as the mitotic spindle appeared to raise from tw o 
dot-like objects one at each pole of the spindle (Glover et al., 1993). How ever, 
in non-dividing cells, one single centrosome w as observed next to the nucleus; 
as the cell started to divide, the centrosome appeared to divide and started to 
move apart. The identical centrosomes became the centres that organized 
microtubules. This separation of centrosomes occurs only once during mitosis 
and ensures the equal distribution of genetic material to the tw o daughter cells.  
More than a century later af ter its discovery w e now  know  that the centrosome 
serves as a microtubule organising centre, regulating microtubule dynamics 
(assembly and stability) to facilitate several microtubule-dependent processes 
including cell motility, cell shape and integrity, cell polarity, vesicular and 
molecular transport (Bornens, 2012; Kramer et al., 2004; Lukasiew icz and 
Lingle, 2009; Schatten, 2008). This thesis focuses on the role of the 
centrosomes in mitosis. 
During mitosis, microtubule-organizing function of the centrosome is employed 
in the nucleation of a bipolar mitotic spindle, a critical requirement for 
chromosome biorientation and subsequent segregation (Kops, 2009). Given its 
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Figure 1.8: Structure of the centrosome. (A) Schematic diagram of a mammalian 
centrosome, containing two centrioles (blue cylinders) surrounded by a network of 
proteins embedded in the pericentriolar material (PCM, shown in grey). The nucleating 
(purple circles) and anchoring complexes (pink disks) contain proteins such as gamma 
tubulin and the others required to form the gamma tubulin ring complex that are 
responsible for nucleating and anchoring microtubules. Figure adapted from (Schatten, 
2008). (B) Electron microscopy image of a centriole in an animal cell. The centriole is 
at the centre of the centrosome, shown as two geometric arrangements of 
microtubules. Each centriole has a cylindrical bundle of nine rods, each rod consists of 
three microtubules. Electron microscopy image is taken from (Glover et al., 1993).  
 
Structurally, the centrosome is small, non-membranous organelle, composed of 
barrel-shaped microtubule macrostructures called centrioles, surrounded by a 
protein complex called the pericentriolar matrix (PCM) (Lukasiew icz and Lingle, 
2009). An electron microscopy image show ing a schematic diagram of a 
centrosome and the structure of a centriole are show n in Figure 1.8.  
The centriole is an evolutionarily conserved macromolecular structure that is 
essential for the  establishment of f lagella, cilia and centrosomes (Goenczy, 
2012). Most centrioles consists of nine triplet microtubules are elegantly 
arranged into a cylinder and tw o orthogonally organised centrioles are present 
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in centrosomes (Winey and O'Toole, 2014). The formation of cilia and 
microtubule is controlled by the distal end of the centriole (Graser et al., 2007; 
Ishikaw a et al., 2005) . The distal end of the centriole also controls the 
ciliogenesis, in association w ith the plasma membrane.   . Recruitment of 
pericentriolar proteins that are important for microtubule organization is 
regulated by the proximal end of the centriole (Luders and Stearns, 2007). 
The PCM is a f ibrous scaffolding matrix that contains a large number of 
centrosomal proteins including γ-tubulin w hich then forms the γ-tubulin ring 
complex (γ-TuRC) and initiates microtubule nucleation(Schatten, 2008). The 
PCM increases in amount during mitosis, providing a nucleating centre for 
spindle/astral microtubules and anchors signalling molecules and components 
of γ-TuRC, w hich are believed to act as a scaffold for additional proteins to bind 
(Figure 1.8A) (Fu et al., 2015; Lukasiew icz and Lingle, 2009). A recent study 
show ed that in Drosophila, the centriole protein Asterless (Asl) is responsible for 
the recruitment of the essential centriole components, DSpd-2 and Cnn, to 
mother centrioles. This recruitment of essential proteins leads to assembly of 
the pericentriolar lattice w hich then results in the procurement of many other 
PCM components.(Conduit et al., 2014). 
 
1.2.1 Centrosome proteins  
 
A large number of proteins have been identif ied as centrosomal proteins, w hich 
of many have distinct functions and involvement at the centrosome but recent 
studies are continuing to f ind many more centrosomal proteins and revealing 
more than one function for such proteins. (Andersen et al., 2003). The 
classif ication of proteins being centrosomal changes according to the 
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identif ication method used. The centrosome is a small,  non-membranous- 
organelle and it does not have distinct borders, therefore identif ication methods 
can be misleading as they can fail to recover essential  centrosomal proteins or 
include those are not  actual centrosomal proteins (Schatten, 2008). 
Furthermore, as the centrosome is a dynamic structure that changes shape and 
size during cell cycle, the cohort of  centrosomal proteins dif fers according to the 
phase of the cell cycle. Andersen and colleagues have determined f ive hundred 
centrosomal proteins by mass spectroscopy (Andersen et al., 2003).  A review  
by Schatten divided centrosomal proteins identif ied by mass spectroscopy into 
the tw o groups: structural and regulatory (Table 1.1) (Schatten, 2008).  
Table 1.1: Structural and regulatory centrosomal proteins. 
 45 
 
As seen in the table 1.1 many some of the centrosomal proteins w ere w ell 
know n such as gamma, alpha and beta tubulins w hereas some others like 
AKAP450, w ere recently added to the list. A recent study by Jakobsen et al 
found 126 identif ied and 40 new  possible centrosome proteins (Jakobsen et al., 
2011).  This analysis also show ed that  60% of centrosome proteins possess a 
coiled-coil domain, indicating that this domain emerges as important for 
centrosome assembly (Telkoparan et al., 2013). How ever, more w ork is 
required to elucidate the function of many of these proteins in the complex 
cellular processes mediated by centrosomes. 
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Identifying the number of centrosomal proteins is not easy as many proteins use 
centrosomes as a signalling platform w hen participating in regulatory complexes 
that gather and act by signalling via the microtubule netw ork. (Godinho and 
Pellman, 2014). For instance, many of the mitotic kinases (Cdk, Polo, Aurora, 
Nek), described in the previous section, localize to the centrosome, but may not 
be directly involved in the structural or regulatory functions of the centrosome. 
These cell cycle kinases use the centrosome as a docking platform to interact 
w ith other proteins and mediate their cell-cycle specif ic functions (Uetake et al., 
2007). Therefore, in addition to acting as the major microtubule organising 
centre, the centrosome acts as a signalling hub to integrate dif ferent cell cycle 
regulators and orchestrate the cell cycle at several stages (Kramer et al., 2004; 
Nigg and Raff , 2009; Raff , 2002).  
Remarkably, there is an argument about w hether centrosomes are essential for 
microtubule organization and spindle assembly since centrosomes are absent 
in the majority of land plants, fungi and in the female germ cells of many animal 
species (Nigg and Raff , 2009; Picketth.Jd, 1969). When centrosomes are 
absent in Drosophila, either naturally or due to experimental manipulation, 
bipolar spindles can form in the proximity of chromosomes through a 
centrosome-independent pathw ay (Kalab and Heald, 2008). This pathw ay can 
explain the interesting f inding that Drosophila mutants lacking the centriole 
duplication protein DSas-4 nevertheless progressed normally through the 4–5 
days of larval development and 4–5 days of pupal development w ithout 
centrioles (Basto et al., 2006); how ever Drosophila mutants lacking centrioles 
die soon after they hatch. Although many somatic cells lacking the centrosomes 
can divide and retain the ability to from a mitotic spindle and progress through 
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mitosis, daughter cell cycles are compromised and incapable of further cell 
division (Hinchclif fe et al., 2001). Therefore, w hile alternative mechanisms exist 
for the organization of microtubules for spindle assembly (Kalab and Heald, 
2008; Matthies et al., 1996), centrosomal activity is crucial to ensure the high 
f idelity of  subsequent cell cycle progression in vertebrates (Hinchclif fe et al., 
2001).  
 
1.2.2 The centrosome cycle  
 
 As discussed above,  during mitosis, almost all microtubule related events in 
animal cells, including the formation of bipolar spindle , are organised by 
centrosomes (Nigg, 2007). Due to the requirement of tw o centrosomes for the 
formation of bipolar spindle, the centrosome, w hich comprises of tw o centrioles 
and a PCM, must duplicate once prior to mitotic progression. Strict regulation of 
centrosome numbers is essential for ef fective and correct chromosome 
segregation. The centrosome duplication cycle requires a pre-existing 
centrosome (Tsou and Stearns, 2006a; Tsou and Stearns, 2006b). This 
canonical duplication cycle can be split into f ive distinctive events: centriole 
disengagement, centriole duplication, daughter centriole elongation, 






Figure 1.9: The centrosome cycle during mitosis. Five characteristic events are 
associated with the centrosome (centriole) cycle. a- Centriole disengagement at the 
end of M/G1-phase is regulated by separase, cdc20 and APC/C; b- Centriole 
duplication at S-phase is regulated by cdk2; c- Daughter centriole elongation during 
S/G2-phase is regulated by cdc25; d- Centrosome maturation at G2-phase is primarily 
regulated by Nek, Plk1 and Aurora A; e- Centrosome separation regulated by Plk1, 
Aurora A and Eg5. ‘Mother’ centrioles appear as blue cylinders, while daughter 
centrioles are green cylinders. The bipolar mitotic spindle is represented as two blue 
circles with emanating spindle fibres appearing as lines. Image was adapted from 
Fukasawa, 2011.  
 
During f irst event, centriole disengagement in early G1 (at the end of M phase), 
tethered centrioles separate and lose their perpendicular orientation (Vidw ans 
et al., 1999).  
Like DNA replication, centriole duplication also occurs at the S phase. Cyclin-
dependent kinase 2 (Cdk2) initiates centrosome duplication by phosphorylating 
nucleophosmin (Okuda et al., 2000). This phosphorylation leads to 
disassociation of nucleophosmin from the centrosome initiating centrosome 
disengagement and duplication (Okuda et al., 2000). 
Daughter centriole elongation follow s throughout S and G2 phases by the 
synthesis of procentrioles at the proximal ends of separated mother centrioles .  
(Freed et al., 1999; Lukasiew icz and Lingle, 2009; Vidw ans et al., 1999) 
Centrosome maturation, in w hich the PCM increases in size and microtubule 
nucleating capacity, occurs in G2 phase (Mahen and Venkitaraman, 2012). 
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Phosphorylation/dephosphorylation of a netw ork of proteins is involved in the  
centrosome maturation and both Aurora A and Plk-1 kinases play an essential 
role in this maturation event (Blagden and Glover, 2003). 
Centrosomes undergo separation in late G2 for subsequent migration to 
opposite poles and mitotic spindle assembly in prophase (Ault and Rieder, 
1994). 
1.2.2.1 The regulation of the centrosome cycle 
 
All f ive events in the centrosome duplication cycle (described above)  are 
regulated by a multitude of proteins, of  w hich central mitotic kinase families, Plk, 
Aurora and NIMA (described above), play essential roles (Ma and Poon, 2011; 
Salaun et al., 2008) (Figure 1.10). This section w ill focus on how  the 
centrosome cycle is regulated, w ith an emphasis on the protein kinases.  
 
Figure 1.10: The proteins involved in the centrosome duplication cycle during 
mitosis. Cell cycle phases are shown in pink boxes. Centrioles are shown as purple 
cylinders. Plk4 is the major regulator of the centrosome duplication cycle. 
Oligomerization of SAS-6 and activity of Cdk2 is required for the formation of centriole 
nine fold symmetry. CP110, Cep97 and SAS-4 complex controls pericentriole 
elongation. PLk1 and Aurora A promote centrosome maturation which is followed by 
centrosome disengagement controlled by Plk1 and seperase activity. Image adapted 
from (Godinho and Pellman, 2014). 
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The centrosome cycle starts w ith the disengagement of mother and daughter 
centrioles. This requires Plk1 activitation in the beginning of the mitosis and 
separase activity after anaphase-promoting complex/cyclosome (APC/C) 
activity mediates securin degradation (Hatano and Sluder, 2012). Centriole 
disengagement w as initially thought to be regulated by cell division cycle protein 
20 (cdc20) and APC/C (Vidw ans et al., 1999), but a more recent study show ed 
that it relies on APC/C-Cdh1 activity (Hatano and Sluder, 2012). The same 
study also show ed Plk1 and APC/C-Cdh1 activities can autonomously stimulate 
centriole disengagement in G2 arrested cells (Hatano and Sluder, 2012). 
Therefore, during centriole disengagement, Plk1 and APC/C–Cdh1 complexes 
act independently and slow ly ensuring that centriole separation occurs at the 
right time and under the right conditions thereby avoiding the risk of multipolar 
spindle assembly by disengaging in a timely fashion at G2 (Hatano and Sluder, 
2012). 
The second event, centrosome duplication is strictly regulated and occurs 
contemporaneously w ith DNA replication. Duplication initiation requires 
activation of cyclin-cdk complexes; cyclin-A-cdk2 and cyclin-E-cdk2, w hich 
exchange betw een the nucleus and the cytoplasm to promote the initiation of 
centriole duplication as w ell as to promote DNA synthesis (Balczon, 2001; 
Hinchclif fe et al., 1999; Matsumoto et al., 1999; Meraldi et al., 1999).  
One model suggests that the Cyclin-E-cdk2 complex regulates centrosome 
duplication by phosphorylating nucleophosmin (Okuda, 2002; Tokuyama et al., 
2001). During G1 to S transition, Cdk2/E phosphorylates nucleophosmin, w hich 
leads removal of  nucleophosmin from the centrosome. This removal is thought 
to be essential for centriole duplication. When a cell enters mitosis, 
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nucleophosmin relocates to the centrosomes and inhibits centrosome over -
duplication.Therefore, it has been suggested that nucleophosmin could be 
controlling centrosome duplication to once per cell cycle (Okuda et al., 2000). 
Related to an inhibitory role in centrosome duplication, another study indicated 
that the centrosomal localisation of nucleophosmin depends on Ran–Crm1 
(Wang et al., 2005), a nuclear-cytoplasmic shuttle complex that, w hen ablated, 
causes centrosome amplif ication. How ever, this does not explain w hy 
centrosomes cannot re-duplicate normally during S and G1, as nucleophosmin 
is not at the centrosomes. Therefore it is more likely that nucleophosmin acts a 
dow nstream effector of Cdc2/E complex during centrosome assembly (Tsou 
and Stearns, 2006a). 
Cdc2/E complex also phosphorylates the centrosomal protein of 110 kDa 
(CP110) and this phosphorylation regulates centrosome duplication as the 
ablation of CP110 w ith siRNAs interferes w ith centrosome duplication in U20S 
cells (Chen et al., 2002).  
Cyclin-E carries DNA-replication initiating factors such as Mcm5 and Orc1 onto 
chromatin (Geng et al., 2007), Mcm5 supresses overduplication of centrosomes 
at S-phase (Ferguson and Maller, 2008) and Orc1 prevents Cyclin-E-driven 
overduplication of centrioles (Hemerly et al., 2009). Interestingly, 
overexpression of Geminin, w hich is a DNA replication inhibitor, interferes w ith 
the centrosome duplication cycle (Tachibana et al., 2005). Therefore regulation 
of DNA replication and centrosome replication overlaps at a molecular level.  
Polo-like kinase 4 co-operates w ith cyclin-cdk complexes to initiate the 
formation of a new  centriole, and therefore plays a crucial role in the initiation of 
centrosome duplication (Habedanck et al., 2005). Depletion of  Plk4 from 
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dividing cells leads to loss of centrioles, w hereas overexpression of Plk4 causes 
establishment of several daughter centrioles (Holland et al., 2012; Holland et 
al., 2010). In most cells, Plk4 is a low  abundance protein and capable of 
dimerization and transautophosphoryalation(Guderian et al., 2010). These 
features of Plk4 cause the recruitment of the ubiquitin ligase β-TrCP, and 
proteasome-mediated degradation of the protein (Cunha-Ferreira et al., 2009). 
This data suggests that the restriction of the new  centriole formation to one per 
cell cycle is controlled by timely degradation of Plk-4 via ubiquitin ligases 
(Cunha-Ferreira et al., 2009; Rogers et al., 2009).  
Essential centriole components required for centrosome duplication include δ- 
and ε- tubulin, Sas4, Sas6 and CP110 (Chen et al., 2002; Dutcher et al., 2002; 
O'Toole et al., 2003). The cell-cycle dependent expression of Sas6 and CP110 
presents an important barrier to control centrosome overduplication in human 
cells (Chen et al., 2002; Habedanck et al., 2005; Strnad et al., 2007) . In 
Drosophila and humans the centriole protein Asterless/Cep152 creates a 
netw ork w ith Sak/Plk4 and Sas-4/CPAP complexes and the formation of this 
protein netw ork is essential for centriole duplication, although its exact role in 
the  centrosome assembly is unknow n (Blachon et al., 2008; Cizmecioglu et al., 
2010; Dzhindzhev et al., 2010; Hatch et al., 2010). 
Centriole assembly during centrosome duplication also requires the PCM and 
core centrosomal components such as pericentrin. Overexpression of 
pericentrin increases the number of new ly formed centrioles, indicating a 
regulatory role for the PCM cloud (Loncarek et al., 2008). Other PCM proteins 
essential for centrosome duplication include NEDD1, γ-tubulin and Cep192 
(Haren et al., 2006a; Haren et al., 2006b; Zhu et al., 2008).  
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The machinery that restricts centrosome duplication to one per cell cycle still 
remains to be elucidated. The know n proteins that associate w ith duplication 
cycle have been discussed above.  
The third event, the centriole elongation, requires cdc25 (Lukasiew icz and 
Lingle, 2009; Vidw ans et al., 1999), as show n in cdc25 mutant Drosophila 
embryos, w hich revealed daughter centrioles that w ere shorter than mother 
centrioles compared to w ild type (Freed et al., 1999; Vidw ans et al., 1999). A 
recent study identif ied that knocking dow n seven centrosomal proteins (FOP, 
CAP350, CPAP, hSAS-6, Cep170, ninein, and C-Nap1) reduced daughter 
centriole elongation w hereas depletion of tw o of the centrosomal proteins  
(Cep97 and CP110) enhanced the elongation of centrioles (Korzeniew ski et al., 
2010). The same study also demonstrated that the daughter centrosome 
elongation is controlled by proteolysis (Korzeniew ski et al., 2010). 
The fourth event, centrosome maturation is controlled by a combination of three 
proteins: Polo-like kinase 1 (Plk1) (Lane and Nigg, 1996), Nek2 protein kinase 
(Prigent et al., 2005) and protein phosphatase 4 (Martin-Granados et al., 2008). 
The process of centrosome maturation additionally requires numerous other 
proteins such as Hef1 (Pugacheva and Golemis, 2005), TPX2 (De Luca et al., 
2006), Bora (Hutterer et al., 2006), NDEL1 (Mori et al., 2007), and LATS2 (Toji 
et al., 2004). Signif icantly, all these proteins participate in Aurora A  signalling 
either via recruitment of aurora A to the centrosome (De Luca et al., 2006; 
Hutterer et al., 2006; Pugacheva and Golemis, 2005) or as dow nstream 
effectors of Aurora A (Mori et al., 2007; Toji et al., 2004).  
Aurora A localises to the centrosome after the centrosome duplication at S 
phase and remains at the centrosome until telophase (Gopalan et al., 1997). 
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Aurora A has an established role in facilitating the characteristic increase in 
microtubule-nucleating activity through the recruitment of complexes such as γ-
TuRCs and D-TACC-Msps (Barr and Gergely, 2007; Barros et al., 2005). 
Indeed, in Drosophila, depletion of Aurora A resulted in the failure of γ -tubulin to 
accumulate at the centrosome; the resulting centrosomes failed to mature and 
separate w hich led to monopolar spindle formation (Berdnik and Knoblich, 
2002). Formation of the bipolar spindle is very important function of the 
centrosome. Aurora A localises to spindle pole microtubules after nuclear 
envelope breakdow n (Gopalan et al., 1997; Kimura et al., 1997) and operates 
via a Ran-regulated spindle assembly pathw ay (Fu et al., 2007). Ran is a small 
GTPase, w hich controls the nucleocytoplasmic transport and regulates spindle 
assembly by controlling the release of proteins involved in spindle assembly 
(Clarke and Zhang, 2001). Therefore, at the onset of mitosis, spindle assembly 
factors such as Tpx2 and Numa are released and allow ed to localise to the 
centrosome by Ran (Clarke and Zhang, 2001; Gruss et al., 2001). In return, 
Tpx2 mediates Aurora A spindle localisation and subsequent spindle formation 
(Kufer et al., 2002). Intriguingly, Aurora A alone (w ithout the centrosome) could 
function as microtubule-organising centre in the presence of GTP-bound Ran to 
induce bipolar spindle assembly (Tsai and Zheng, 2005). The mechanism 
responsible for driving this process is currently unknow n. Thus, identif ication of 
Aurora A substrates w ill help to improve our understanding of Aurora A 
mediated spindle assembly (Barr and Gergely, 2007). For instance, one Aurora 
A substrate, HERP, w as show n to localise at the proximal ends of mitotic 
spindles and ensure effective kinetochore capture by spindle microtubules 
(Wong and Fang, 2006).  
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Cyclin-cdk activity is required for centrosome maturation as w ell as the 
centrosome duplication (Saunders and Hoyt, 1992) and this activity is also 
regulated by Aurora A. During centrosome maturation, cyclin-B-Cdk1 is initially 
targeted to the centrosome by Aurora A, w here Aurora A phosphorylates Cdc25 
to activate cyclin-B-Cdk1 (De Souza et al., 2000; Dutertre et al., 2004). 
Activation of Cyclin-B-cdk1 complex is important for orchestrating timing of the 
mitotic entry (De Souza et al., 2000; Kramer et al., 2004).  
The role of Plk1 in centrosome maturation w as demonstrated in cells injected 
w ith anti-Plk1 antibodies, w hich resulted in mitotic arrest, monopolar spindles 
comprising of tw o un-separated centrosomes, and failure to accumulate 
maturation markers such as MPM-2 (mitotic phosphoprotein monoclonal 
antibody 2) and γ-tubulin (Lane and Nigg, 1996; Lens et al., 2010; Nigg et al., 
1996). Collectively, these data establish that centrosome maturation is 
regulated in a complex manner and that Aurora A has a critical role. 
The f inal event, centrosome separation, is mainly mediated by Nek2 through 
phosphorylation of C-Nap1 (centrosomal Nek2-associated protein 1, also called 
Cep250) and rootletin that are both centrosome linker components that tether 
mother centrioles after centriole duplication (Bahe et al., 2005; Hayw ard and 
Fry, 2006). Inactivation of Nek2 by mutation led to duplicated but un-separated 
centrosomes follow ed by cell cycle arrest in late G2 (Osmani et al., 1991). 
Mutations in Aurora A caused similar phenotypes to mutants def icient for the 
Plk-1 and Nek2; Drosophila mutants w ere often tetraploid as a result of  the 
inability of  monopolar mitotic spindle (formed by unseparated centrosomes) to 
segregate chromosomes in anaphase (Glover et al., 1995). Additional matching 
phenotypes w ere seen also upon antibody-interference of motor proteins dynein 
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(minus-end directed) and Eg5 (plus-end directed), indicating their role in 
controlling the dynamic movements of centrosome separation (Lukasiew icz and 
Lingle, 2009; Saunders and Hoyt, 1992). 
Aurora A also mediates centrosome separation (Barr and Gergely, 2007) but 
the molecular mechanism behind this role remains elusive although several 
putative roles have been suggested. One possibility is Aurora A mediates the 
separation via phosphorylation of the kinesin motor protein, Eg5, w hich can 
slide antiparallel microtubules and tether microtubule plus -ends (Kapitein et al., 
2005). Regulation of centrosome separation by Aurora A through Eg5 w as also 
demonstrated w ith orthologues in Xenopus (Giet et al., 1999). 
In summary, as w ith many cell-cycle processes, the principal events of the 
centrosome cycle are regulated by a combination of protein phosphorylation/ 
dephosphorylation and stability.  
1.2.3 Dysregulation of centrosomes in cancer 
 
Centrosomes are not only key players in mitosis but are also of w ider medical 
interest as centrosome amplif ication is a frequent characteristicof many cancer 
cells (D'Assoro et al., 2002a; D'Assoro et al., 2002b; Nigg, 2006; Pihan et al., 
1998; Pihan et al., 2001) that has been associated w ith promoting genetic 
instability (Brinkley, 2001; Ghadimi et al., 2000; Lingle et al., 2002) and so 
therefore tumorigenesis (Figure 1.11). This hypothesis is supported by w ork 
show ing that centrosome amplif ication can initiate tumorigenesis in Drosophila 
(Basto et al., 2008). In addition, aberrant centrosome number has been 
proposed to cause aneuploidy in several pre-invasive carcinomas via abnormal 












Figure 1.11: The importance of regulation of centrosome number in animal cell 
mitosis. (A) A mitotic mother cell with two centrosomes establishes a bipolar spindle 
and segregates its genetic material equally to the daughter cells. (B) A mitotic cell with 
centrosomal abnormalities such as an additional centrosome; the spindle forms 
abnormally, leading to missegregation of the genetic material. Centrosomes are shown 




1.2.3.1 Types of centrosomal defects 
 
Centrosomal defects in human cancers are classif ied as numerical or structural 
aberrations according to their origins (Nigg, 2006). Numerical centrosome 
aberrations (more than 2 centrosomes per cell) such as centrosome 
amplif ications are the most commonly identif ied centrosomal defects in cancer. 
In addition to numerical aberrations, structural centrosomal defects are also 
thought to occur in tumours (Fukasaw a, 2011; Nigg, 2006). Structural 
centrosome defects can be divided into tw o groups: defects in either centriole 
structure or in the amount of PCM (Godinho and Pellman, 2014). Centriole 
structural defects include alterations in centriole size (increase in length and 
increase in the variability of  centriole length). How ever, investigating the origins 
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of centriole defects is dif f icult due to the size of centrioles (0.2-0.5 µm long), 
w hich requires specialized f luorescence techniques or electron microscopy for 
ef fective visualisation. The increase in the amount of PCM has been also 
considered as a centrosome structural defect (Nigg, 2006). How ever, the 
assays commonly used to classify tumours as having ‘structural’ defects can be 
dif f icult to interpret (Godinho and Pellman, 2014). For instance, an increased 
amount of PCM can be classif ied as a structural defect (Nigg, 2006) although 
increased PCM  can be either related w ith the increase in size (D'Assoro et al., 
2002b) or can be related to supernumerary centrosomes that are clustered 
during interphase, w hich can be classif ied as a ‘numerical defect’ (D'Assoro et 
al., 2002a; Godinho et al., 2014; Lingle et al., 2002). Therefore, it is not trivial to 
determine the origin of centrosomal aberrations from f ixed cell imaging and 
moreover studies from many primary tumours only examine PCM markers, not 
centriole markers (Godinho and Pellman, 2014). Thus, improved methods to 
categorize centrosome abnormalities are needed. 
Centrosomal defects can arise via several fundamentally distinct but as yet not 
mutually exclusive mechanisms. These w ill be discussed below . 
 
1.2.3.2 Causes of centrosome defects/amplifications 
 
Firstly, one major cause of centrosome defects is the deregulation of the 
centrosome duplication cycle, w hich is in partly controlled by strict regulation of 
its ow n components. Deregulation of the centrosome cycle can lead to centriole 
overduplication (loss of cell-cycle control) or excessive centriole multiplication 
(loss of copy number control), w hich both result in formation of supernumerary 
centrosomes (Chan, 2011). The underlying mechanisms of such centriole 
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defects in cancer are still not clear. One idea is that changes in the expression 
(over or under expression) of genes associated  w ith controlling the centriole 
structure such as Plk4, SAS-6/4, CPAP, CP110 as described above, can drive 
centriole defects (Brownlee and Rogers, 2013). For example, overexpression of 
CPAP/SAS-4 complex, increases centriole length, in several model systems 
including C. elegans (Kirkham et al., 2003), Drosophila (Peel et al., 2007), and 
proliferating human cells (Kohlmaier et al., 2009) (Schmidt et al., 2009; Tang et 
al., 2009). SAS-6 is also essential for the correct centrosome duplication cycle 
as it is involved in the establishment of the cartw heel structure that w arrants the 
nine-fold symmetry of the centriole (Dammermann et al., 2004; Kitagaw a et al., 
2011; Leidel et al., 2005; Rodrigues-Martins et al., 2007; van Breugel et al., 
2011). 
Another important master regulator of centrosome duplication cycle is Plk4, as 
additional Plk4 activity leads to extra centrioles (Habedanck et al., 2005; 
Kleylein-Sohn et al., 2007), w hereas its depletion causes a decrease in 
centriole number (Bettencourt-Dias et al., 2005; Habedanck et al., 2005; 
O'Connell et al., 2001). 
Moreover, ubiquitin regulators can alter the stability of  centriolar proteins and 
play an important role in preventing centriole overduplication (Godinho and 
Pellman, 2014). For example, dow nregulation of βTrCP causes centrosome 
amplif ication by stabilizing Plk4 (Cunha-Ferreira et al., 2009; Rogers et al., 
2009; Wojcik et al., 2000), w hereas overexpression of USP33 leads to 
increased CP100 levels and therefore centrosome amplif ication (Li et al., 
2013a). Overexpression of PCM components, such as pericentrin (Loncarek et 
al., 2008) can also induce centrosome overduplication. Additionally, loss of the 
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tumour suppressor BRAC1 leads to centrosome amplif ication due to increased 
levels of the PCM protein, γ-tubulin (Sankaran et al., 2004; Starita et al., 2004).  
Secondly, failure of cytokinesis can generate polyploid cells w ith supernumerary 
centrosomes (Meraldi et al., 2002). In this case, centrosome number in 
polyploid cells increases w ith nuclear abnormalities but do not originate from 
overduplication. The potential for such cells to re-enter S phase and give rise to 
normal progeny depends on the tetraploidy checkpoint governed by p53 
function, w hich in such cells triggers cell cycle arrest and apoptosis (Chan, 
2011; Meraldi et al., 2002).  
Thirdly, centrosome amplif ication can be caused by errors in cell fusion (Ganem 
et al., 2007). For example, w hen cells are under the inf luence of fusogenic 
viruses, centrosome number can increase (Duelli et al., 2005; Shekhar et al., 
2002).   
Lastly, f ragmentation of PCM can lead to disintegration of centrosomes, w hich 
blocks normal centrosome function thereby causing centrosome amplif ications 
(Dif ilippantonio et al., 2009; Mikule et al., 2007).  
All these studies help provide a better understanding of how  the process of 
centrosome biogenesis is affected in tumour cells. How ever, there is much to 
investigate to understand both the origins and consequences of centrosome 







1.3 Introduction to the RASSF proteins 
 
One group of proteins linked to mitosis, centrosomes and cancer is the RASSF 
family of proteins; therefore the next section w ill focus on them. 
The f irst of f icial member of the Ras-association domain family (RASSF) w as 
initially identif ied in a yeast-tw o-hybrid screen as exhibiting high sequence 
homology to an already know n Ras-effector, Nore1 (now  included in the family 
as RASSF5) (Dammann et al., 2000). Currently the RASSF family represent a 
group of ten proteins that contain a Ras assoc iation (RA) domain either in their 
C-terminus (Classical RASSF proteins, RASSF1-6) or N-terminus (N-terminal 
RASSF proteins, RASSF7-10) (Sherw ood et al., 2010) (Figure 1.12) in 
mammals and in Xenopus. In contrast, the Drosophila genome encodes tw o 
RASSF family proteins: dRASSF w hich is similar to human RASSF1-6; and 
dRASSF8, w hich is similar to human RASSF7 and 8 (Langton et al., 2009).  
RASSF proteins are def ined by the possession  of  a characteristic  RA domain 
(Sherw ood et al., 2010). Comparing sequences from dif ferent Ras-binding 
proteins identif ied this domain (Ponting and Benjamin, 1996). How ever, the 
name ‘RA’ can be misleading since this does not necessarily mean that a 
protein containing an RA domain w ill def initely bind Ras. In reality, the binding 
aff inities of the RA domains of the RASSF family members  display a great 
variation and some members do not bind Ras (Rodriguez-Viciana et al., 2004; 
Wohlgemuth et al., 2005). A conserved feature of RA domains is their  is their 
proposed ability to form 3-dimensional ‘ubiquitin fold’ structure (Herrmann, 
2003).  It is important to study proteins w ith an RA domain such as RASSF 
family proteins to establish w hether they are Ras effectors or not.  
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RASSF family proteins have no intrinsic enzymatic activity, but instead are 
thought to act as scaffolding proteins. RASSFs regulate  a w ide range of 
functions including apoptosis, autophagy, microtubule dynamics, Ras signalling, 
cell cycle control, epigenetic silencing, regulation of immune system and many 
act as tumour suppressor proteins (Avruch et al., 2009; Clark et al., 2012; 
Richter et al., 2009; van der Weyden and Adams, 2007; Volodko et al., 2014) 
 
Figure 1.12: Domain architectures and differences in classical RASSF and N-
terminal RASSF proteins (A) Structural differences among RASSF family proteins in 
domain architecture. Classical RASSF proteins have the RA domain (represented as 
pink cylinder) at the C-terminus end, whereas the N-terminal RASSF proteins have the 
RA domain at the N-terminus end. Classical family proteins contain a SARAH domain 
(represented as a yellow cylinder) but the N-terminal family lacks the SARAH domain 
whilst containing a coiled-coil domain (represented as green cylinder). (B) Phylogenetic 
differences between classical and N-terminal families. Figures adapted from 
(Sherwood et al., 2010). 
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1.3.1 The classical RASSF proteins 
 
The classical RASSF members (RASSF1-6) share approximately 30-50% 
amino acid homology and contain several distinct domains including, the RA, 
SARAH (named after Salvador-RASSF and Hippo tumour suppressors), C1 
(protein kinase C conserved region 1, only in RASSF1A, RASSF1C and 
RASSF5) and ATM domain (ATM-kinase phosphorylation motif , only in 
RASSF1A and RASSF1C) (Figure 1.12) (Richter et al., 2009; Sherw ood et al., 
2010). The SARAH domain is a protein-protein interaction domain, w hich can 
mediate hetero- or homodimerization of proteins w ith tw o α-helices that form a 
novel antiparallel helix conformation (Scheel and Hofmann, 2003). This domain 
is found in proteins involved in the emerging tumour suppressor pathway Hippo, 
w hich is, evolutionary conserved betw een Drosophila and mammals that 
regulates cell contact inhibition, organ size and tumorigenesis (Saucedo and 
Edgar, 2007).  
The C1 domain is a diacylglycerol /phorbol ester binding (DAG) domain that 
facilitates the association w ith death receptor complexes including TNF-R1 and 
TRAIL (El-Kalla et al., 2010). DNA damage/repair results in the phosphorylation 




The RASSF1 gene is located at 3p21.3 w ithin a region of common homozygous 
and heterozygous deletions that are frequently associated w ith a variety of 
human tumours (Dammann et al., 2000; Kok et al., 1997; Lerman et al., 2000; 
Sekido et al., 1998). RASSF1, w hich is the best-studied RASSF protein among 
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classical members, has 8 transcripts (A -H), resulting from alternative splicing 
and use of dif ferential promoters (Volodko et al., 2014). RASSF1A and 
RASSF1C are the most extensively studied splice variants and they w ill be 
discussed separately below . 
1.3.1.1.1 RASSF1A   
 
RASSF1A w as the f irst RASSF gene identif ied and is one of the most 
methylated human cancer genes and a bona fide tumour suppressor (Gordon 
and Baksh, 2011; Richter et al., 2009). It is epigenetically silenced in numerous 
cancers including cervical, breast, lung and prostate cancers and its loss is also 
considered among the earliest changes  detectable in cancer (Klajic et al., 
2013). Several studies have described the correlation betw een RASSF1A 
methylation and dif ferent tumour characteristics. RASSF1A promoter 
methylation show ed an inverse correlation w ith K-Ras and B-Raf mutation 
condition in cervical tumours (Kang et al., 2007) and thyroid cancers (Brait et 
al., 2012; Kang et al., 2007; Nakamura et al., 2005; Xing et al., 2004a; Xing et 
al., 2004b). RASSF1A hypermethylation w as correlated w ith chromosome 
instability in Wilms’ tumours (Haruta et al., 2008) suggesting that RASSF1A has 
a function in controlling genomic stability. 
The various domains in RASSF1A ref lect the various signalling pathw ays that 
are possibly regulated by RASSF1A. For example, several studies have 
provided evidence that RASSF1A is a dow nstream effector of Ras, and 
interaction w ith Ras is achieved via its RA domain (Rodriguez-Viciana et al. 
2004, Vos et al. 2000). In contrast, other data suggest that RASSF1A forms a 
heterodimer w ith RASSF5 (Nore1a), w hich links it to activated Ras, rather than 
binding directly to Ras(Ortiz-Vega et al. 2002).   
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The presence of the SARAH domain facilitates interaction w ith Mst kinases and 
suggests that RASSF1A is potentially a component of the tumour suppress or 
Hippo signalling pathw ay. The Hippo pathw ay was f irst discovered in Drosophila 
and is important in the regulating apoptosis and organ size (Saucedo and Edgar 
2007). The proteins that are involved in Hippo pathw ay show very high levels of 
conservation and in mammals are know n variously as Mst1/2 kinases, Lats1/2 
(large tumour suppressor), WW45, and YAP (Yes-Activated Protein) (Saucedo 
and Edgar 2007). RASSF1A can associate w ith the MST1/2 but its exact role in 
regulating Hippo pathw ay (especially Mst kinases) is complicated. RASSF1A 
described to have tw o opposing roles on Mst1 kinase activity. RASSF1A 
inhibited the Mst1 kinase activity in transfected HEK293 cells (Praskova et al., 
2004), w hereas recombinant RASSF1A is show n to activate Mst1 activity in an 
in vitro  kinase assay (Oh et al., 2006).  
The presence of an ATM phosphorylation site in RASSF1A suggests this 
member of the family is a dow nstream effector of the ATM kinase that functions 
to ensure genomic stability (Hamilton et al. 2009). DNA damage activates ATM 
kinase w hich then acts by controlling the rate of cell proliferation (Shiloh 2003). 
RASSF1A may also participate in this process via transduction of the signal 
betw een ATM and the cell proliferation system.  
RASSF1A w as shown to be localised to microtubules via its C1 domain (Gordon 
and Baksh, 2011). The C1 domain is show n to facilitate the link  betw een 
RASSF1A and death receptor complexes, such as TNF-R1 and TRAIL (El-Kalla 
et al., 2010). Several groups have show n the important role that RASSF1A 
plays in microtubule stabilisation (Dallol et al., 2004; El-Kalla et al., 2010; Liu et 
al., 2003; Rong et al., 2004; Vos et al., 2004). RASSF1A modulates the cell 
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cycle by forming a complex w ith microtubules (Dallol et al., 2004; El-Kalla et al., 
2010; Song et al., 2004; Vos et al., 2004) and enhances microtubule 
polymerization (Liu et al., 2003; Vos et al., 2004). It co-immunoprecipitates w ith 
α-, β-, γ-tubulins (Dallol et al., 2004; El-Kalla et al., 2010; Rong et al., 2004; Vos 
et al., 2004). RASSF1A interaction w ith microtubules occurs through specialised 
microtubule associatied proteins such as MAP1B (microtubule-associated 
protein 1B) and MAP1S (microtubule-associated protein 1S) (Dallol et al., 
2004). As these proteins bind to tubulin directly, the interaction of  RASSF1A 
w ith tubulin could be indirect via MAPs (Donninger et al., 2014). The loss of 
RASSF1A microtubule localisation leads to inhibition of tumour suppressor 
properties, tubulin instability and promotes genomic instability via the loss of 
centrosome and mitotic spindle structures (Dallol et al., 2004; Liu et al., 2003; 
Vos et al., 2004). Therefore, the regulation of microtubule stability, spindle 
assembly and chromosome attachment by RASSF1A indicate that the tumour 
suppressor properties of RASSF1A are manifest through its control of  cell 
grow th, transformation, motility and invasiveness (Dallol et al., 2005; Korah et 
al., 2013; Vos et al., 2004).  
In addition to its roles in mitosis, RASSF1A is also involved in other aspects of 
the cell cycle and apoptosis. RASSF1A prevents accumulation of cyclin-D1 
either through JNK kinase pathw ay (Shivakumar et al., 2002; Whang et al., 
2005) or by suppressing AP-1 activity (Song and Lim, 2004) and blocks the cell 
cycle at the G1/S phase (Shivakumar et al., 2002; Whang et al., 2005). 
RASSF1A also disrupts the MDM2-DAXX-HAUSP complex, w hich then leads to 
MDM-2 self -ubiquitination and stabilization of p53 (Song et al., 2008). 
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In addition to regulating microtubules and the cell cycle, RASSF1A controls at 
least tw o apoptotic pathw ays, Hippo (discussed above) and Bits ax (Avruch et 
al., 2006; Baksh et al., 2005; Donninger et al., 2011; Vos et al., 2006) . 
RASSF1A activates Bax by direct binding to the Bax activator MOAP-1 (Baksh 
et al., 2005; Foley et al., 2008; Vos et al., 2006). The association w ith Hippo 
and Bax pathw ays prevents extreme grow th and allow  RASSF1A to act as a 
tumour suppressor.  
Tw o studies have generated Rassf1a knockout mouse (Tommasi et al., 2005, 
Van Der Weyden et al., 2005). The most striking phenotype exhibited by these 
studies w as increased susceptibility to tumour formation. The mice reportedly 
displayed increased prevalence of various cancers including lung adenomas, 
lymphomas, and breast adenocarcinoma compared w ith w ild-type mice 
(Tommasi et al., 2005; van der Weyden et al., 2005). 
In summary, RASSF1A is a tumour suppressor protein w hose inactivation is 
associated w ith the development and formation of numerous important human 
tumours. How ever, RASSF1A can be inactivated by point mutations or gene 
deletions, transcriptional silencing by aberrant promoter methylation is the most 
common provider to loss or decrease in RASSF1A function. This epigenetic 
mechanism is now  implicated in the inactivation of various tumour suppressors 
and is therefore established as a major effector to the development of a tumour. 
Although RASSF1A lacks obvious enzymatic activity, its possession of a Ras 
association (RA) domain indicates potential as an effector of the Ras 
oncoprotein. RASSF1A participates in the regulation of multiple apoptotic and 
cell cycle checkpoint pathw ays. Contemporary evidence supports the 
hypothesis that RASSF1A acts as a scaffold for assembly of multiple tumour 
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In contrast to RASSF1A, RASSF1C does not display tumour suppressor 
properties and it is not silenced in tumours w hilst increasing evidence suggests 
activity as an oncogene; overexpression of RASSF1C in breast and lung cancer 
cells caused enhanced cell migration/invasion (Amaar et al., 2006; Reeves et 
al., 2010; Volodko et al., 2014).  
Other w ork show s that RASSF1C localises to the nucleus (in HeLa cells), but 
does not modulate mitosis (Kitagaw a et al., 2006). Instead, RASSF1C appears 
to play a role in Ras-mediated cellular activities including apoptosis (Vos et al., 
2000). It forms a complex w ith DAXX, localises to nuclear located promyelocytic 
leukaemia-nuclear bodies, and is degraded in response to DNA damage w here 
upon RASSF1C is released into cytoplasm to activate the SAPK/JNK pathw ay 
(Kitagaw a et al., 2006). RASSF1C may also associate and co-localise in the 
nucleus w ith the serine-proteinase inhibitor TFPI-2, w hich is involved in 
inf lammation, angiogenesis and tumour grow th/metastasis (Chen et al., 2012) 
Both the structure and subcellular localisation of RASSF1A and RASSF1C dif fer 








1.3.1.2 RASSF5  
 
RASSF5 (also called NORE1 or RAPL) w as the f irst member of RASSF protein 
family characterized (Dammann et al., 2000); the RASSF5 gene is localised at 
1q32.1 (Tommasi et al., 2002). RASSF5 has three isoforms (A-C) generated via 
use of dif ferential promoter and alternative splicing; among RASSF5 isoforms, 
RASSF5A displays 40% amino acid similarity w ith RASSF1A (Volodko et al., 
2014).  
Data obtained by several laboratories strongly suggest that RASSF5 is a 
tumour suppressor (Khokhlatchev et al., 2002; Moshnikova et al., 2006; Ortiz -
Vega et al., 2002; Praskova et al., 2004; Vavvas et al., 1998) . Most normal 
tissues express RASSF5, but its expression is repressed in various cancer cell 
lines (Hesson et al., 2003; Irimia et al., 2004; Nakamura et al., 2005). Related 
w ith its role as a tumour suppressor, in RASSF5 knockout, K-Ras transfected 
mouse embryonic f ibroblasts developed large numbers of tumours w hen 
injected into immune compromised mice, supporting the role of RASSF5A in 
restricting abnormal grow th (Park et al., 2010a). 
The other isoform, RASSF5C, is expressed mainly in lymphoid tissues and has 
been implicated in T-cell receptor stimulation (Katagiri et al., 2003). It can also 
suppress grow th in cells similar to RASSF1A (Aoyama et al., 2004). Importantly, 
RASSF5C participates in the regulation of cell cycle progression via p27 
(Katagiri et al., 2011).  
RASSF5A is a centrosomal protein able to bind microtubules, for w hich the RA 
domain is essential, and is know n to be involved in cell grow th regulation 
(Moshnikova et al., 2006). It associates w ith cytoskeletal proteins through its RA 
domain and promotes grow th suppression via the ERK pathw ay (Moshnikova et 
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al., 2006). In addition, RASSF5A can interact w ith MST1 kinase follow ing cell 
death receptor activators (TNF-α and TRAIL) and regulates apoptosis (Park et 
al., 2010a).  RASSF5A also interacts w ith RASSF1A and promotes cell death 
(Ortiz-Vega et al., 2002). There is also evidence that RASSF5A is able to inhibit 
cell proliferation in a MST kinase-independent w ay by delaying cell cycle 
progression (Aoyama et al., 2004). Thus, the control of  apoptosis is a key 
function of RASSF5. 
1.3.1.3 RASSF2 
 
The RASSF2 gene is located on chromosome 20 (locus 20p12.1) and has three 
dif ferent isoforms (A-C) (van der Weyden and Adams, 2007). The literature 
focuses on isoform A, RASSF2A, w hich w ill be referred as RASSF2. RASSF2 is 
a primarily nuclear protein (Cooper et al., 2008) and displays several tumour 
suppressor properties, including inhibition of cell grow th and induction of 
apoptosis (Vos et al., 2003; Zhang et al., 2007). Regulation of cell grow th by 
RASSF2 w as reportedly regulated by the MAPK pathw ay; MAPK/ERK2 
mediated phosphorylation enhances export of  RASSF2 from the nucleus and a 
RASSF2 nuclear import mutant failed to arrest the cell cycle at G1/S phase and 
apoptosis (Kumari and Mahalingam, 2009; Vos et al., 2003). 
Although RASSF2 binds directly to K-Ras in a GTP dependent manner via the 
RA domain its interaction w ith H-Ras is w eak (Vos et al., 2003). RASSF2 also 
associates w ith MST1, engages the JNK pathw ay and induces apoptosis in a 







The RASSF3 gene is located at 12q14.2 and is the shortest member of the 
classical RASSF proteins (Richter et al., 2009). It has three transcripts (A-C) 
resulting from alternative splicing of the exons (van der Weyden and Adams, 
2007). The isoform described in the literature is RASSF3A. RASSF3 expression 
levels w ere subject to dow n-regulation in the majority of non-small-cell lung 
carcinomas, although this w as not the result of  DNA hypermethylation. 
Overexpression of RASSF3 in breast cancer cell lines inhibited the cell 
proliferation w hich suggests a protective role for RASSF3 in tumorigenesis 
(Jacquemart et al., 2009). A recent study show ed that RASSF3 expression 
induces p53 stabilization by ubiquitination of MDM2 (E3 ligase for p53) (Kudo et 
al., 2012). Therefore it is possible to say that RASSF3 can exert potential 
tumour suppression properties via p53-dependent apoptosis and DNA damage 
mechanisms (Volodko et al., 2014). Overall, little data exists on RASSF3 





The RASSF4 gene is located at 10q11.21 and its alternative splicing is 
predicted to produce numerous transcripts (A -F) (van der Weyden and Adams, 
2007). The only variant described in the literature is the RASSF4A isoform and 
is simply referred to as RASSF4. 
RASSF4 is frequently dow nregulated in human tumour cells and in several 
cancer cell lines by promoter methylation, but is extensively expressed in 
normal tissue (Chow  et al., 2004; Eckfeld et al., 2004), suggesting a tumour 
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suppressor function for RASSF4. A recent paper demonstrated that RASSF4 
interacts w ith and inhibits the tumour suppressor MST1/Hippo, indicating that 
RASSF4 may act as a Hippo pathw ay inhibitor (Crose et al., 2014). There is 
also evidence for RASSF4 attenuating the MAP kinase signal by suppression of 
ERK phosphorylation (Michifuri et al., 2013) w hich suggests a further possible 
mechanism for RASSF4-mediated tumour suppression. Similar to RASSF3, the 
literature on RASSF4 is limited and requires further investigation to conf irm its 




The RASSF6 gene is localised at chromosome 4q13.3 and three transcripts are 
predicted from the RASSF6 locus (A-C) (van der Weyden and Adams, 2007). 
Similar to other RASSFs, RASSF6 behaves as a tumour suppressor protein 
(Djos et al., 2012; Hesson et al., 2009). In HeLa cells overexpression of 
RASSF6 induced apoptosis (Ikeda et al., 2007). RASSF6 activates Bax, 
induces cytochrome c release, and triggers both caspase-dependent and 
independent pathw ays of apoptosis (Ikeda et al., 2007). Moreover, RASSF6 
associates w ith MST2 and inhibits Hippo pathw ay activation (Ikeda et al., 2009). 
RASSF6 also regulates apoptosis and the cell cycle by binding to MDM2 and 
facilitates its self -ubiquitination/degradation by stabilising p53 (like RASSF1A 
and RASSF3) (Iw asa et al., 2013). It has also been demonstrated that RASSF6 
can inhibit NFĸB activity (Allen et al., 2007) and possibly inf lammation by 
respiratory syncytial virus (RVS) (Bitko et al., 2004). 
In summary, the biological function of the classical RASSF proteins is too 
complicated to be ascribed to one process only. The members of classical 
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family have been associated w ith microtubule stability, cell cycle control and 
apoptosis, all of  w hich can contribute to the tumour suppressor activity of at 
least some of these proteins.  
 
1.3.2 The N-terminal RASSF proteins 
 
The N-terminal RASSF proteins (RASSF7-10, Figure 1.12) are a recent addition 
to the RASSF family and thus, have been studied less extensively than some of 
their classical counterparts (Sherw ood et al., 2010; Underhill-Day et al., 2011).  
The N-terminal family members have their RA domain at the opposite end (N-
terminus) compared to classical members (Figure 1.12B). Additionally, unlike 
classical family members, the N-terminal family do not possess a SARAH 
domain but three (7, 8 and 10) have a coiled-coil domain, a protein-protein 
interaction domain that is variable and sensitive to sequence changes 
(Grigoryan and Keating, 2008; van der Weyden and Adams, 2007). 
Nevertheless, the dif ferences betw een RASSF7-10 and RASSF1-6 suggest that 
the N-terminal RASSF proteins should not regarded as an extension of the 
Classical RASSF proteins, opening up the possibility of  divergent roles 
(Sherw ood et al., 2010).  These w ill be discussed individually for each N-




The RASSF8 gene is located close to KRAS2 gene on chromosome 12p11 and 
seven isoforms (A-G) have been predicted (van der Weyden and Adams, 2007). 
Both the RASSF8 and KRAS2 genes lie in a chromosomal region called Pals1 
that has know n sensitivity in a mouse model for lung carcinogenesis and its 
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association w ith lung adenocarcinoma risk has been show n in human 
homologous region (Falvella et al., 2006). 
A tumour suppressor role w as proposed as a result of  reduced RASSF8 
transcript levels in lung adenocarcinomas (Falvella et al., 2006). 
Overexpression of RASSF8 protein in lung cancer cell lines also inhibited 
anchorage-independent grow th that correlates w ith both tumour progression 
and metastasis. In addition to lung adenocarcinoma, male germ cell tumours  
also exhibit RASSF8 transcriptional dow n regulation, but the mechanism behind 
this remains to be elucidated. Loss of RASSF8 does not appear to result f rom 
promoter methylation, except possibility in childhood leukaemia (Hesson et al., 
2009).  
RASSF8 may regulate cell-cell adhesion due to its localisation adjacent to the 
membrane at adherens junctions, specif ically interacting w ith the components 
E-cadherin and β-catenin. In lung cancer cells endogenous RASSF8 localizes 
to AJs and binds to E-cadherin (Lock et al., 2010). Follow ing RASSF8 
depletion, E-cadherin localization is lost f rom discrete sites at the cell 
membrane and β-catenin is lost f rom adherens junction and accumulates in 
both the cytoplasm and nucleus (Lock et al., 2010). This suggests that RASSF8 
depletion results in loss of both adherens junction formation and function. Lack 
of stabilization of β-catenin at adherens junctions allow s β-catenin relocalization 
to the nucleus, w here it is able to promote activation of the canonical Wnt 
signalling pathw ay (Brembeck et al., 2006; MacDonald et al., 2009) suggesting 
that RASSF8 depletion can cause increased β-catenin signalling as part of  the 
Wnt signalling (Lock et al., 2010). Promoter activity analysis conf irmed a 
substantial increase in NF-kB-dependent activity follow ing RASSF8 knockdow n 
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w hich suggests a role for RASSF8 in the NF-kB signalling pathw ay as well as in 
Wnt signalling (Lock et al., 2010). A recent study from Drosophila eye 
development also show ed that RASSF8 is required to regulate E-cadherin and 
adherens junctions stability (Zaessinger et al., 2015).  
Wound healing assays revealed increased cell migration in cells lacking 
RASSF8 expression, suggesting tumour aggressiveness may result f rom loss of 
RASSF8 (Lock et al., 2010). On the other hand, serum analysis indicated that 
breast cancer patients had increased mRNA levels of RASSF8 in blood plasma 




The RASSF9 gene is located at 12q21.31 and interestingly RASSF9 is not 
transcribed from a CpG island region like other RASSF proteins (Richter et al., 
2009). RASSF9 w as f irst found in a yeast-tw o-hybrid screen searching for new  
partners of PAM (peptidylglycine α-amidating monooxygenase) and named as 
P-CIP1 (PAM COOH-terminal interactor protein 1) (Alam et al., 1996). BLAST 
analysis revealed that P-CIP1 has structural homology to RASSF7 and 
RASSF8 and w as later named RASSF9 (Sherw ood et al., 2010). Little is know n 
about the expression and functional signif icance of RASSF9. Chen et al., 
characterised RASSF9 and found high levels of sequence conservation from rat 
to human.  
RASSF9 interacted w ith the cytosolic domain of w ild type PAM-1 and w as 
associated w ith endosomes (Chen et al., 1998). A more recent study reported 
the predominant expression of RASSF9 in epithelial tissue (Lee et al., 2011). 
RASSF9 def icient mice displayed signs of senescence including increased 
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alopecia (hair loss), shorter life span and grow th retardation suggesting a novel 
role for RASSF9 in maintaining epidermal homeostasis by recycling of integral 




Sherw ood et al. f irst discovered the RASSF10, because the protein w as similar 
in sequence to RASSF9 and named it RASSF10 (Sherw ood et al., 2008). The 
RASSF10 gene is located at 11p15.2 (Richter et al., 2009). RASSF10 is 
expressed in several tissues (bone marrow , thyroid, brain, prostate and caner) 
(Dansranjavin et al., 2012; Hesson et al., 2009; Hill et al., 2011; 
Schagdarsurengin et al., 2009) and hypermethylation of RASSF10 w as linked 
to loss of gene expression in cancer cells (Dansranjavin et al., 2012; Hesson et 
al., 2009; Schagdarsurengin et al., 2009). In vitro analysis of RASSF10 in U87 
glioma cells show ed that RASS10 knockdow n increased cell proliferation and 
survival w hereas re-expression of RASSF10 blocked cell grow th and colony 
formation, indicating a tumour suppressor function of RASSF10 (Hill et al., 
2011). The tumour suppressor activity of RASSF10 w as also assessed in 
gastric cancer cells and  show ed reintroduction of RASSF10 in JRST and 
BGC823 cell lines reduced cell viability and promoted apoptosis (Wei et al., 
2013). The same study also show ed that the pro-apoptotic feature of RASSF10 
involves the Wnt/β-catenin signalling pathw ay (Wei et al., 2013). Additionally, 
RASSF10 has a potential role in regulation of mitotic progression related to its 
centrosomal localisation and localisation at microtubules (Hill et al., 2011).  
The N-terminal RASSF proteins possess a dif ferent domain architecture from 
the classical RASSF proteins and are considered a separate family (Sherw ood 
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et al., 2010). Although, RASSF7 and RASSF1A show  similar centrosomal 
localization and mitotic defects w hen knocked dow n, and promoter 
hypermethylation occurs in both RASSF10 and members of the classical 
RASSF family. Although these similarities suggest that the N-terminal RASSF 
proteins are genuine RASSF proteins, the dif ferences betw een them still 
outw eigh the similarities reinforcing the idea that the N-terminal RASSF proteins 
are a separate family. Emerging evidence suggests that the N- terminal RASSF 
proteins could play a role in tumour formation. Further detailed study w ill 





The RASSF7 gene is located at locus 11p15.5 surrounding the HRAS1 cluster 
1 (Weitzel et al., 1992). RASSF7 w as originally identif ied as HRC1 in a study 
w hich searched for genes that are close to HRAS1 in the genome (Weitzel et 
al., 1992). Due to alternative splicing, RASSF7 is predicted to have three 
transcripts (A-C). Our laboratory identif ied RASSF7 in a microarray screen 
comparing superf icial and deep cells in early Xenopus embryos, w here it w as 
initially called carcinoma associated protein (Chalmers et al., 2006). RASSF7 
has broad expression in early Xenopus embryos, w ith high levels in neural and 
epidermal tissue (Sherw ood et al., 2008). Studies of human cell lines and 
mouse embryos also show ed it to be expressed in a w ide range of cell and 
tissue types (Recino et al., 2010). Functional analysis demonstrated that 
RASSF7 is required for mitosis in cells from Xenopus embryos, w here 
morpholino knockdow n caused mitotic defects (Sherw ood et al., 2008). In 
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human cells shRNA knockdow n also caused defects in mitosis, including 
aberrant microtubule regrow th, a failure in chromosome congression (coming 
together) and reduced Aurora B activity at the kinetochores (Recino et al., 
2010). An independent study show ed that RASSF7 negatively regulates pro-
apoptotic JNK signalling by inhibiting the activity of phosphorylated mitogen-
activated protein kinase 7 (MKK7) and binds to N-Ras (Takahashi et al., 2011), 
but it is not currently clear w hether the stress and mitotic roles are linked. 
Consistent w ith its role in mitosis, both human and Xenopus studies show ed 
that RASSF7 localises to centrosomes. The aforementioned studies w ere 
performed using fusion proteins in Xenopus embryos and in human cell lines by 
staining for endogenous RASSF7 (Recino et al., 2010; Sherw ood et al., 2008). 
While RASSF7 localization and function in mitosis have been conclusively 
determined, the mechanism by w hich RASSF7 mediates this role has yet to be 
elucidated. The role of domains mediating RASSF7 localisation is not 
understood. Due to the lack of a catalytic domain, functional elucidation through 
loss-of-function analysis is limited due to the indirect dow nstream effects that 
could be elicited. Interestingly, yeast-tw o-hybrid studies (Morris et al., 2003; 
Porteous et al., 2011; Tsang et al., 2006; Yasui et al., 2007) have identif ied a 
potential RASSF7-binding partner, disrupted-in-schizophrenia 1 (DISC1), w hich 
exhibits a scaffolding function and has been associated w ith centrosomal 
function (Porteous et al., 2011). How ever, this interaction and functional 
signif icance requires conf irmation.  
In contrast to the loss of expression seen w ith many classical RASSF proteins, 
microarray studies have show n that RASSF7 expression is up-regulated in 
pancreatic, islet cell, endometrial, ovarian cell and thyroid cancers (Friess et al., 
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2003; Li et al., 2013b; Logsdon et al., 2003; Low e et al., 2007; Tan et al., 2009)  
and the increase in expression may be driven in some of these tumours by the 
fact that RASSF7 is up-regulated by hypoxia (Camps et al., 2008; Liang et al., 
2009; Recino et al., 2010). Despite an increase in expression in many tumours 
it is not clear w hether RASSF is acting as an oncogene and contributing to 
tumour formation or w hether its increased expression in tumours is simply a 
consequence of tumour formation. To begin to understand if  RASSF7 might act 



















1.4 Aims of the thesis 
 
The primary goal of  the project w as to investigate the molecular basis of rassf7 
function, w hich w ould help to increase our understanding of how  RASSF7 
functions in mitosis and also establish w hether increased levels are likely to 
promote tumour formation. In order to address this fundamental goal, the w ork 
w as split into three aims:  
1. Determine w hich domains of RASSF7 are required to localise it to the 
centrosome in cells from Xenopus embryos.  
2. Investigate the effect of  expression of the C-terminal truncation of raasf7 
on mitosis and in centrosomes, and f ind out if  similar truncations occur in 
human cancers. 
3. Investigate the junctional localisation pattern of RASSF7 in Xenopus 


















Unless otherw ise specified, all chemicals and general laboratory reagents w ere 
of molecular biology grade and w ere purchased from either Sigma-Aldrich 
Chemical Company or Fisher Scientif ic UK Ltd. 
2.1.1 Reagents 
 
The follow ing reagents w ere used: 
Luria Broth (LBB): 
1% (w /v) BactoTM Tryptone (BD Biosciences), 0.5% (w /v) BactoTM Yeast Extract 
(BD Biosciences), 0.5% (w /v) NaCl. Autoclaved. 
LB Agar Plates: 
1% (w /v) BactoTM Tryptone (BD Biosciences), 0.5% (w /v) BactoTM Yeast Extract 
(BD Biosciences), 0.5% (w /v) NaCl. Autoclaved and once cooled dow n, 100 
μg/ml ampicillin w as added and poured into plastic plates. Kept at 4°C. 
Phosphate Buffered Saline (PBS): 
Purchased from OXID 
NZY Broth:  
10g NZ amine, 5g yeast extract, 5g NaCl, f inal volume of 1 litre w ith ddH2O, pH 
adjusted to 7, autoclaved and stored 4°C. Prior to use 12.5mls 1M MgCl2, 
12.5mls 1M MgSO4, 20mls 20% (w /v) glucose.  
2.5% Cysteine: 
2.5g/100mls dH2O, ~7 pellets NaOH, pH adjusted to 7.8-8.1 
10x Marc’s Modif ied Ringer’s (MMR) solution: 
2M NaCl, 0.04M KCl, 20mM MgCl2.6H2O, 4omM CaCl2.2H2O, 2mM EDTA 
disodium salt, 1M Hepes, pH adjusted to 7.8-8.1 
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10x MOPS/EGTA/Magnesium (MEM) salts: 
1M MOPS 104.65g, 20mM EGTA 3.8g, 10mM Magnesium Sulphate (MgSO4) 
5mls of 1M, 400 mls ddH2O, pH adjusted to 7.4 w ith NaOH, made up to 500ml, 
f ilter sterilized and stored at 4°C. 
MOPS/EGTA/Magnesium/Formaldehyde (MEMFA) Solution: 
5mls 10xMEM salts, 5mls Formaldehyde 40mls ddH2O. 
10% (w /v) Ficoll:  
50g Ficoll in 500mls ddH2O f ilter sterilized and stored at 4°C. 
Injection Buffer: 
50mls 10% Ficoll, 25mls 10xMMR, 425mls autoclaved ddh2O f ilter sterilized 
and stored at 4°C. 
10x TAE (Tris-acetate-EDTA) Buffer: 
48.5g Tris, 11.4mls glacial acetic acid, 20mls 0.5M EDTA (pH 8) f inal volume of 
1 litre w ith ddH2O. 
Serum Gonadotrophin PhEur (PMSG):  
PMSG-Intervet contains 5000 i.u. diluted in ddH2O at concentration of 
100units/ml 
Human Chorionic Gonadotrophin (HCG): 
(Chorulon, Intervet; 2500 i.u./cow ) 1000 units/ml 
10% (w /v) Benzocaine:  
480mls ethanol, 20mls w ater, 50g benzocaine  
Blocking Buffer for antibody staining: 
1% BSA, 5% HTLS in PBS 
Gelatin from cold w ater f ish skin: 
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15% (16.67mls 45% stock, 7.5g sucrose), 20% (22mls 45% stock, 7.5g 

























2.1.2 Antibodies  
 
Table 2.1 Primary antibodies used for immunofluorescence  







Active caspase 3 Rabbit  Abcam 
Ab13847 
IF-1:100 







ZO-1 Mouse Invitrogen 
33-9100 
IF-1:25 








Table 2.2 Secondary antibodies used for immunofluorescence  









goat  Molecular probes 
A11004 
IF-1:500 
Rabbit  Alexa® 
Fluor 488 
goat  Molecular probes 
A11008 
IF-1:500 
Rabbit  Alexa® 
Fluor 568 














Table 2.3 Primers used for site directed mutagenesis and domain deletion 
Construct Forward Primer (5’-3’) Reverse Primer (3’-5’) Internal 
Primer No 



































































Table 2.4 Primers used for site directed mutagenesis (continued) 
Construct Forward Primer (5’-3’) Reverse Primer (3’-5’) Internal 
Primer 
No 














































































2.1.4 Plasmids  
 
























Plasmid Name Primers used 
for PCR  




GFP-rassf7 (Wild type) - - 301 
GFP-rassf7 (RA+A+CC) 183-184 301 433 
GFP-rassf7 (RA+A) 181-182 301 432 
GFP-rassf7 (RA) 202-203 301 448 
GFP-rassf7 (A+CC+B) 204-205 301 449 
GFP-rassf7 (A+CC) 183-184 449 452 
GFP-rassf7 (CC) 220-221 452 457 
GFP-rassf7 (A) 218-219 449 458 
GFP-rassf7 (CC+B) 222-223 449 459 
GFP-rassf7 (B) 224-225 459 460 
GFP-rassf7 (S374-A) 206-207 301 450 
GFP-rassf7 (S374-D) 208-209 301 451 
GFP-rassf7 (S104,105-A) 210-211 301 453 
GFP-rassf7 (S104,105-D) 212-213 301 454 
GFP-rassf7 (S/T5-A) 214-215 301 455 
GFP-rassf7 (S/T5-D) 216-217 301 456 
GFP-rassf7 (RA+A+CC'+B) 226-227 301 461 
GFP-rassf7 (RA+A+CC''+B) 228-229 461 462 





2.2.1 Xenopus Methods 
 
2.2.1.1 DNA sequences, plasmids and database/bioinformatics analysis 
 
Xenopus RASSF7 pBlueScript SK(-) clone (X1095b08) w as previously cloned 
into the gatew ay system (Life technologies, K4500-01) to generate an N-
terminal GFP-rassf7 fusion pCS2 construct (Sherw ood et al., 2008). A pCS2 
GFP construct w as also used as previously described (Chalmers et al., 2005). 
The sequence of the Xenopus RASSF7 protein w as obtained from NCBI: Ras-
association domain family 7 [Xenopus laevis] (ABR21988.1). The Simple 
Modular Architecture Research Tool (SMART : http://smart.embl-heidelberg.de/) 
w as used to identify potential protein domains and this information w as then 
used to inform design of the GFP-rassf7 truncation constructs and the coiled 
coil mutations w hich w ere generated as described below . 
Mutations in RASSF7 from human cancer samples w ere identif ied using 
cBioPortal f rom the Cancer Genomics w ebsite (http://w ww.cbioportal.org/public-
portal/index.do) w hich contained data from 89 cancer genomic studies covering 
a total of  20,958 tumour samples (August-Nov 2014). Sequence of the human 
protein w as obtained from the NCBI (Ras-association domain containing protein 
7 isoform 1 [Homo sapiens]:NP_003466.1) and SMART w as then used to 
predict the effect of  the mutations on the expected domains produced by human 





2.2.1.2 Primer design and site-directed mutagenesis 
 
The QuickChange site-directed mutagenesis kit (Agilent Technologies) w as 
used to make plasmids coding for a series of truncated versions of GFP-rassf7 
(Figure 1), by mutating the original GFP-rassf7 CS2 plasmid. Primers w ere 
designed according to the kit guidelines and PCR w as carried out follow ing the 
protocol supplied by the manufacturer. Follow ing mutagenesis all constructs 
w ere sequenced to conf irm the mutations w ere made correctly. The PCR 
primers w ere used to generate the constructs are show n in Table 2.3 and 2.4. 
The source plasmids used to generate the constructs and f inal plasmids 
generated are show n in Table 2.5. 
Table 2.6 Cycling parameters for the QuickChange site-directed mutagenesis 
(Segment 2 is adjusted accordance w ith the type of mutation desired: Point 
mutations 12 cycles, single amino acid changes 16 cycles and multiple amino 
acid deletions/insertions 18 cycles) 
Segment Cycles Temperature Time 
1 1 95°C 30 sec 
2 12-18 95°C 30 sec 
           55°C 
 
1 min 










2.2.1.3 Dpn1 digestion of PCR products 
 
PCR amplif ication products w ere subsequently added w ith 1µl restriction 
enzyme Dpn 1, thoroughly mixed and incubated (at 37°C) for 1 hour to digest 
non-mutated parental DNA. 
 
2.2.1.4 Transformation of competent cells 
 
XL1-Blue supercompetent cells (Agilent Technologies) w ere gently thaw ed 
(from -80°C) on ice and aliquoted (50μL) into a pre-chilled 14-mL BD Falcon 
polypropylene round-bottom tubes, into w hich 1μL of Dpn I-treated DNA (per 
mutation) w as transferred, follow ed by gentle mixing and incubation (at 37°C) 
for 1 hour. Transformation reactions w ere then heat-pulsed for (strictly) 45 
seconds at 42°C, lef t on ice shortly, and added w ith 0.5mL pre-heated (to 42°C) 
NZY broth to allow  expression of antibiotic resistance during 1 hour incubation 
at 37°C w ith shaking (at 225-250rpm). 250μL of the resulting transformation 
reactions w ere plated onto LB+AMP agar plates and lef t to colonise at 37°C 
overnight. 
 
2.2.1.5 Mini-prep for sequencing 
 
Successfully transformed colonies, selected w ith ampicillin resistance w ere 
subsequently used for DNA isolation w ith GenElute Plasmid Miniprep Kit 
(Sigma). Overnight cultures of tw o transformed colonies (per mutation) w ere 
pelleted by brief  centrifugation (at ≥12,000xg for 1min) and thoroughly 
resuspended, followed by cell lysis for no longer than 5 minutes. Cell debris w as 
then precipitated and pelleted by centrifugation (at ≥12,000xg for 10min). 
Cleared lysates (containing DNA and low  density debris) w ere then transferred 
into Miniprep binding columns already-prepared (w ith column preparation 
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solution to maximise DNA binding to the column) and brief ly centrifuged. 
Binding columns w ere subsequently w ashed and brief ly centrifuged tw ice to 
remove excess ethanol. Finally, columns w ere transferred to a sterile collection 
tube, w here plasmid DNA w as eluted w ith 50μL of ddH2O by brief  
centrifugation. Successful isolation and recovery of plasmid DNA w as assessed 
by agarose gel electrophoresis (at 150 mV for 15mins). 
Eluted DNA w as subsequently sent for sequencing by Eurof ins MWG Operon. 
An appropriate primer w as required (to bind ~800bp upstream from the site of 
mutagenesis). Upon receipt of  sequencing results, mutations w ere verif ied 
through translation w ith ExPASy translate tool (Artimo et al., 2012) and 
alignment via CLUSTAL Omega (to ensure no disruption to the rest of  the 
amino acid sequence) (Sievers et al., 2011). 
 
2.2.1.6 Maxiprep for plasmid isolation 
 
Once successful mutations w ere detected, plasmid DNA w as isolated at high 
yields w ith GenElute HP Plasmid Maxiprep Kits (Sigma) for subsequent 
linearization and transcription of RNA.   
Overnight cultures (in 150mL LB+ media w ith 0.1mg/mL ampicillin) of  colonies 
originally sequenced, were pelleted by centrifugation (at 4000xg for 10min), and 
thoroughly re-suspended, follow ed by lysis for no longer than 5 minutes. Cell 
lysate w as then precipitated and added w ith 9ml of binding solution, shortly 
follow ed by f iltering into prepared binding columns and centrifugation (at 
3000xg for 2min). Binding columns w ere sequentially w ashed and centrifuged 
(at 3000xg for 2-5mins, respectively), transferred to a sterile collection tube, 
w here plasmid DNA w as eluted w ith 3mL of ddH2O by centrifugation (at 3000xg 
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for 5min). Eluted plasmid DNA w as then precipitated w ith 10 % (v/v) 3M NaOAc 
(pH 5.2) and 70%(v/v) isopropanol and pelleted (at 4000xg at 4°C for 30min). 
Supernatant w as discarded and the DNA pellet w ashed w ith 1.5mL 70% 
ethanol, follow ed by centrifugation (as before for 10min). Finally once as much 
ethanol has been manually decanted, the pellet w as allow ed to air -dry before 
resuspending in 50μL of ddH2O. The successful isolation of plasmid DNA w as 
verif ied w ith gel electrophoresis and the yield quantif ied by spectrophotometric 
analysis.  
 
2.2.1.7 DNA linearization and mRNA transcription 
 
Isolated plasmid DNA (w ith the desired mutations) w as then linearized for 
subsequent transcription into RNA for injection. 10μg of plasmid DNA w as 
linearized in a 100μL reaction volume w ith the restriction enzyme Nsi1 in Buffer 
H (Agilent Technologies) overnight at 37°C. The resulting digested (linear) 
plasmid DNA w as treated w ith 5μL 25mg/mL proteinase K and 6μL 10% sodium 
dodecyl sulphate (SDS) for 30mins to the digest proteins (including Nsi1). 
Linear DNA w as subsequently isolated and purif ied by phenol chloroform 
extraction, follow ed by precipitation w ith 10% (v/v) 3M NaOAc (pH 5.2) and 
200% (v/v) ethanol and centrifugation. Pelleted (linear) DNA w as w ashed w ith 
70% ethanol and re-suspended in 10μL of nuclease-f ree DEPC dH2O. Again, 
the successful recovery of linearized DNA w as assessed by agarose gel 
electrophoresis. 
Linearized GFP-RASSF7 cDNA w as transcribed into capped sense mRNA for 
subsequent injection using the mMessage mMachine Kit (Ambion); as per 
instructions, the reaction mixture [3μL nuclease-f ree DEPC dH2O, 2μL 10x 
reaction buffer, 10μL 2x ribonucleotide (NTP/CAP) mix, 3μL of linearized 
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plasmid DNA and 2μL 10x enzyme (SP6 RNA polymerase) mix] w as incubated 
at 37°C for 2hrs. Remaining linearized plasmid DNA in the resulting RNA 
sample w as digested w ith 1μLTurbo DNase for 15mins and the reaction 
stopped w ith ammonium acetate (15μL in 115μL nuclease-free DEPC dH2O). 
RNA w as isolated and purif ied through phenol extraction, follow ed by 
precipitation w ith an equal volume of isopropanol (for 20mins at -20°C). RNA 
w as pelleted via centrifugation (at ≥12000xg for 15mins), w ashed w ith 70% 
ethanol and thoroughly re-suspended in 12.5μL nuclease-f ree DEPC dH2O. 
Isolated RNA w as run on fresh agarose for verification of transcription recovery. 
1µl RNA aliquots (~500ng/μL) w ere stored at -80°C. 
 
2.2.1.8 Fertilisation of Xenopus laevis eggs 
 
Male X. laevis (Xenopus) w ere killed by a schedule 1 method using benzocaine. 
Testes w ere harvested from the freshly killed male and used immediately, or 
stored for up to 1 day in L-15 medium (Sigma) at 4°C. Female Xenopus w ere 
injected w ith 50units of Pregnant Mare Serum Gonadotrophin (PMSG - 
Intervet®) 3 days prior to egg collection and w ith 500units of chorionic 
gonadotrophin (hCG - Intervet®) 12 hours prior to egg collection as per Home 
Off ice approved procedure. The female Xenopus w ere put into 1x MMR (Marcs 
Modif ied Ringers) to maintain the ability of  the laid eggs to be fertilised and 
eggs w ere collected from this medium. The collected eggs w ere w ashed once 
w ith 0.1x MMR and fertilised w ith the harvested testes, in this procedure, a 
small piece of the testes, approximately 5mm w ide w as cut f rom a testis. It w as 
placed into the dish containing the Xenopus eggs and then torn apart and w iped 
over the eggs. This w as to release all of  the sperm allow ing fertilisation. The 
fertilised eggs w ere de-jellied approximately 40mins post fertilisation, 2.5% (w /v) 
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cysteine w as added to the fertilised eggs and lef t for 2-3mins until the jelly could 
be seen to have been removed. The eggs w ere then w ashed 4 times w ith 0.1x 
MMR. Embryos w ere staged according to Nieuw koop and Faber (Nieuw koop 
and Faber, 1967) or by cell number. Embryos w ere cultured in 0.1 X MMR until 
the required stage or transferred to injection buffer for microinjection. 
 
2.2.1.9 Microinjection of RNA 
 
Glass capillary tubes (0.53” w idth, Drummond Scientif ic) w ere pulled us ing a 
Sutter P-97 needle puller. Xenopus Embryos w ere transferred to the injection 
buffer and 9.2 nl of  RNA (1:1 dilution) w as injected into one cell of  the embryo 
at the tw o-cell stage using a Nanoject II injector (Drummand Scientif ic 
Company).  The embryos w ere examined using a Leica M26 microscope 
(Deerf ieled, Illinois) and any dead embryos removed. Embryos w ere then 
cultured until stage 10 or stage 30. Once at the required stage, GFP w as 
visualised in w hole embryos using a Leica MZFL III microscope (Deerf ield, IL) 
and the embryos f ixed in MEMFA (0.1 MOPS, pH 7.4, 2 2 mM EGTA, 1 mM 
MgSO4, and 3.7% formaldehyde) for 2 hours at room temperature and w here 




For antibody staining embryos w ere embedded in f ish gelatin as described 
previously (Chalmers et al., 2003), except tadpole-stage (stage 30) embryos, 
w hich were incubated in 20% sucrose for 2 h, w ashed several times in PBS and 
then embedded in 15% f ish gelatin for f reezing. The embryos w ere 
cryosectioned and antibody stained as described (Chalmers et al., 2003). The 
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follow ing antibodies w ere used: monoclonal anti-γ-tubulin produced in mouse 
clone GTU-88 (Sigma; T6557, 1 in 100), polyclonal rabbit anti-active caspase 3 
(Abcam; ab13847, 1 in 100) rabbit polyclonal anti-histone H3 phospho S10 
(Abcam; ab5168, 1 in 500). The follow ing secondary antibodies w ere used: anti-
mouse Alexa 568 (A-11004, Molecular Probes, Eugene, OR); anti-rabbit Alexa 
568 (A-11011, Molecular Probes). All secondary antibodies w ere used at a 1 in 
200 dilution. The nuclear stain, DAPI (Sigma, D9542, 1 mg/mL) w as used at 1 
in 1000 dilution. Stained sections w ere mounted in Vectasheild (Vector 
Labroratories, Burlingame, CA) and imaged on a Zeiss LSM META confocal 
microscope w ith a 63X Plan-Apo/1.4 NA oil lense w ith DIC capability 
(Thornw ood, NY). GFP f luorescence w as visualised directly w ithout the use of 
antibody staining. All f luorescencent images w ere captured in the linear range 
of the confocal to allow  quantif ication w ith extra care w as taken to avoid pixel 
saturation. To achieve this all images w ere collected using the range indicator, 
w hich is found w ithin the Palette f ilter. Saturated pixels w ould appear red and 
pixels below  zero blue, the absence of such pixels conf irmed the images w ere 
collected in the linear range. Each pixel in the image has a dynamic range grey 
scale value ranging from zero to a maximum of 256. The background w as kept 
close to zero and the intensity adjustments done to create and image w ith grey 
levels w ithin the dynamic range of 256, settings w ere then kept constant for  all 






2.2.1.11 Quantification and statistics 
 
Quantif ication of cells expressing GFP w as carried out by identifying GFP 
positive cells (GFP positive cells w ere identif ied qualitatively, as those w hich 
had signif icantly above background levels of GFP f luorescence) w ith a 
centrosome(s) in the section being analysed (clear γ -tubulin staining adjacent to 
the nucleus). GFP show s a pattern of localisation w hen expressed in early 
Xenopus cells, it is enriched in the nucleus, perinuclear region and cell cortex. 
This is due to large amounts of yolk excluding GFP from other regions of the 
cell. The nuclear localisation explains w hat can appear as apparent 
heterogeneity in expression, some cells w ill have been sectioned through the 
nucleus (appearing to have strong staining) and some cells w ill not have their 
nucleus in the section and so appear to have w eaker levels of staining. 
How ever, the levels across several sections w ere fairly even as expected for 
such injections. The perinuclear region does overlap w ith w here the 
centrosomes sometimes localises, so GFP cells can have some signal in this 
area. For this reason, and to allow  rigorous analysis of the mutations, very 
careful quantif ication w as carried out. All cells w ith clear centrosomes (def ined 
as clear spot of gamma-tubulin staining in close proximity to the nucleus) in the 
sections being analysed w ere quantif ied. For each mutant/control data from 
three independent experiments w ere analysed and a large number of individual 
cells w ere used (>100). Example of images used for this quantif ication are 
illustrated w ith four f igures (Appendix 1-2) and in a table of quantif ication is 
included (Appendix-3).  
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The area and intensity of the centrosomal GFP w as then measured by using the 
LSM510 Image Brow ser softw are (ZEISS) and the integrated density w as 
calculated by multiplying the area by the average intensity across the region of 
interest. The area, intensity and integrated density of the γ -tubulin, DAPI and 
nuclear GFP staining w as measured in the same w ay. The centrosome number 
in GFP positive cells w as quantif ied based on the number of clear γ -tubulin 
spots, each cell w as classif ied as containing 1, 2 or ≥3 centrosomes and each 
group w as displayed as a percentage of the total GFP positive cells. 
Quantif ication of mitotic cells (Phospho-H3 positive) or apoptotic cells (active 
caspase-3) was carried out by calculating the % of GFP positive cells that w ere 
also positive for the marker of interest.  
Means and standard deviations w ere calculated and plotted using GraphPad 
Prism 6 (San Diego, CA). Statistical analysis w as carried out using One-w ay 
Anova tests w ith Bonferroni post-test corrections, p < 0.05 w as considered 
signif icant. Statistical analysis w as based on data from at least three 
independent experiments and w ith a minimum sample size as described in the 
f igure legends. 
 
2.2.2 Cell culture 
 
HEK293 (human embryonic kidney 293) cells (kindly provided by Chris Bryant, 
University of Bath PhD student) w ere maintained betw een passages 30 and 40 
at 37°C, 5% CO2 in DMEM (Invitrogen) supplemented w ith 10% (v/v) FBS. Cells 
w ere passaged tw ice w eekly by brief ly w ashing in PBS and incubating w ith 
trypsin-EDTA for 5 minutes at 37°C, 5% CO2. Cells w ere resuspended in 12ml 
of complete DMEM and passaged at a dilution of 1/12. HEK293 cells w ere 
frozen for storage and thaw ed as outlined above. All cell lines w ere routinely 
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tested for mycoplasma using the MycoAlert detection kit (Lonza), according to 
the manufacturer’s instructions. 
MDCKII cells (Madin-Darby canine kidney cells #00062107, European 
Collection of Cell Cultures, Salisbury, UK) w ere maintained at 37°C and 5% 
CO2 in Dulbecco’s modif ied Eagle’s medium (DMEM) w ithout phenol red 
(Lonza, Slough, UK) supplemented w ith 10% (v/v) fetal bovine serum (FBS) 
(Invitrogen) and 2mM L-glutamine (Invitrogen). Cells w ere passaged tw ice 
w eekly at a dilution of 1/10 and maintained in culture for a maximum of 15 
passages (approximately 2 months). Cells w ere w ashed once in PBS and once 
quickly w ith trypsin-EDTA (Invitrogen), prior to incubation in fresh trypsin-EDTA 
for 10 minutes at 37°C, 5% CO2. Trypsin w as neutralised by re-suspending cells 
in DMEM containing serum and pelleting at 200 x g for 2 minutes. The pellet 
w as re-suspended in 10ml of complete DMEM and passaged at a 1/10 dilution. 
For freezing MDCKII cell stocks, one T75 tissue culture f lask w as trypsinised 
and pelleted as outlined above. The resulting pellet w as re-suspended in 2ml of 
10% (v/v) DMSO in FBS and split into four 0.5ml aliquots in sterile cryogenic 
storage vials (Invitrogen). Vials w ere frozen at a controlled rate by placing in an 
isopropanol chamber at -80°C overnight before transferring to liquid nitrogen. 
To thaw  cells, a single vial w as thaw ed at room temperature, re-suspended in 
20ml of complete DMEM in a T75 tissue culture f lask and incubated at 37°C 
overnight. Media w as refreshed after 24 hours to remove excess cell debris and 
DMSO. 
Prior to plating cells for experiments, a sample of re-suspended cells w as 
counterstained w ith trypan blue to assess viability. Cells w ere counted using a 
haemocytometer and diluted to a plating concentration of 2x105cells/ml. MDCKII 
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cells w ere grow n until fully conf luent, for a minimum of 8 days, w ith media 
changes every 2 days prior to experimental use. 
 
2.2.3 IF Staining of MDCKII cells  
 
MDCKII cells w ere plated at a density of 2x105cells/ml on 8-w ell µ-slides (Ibidi, 
Glasgow , UK). Cells w ere f ixed and permeabilised in ice-cold methanol at -20°C 
for 10 minutes and rinsed three times in PBS. Non-specif ic binding sites w ere 
blocked in 10% (v/v) normal goat serum (NGS) in PBS for 30 minutes. Primary 
antibodies w ere diluted in 2% (v/v) NGS/PBS. Appropriate species -specif ic 
secondary antibodies w ere also diluted in 2% (v/v) NGS/PBS. Primary antibody 
incubations w ere performed overnight at 4°C and secondary antibody 
incubations at room temperature for 2 hours. Cells w ere w ashed f ive times in 
PBS betw een antibody incubations. Nuclei w ere counterstained w ith 300nM 
DAPI in PBS and stored at 4°C until required. Slides w ere imaged using a Zeiss 
LSM510META laser-scanning confocal microscope (Plan-ApoChromat 63x/1.4 
Oil Phase objective). Confocal images are presented as overhead composite 
projections of multiple 1µM Z-slices through the MDCKII monolayer. All images 
w ere processed using ImageJ softw are (National Institutes of Health). Images 
from dif ferent experimental conditions w ere processed in an identical fashion. 








2.2.4 Adenoviral production for Human RASSF7 
 
2.2.4.1 Restriction digest and PCR 
 
GFP-RASSF7 (internal plasmid no: 343) w as generated previously by Asha 
Recino (PhD 2011, University of Bath). Restriction enzymes KpnI (Fisher 
ER0521) and EcoRI (Fisher ER0271) w ere used to digest GFP-RASSF7 for 
sub-cloning. Primers w ere designed w ith KpnI and EcoRI restriction sites 
(restriction sites are underlined): GFP-RASSF7 forw ard 5’-
GAATTAGGTACCCACCATGGCCAGCAAAGGAGAAGAAC-3’ and GFP-
RASSF7 reverse 5’-GATTAAGAATTCACCACTTTGTACAAGAAAGCTGGGTC-
3’ and used in the polymerase chain reaction (PCR). PCR w as carried out using 
Phusion® High-Fidelity DNA Polymerase (New  England Biolabs) and Techne 
Genius PCR Thermal Cycler. PCR conditions are presented in Tables 2.7 and 
2.8. Digests w ere performed according to the manufacturers’ instructions; to 
achieve more complete digestion, they kept overnight at 37°C. 
 















5x HiFi buffer 5X 1X 5 
Forward primer 10µM 0.3µM 0.75 
Reverse primer 10µM 0.3µM 0.75 
dNTPs 10mM 0.3mM each 0.75 
Template DNA (GFP-RASSF7) 10ng/µl 10 - 100ng 1 - 10 
ddH2O N/A N/A 16.25 
HiFi DNA polymerase 1U/µl 1U 0.5 
Total N/A N/A 25 
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Table 2.8: PCR conditions. An elongation time of 2 minutes w as used for the 









2.2.4.2 DNA agarose gel electrophoresis 
 
Digested DNA  w as combined w ith bromophenol blue loading buffer and loaded 
onto 0.6 – 1 % (w /v) agarose TBE gels containing SYBR® Safe DNA Gel Stain 
(Thermo Fisher) alongside 5µl of  1kB DNA Ladder (Promega, Southampton, 
UK). DNA gels w ere run at approximately 10V/cm of gel until the gel f ront 
approached the end of the gel. DNA w as visualised using a non-UV Dark 
Reader Transilluminator (Clare Chemical Research, CO, US). Where 
necessary, gel extraction w as performed using the Wizard SV Gel and PCR 
Clean-Up System (Promega) according to the manufacturer’s instructions. 
Digested and purif ied GFP-RASSF7 w as initially ligated into pJET1.2 
intermediate vector (kindly provided by Chris Bryant, University of Bath, PhD 




Cycles Stages Temperature (°C) Time 
1 Initial denaturation 95 3 minutes 
30 Denaturation 98 20 seconds 
Annealing 67 15 seconds 
Extension 72 2 minutes (15 - 60seconds/kb) 
1 Final extension 72 5 minutes 
∞ Hold 10 Hold 
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2.2.4.3 Blunt ligation into the intermediate vector  
 
Clonejet PCR cloning kit (Fermentas Life Sciences, K1232) w as used for the 
ligation of GFP-RASSF7 into the intermediate vector. Ligation conditions are 
show n in Table 2.9. The ligation mixture w as incubated at room temperature for 
5 minutes and the intermediate vector and insert (GFP-RASSF7) w ere 
separated by DNA agarose gel electrophoresis. GFP-RASSF7 w as then purif ied 
w ith Wizard SV Gel and PCR Clean-Up System (Promega) according to the 
manufacturer’s instructions. GFP-RASSF7 plasmid w as then used for 
transformation. The experimental steps are summarized in Figure 2.1. 
 










DH-5-alpha competent E. coli (High Eff iciency) cells (New  England Biolabs) 
w ere thaw ed on ice and dispensed into 25µl aliquots. 2.5µl of  plasmid solution 
w as added to each aliquot and incubated on ice for 30 minutes. Negative “no 
DNA” and positive pUC19 vector control transformations w ere included 
according to the manufacturer’s instructions. Samples w ere heat-shocked at 
42°C for 30s and placed on ice for 2 minutes. 250µl of  prew armed SOC 
Reagent Final  
concentration 
Volume (µl) 
2x Reaction buffer 1X 10 
PCR product (GFP-RASSF7) 10 ng 1  
pJET1.2 cloning vector 0.05pmol 1 
ddH2O N/A 7 
T4 DNA ligase 1U 1 
Total N/A 20 
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medium (New  England Biolabs) w as added and samples w ere incubated at 
37°C for 1 hour w ith vigorous shaking. Bacteria w ere pelleted by brief  
centrifugation at 10,000 x g and resuspended in 100µl SOC medium. The 
bacterial solution w as then spread onto LB agar plates containing 50µg/ml 
ampicillin. Spread plates w ere incubated at 37°C overnight to allow  colony 
formation. 
 
2.2.4.5 Bacterial culture 
 
Successful transformation w as indicated by successful colony formation of 
pUC19 positive control, vector-transformed samples. Colonies corresponding to 
the desired plasmid product w ere expanded by picking a single colony w ith a 
pipette tip and adding to prew armed LB containing 50µg/ml ampicillin (5ml for 
miniprep, and 250ml for maxiprep cultures). Cultures w ere grow n overnight at 
37°C w ith vigorous shaking. 
 
2.2.4.6 Plasmid purification 
 
Plasmids w ere purif ied from overnight cultures using either the Wizard Plus SV 
Minipreps DNA Purif ication System (Promega) or the GenElute™ HP Maxiprep 
Kit (Sigma-Aldrich) according to the manufacturers’ instructions. 
 
2.2.4.7 Adenoviral shuttle vector production 
 
In order to generate recombinant adenoviruses, desired transgenes w ere 
initially subcloned into the pAd5CMV K-NpA adenoviral shuttle vector (from the 
University of Iow a GTVC). Successful subcloning w as conf irmed by 
sequencing, provided by Source Biosciences (Nottingham, UK). 
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Previously generated GFP-RASSF7 w as digested w ith KpnI and EcoRI and 
cloned into the multiple cloning site of pAd5CMV K-NpA. The KpnI/EcoRI-
digested pAd5CMV K-NpA vector w as treated w ith Antarctic Phosphatase (New  
England Biolabs) according to the manufacturer’s instructions to remove 5’ 
phosphates and minimise recircularisation by self -ligation. Antarctic 
Phosphatase w as heat inactivated at 70°C for 5 minutes. Digested vector and 
insert w as ligated using T4 DNA ligase (Promega) according to the 
manufacturer’s instructions. A “no insert” reaction w as included to control for the 
eff iciency of target vector digestion and self -ligation. A vector:insert molar ratio 
of 1:3 w as used to optimise ligation eff iciency, and w as calculated using the 
follow ing equation: 
 
Insert mass (ng) = 3 × [ 
Insert length (bp)
Vector length (bp)
 ] × Vector mass (ng) 
 
Ligation reactions w ere used to transform competent E. coli and spread onto 
plates as previously described. Successful ligation w as indicated by colony 
grow th on the LB plates containing ampicillin. 
 
2.2.4.8 Calcium phosphate transfection 
 
HEK293 cells w ere transfected using a calcium phosphate based method for 
generating recombinant adenovirus. HEK293 cells w ere plated at a density of 
2x105 cells/ml in a T25 tissue culture f lask and incubated at 37°C, 5% CO2 for 
tw o days, until 50 – 80% conf luent. A total of  6µg of plasmid DNA w as diluted to 
a f inal volume of 140µl in DNase/RNase-free ddH2O. 19.8µl of  2M CaCl2 w as 
added dropw ise to the DNA solution. 159.8µl of  2x HBSS w as added dropw ise 
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to form a precipitate. The solution w as incubated at room temperature for 20 
minutes, mixed thoroughly by pipetting and added dropw ise to the cell culture 
medium. Cells w ere incubated at 37°C, 5% CO2 for 4 hours. The media w as 
removed and cells w ere rinsed w ith PBS. Cells w ere then incubated in fresh 
culture medium at 37°C, 5% CO2. 
 
 
2.2.4.9 Generation of recombinant adenovirus 
 
pAd5CMV+GFP-RASSF7 w as cotransfected with the pacAd5 9.2 – 100 sub360 
backbone vector into a HEK293 helper cell line (Anderson et al., 2000). 
Homologous recombination of PacI-digested vectors generates a continuous 
sequence for viral particle production. Individual shuttle vectors and the pacAd5 
9.2 – 100 sub360 backbone vector w ere digested w ith PacI (New  England 
Biolabs, Hitchin, UK), mixed and cotransfected into HEK293 cells by calcium 
phosphate transfection (4.5µg of pacAd5 9.2 – 100 sub360 backbone vector 
combined w ith 1.5µg of pAd5 shuttle vector). Transfected cells w ere incubated 
at 37°C to allow  recombination and for a visible cytopathic effect to become 
evident. Cytopathic plaques w ere expected to localised areas of cell death w ith 
























Figure 2.1: Sub-cloning prep diagram. GFP-RASSF7 f irst digested w ith 
restriction sites and then ligated into intermediate vector (pJET1.2) for better 













Many cell-cycle regulatory proteins or tumour suppressors are localized w ithin 
specif ic cellular compartments and their subcellular localization may inf luence 
their functions. This introduction w ill focus on subcellular localisation of RASSF 
family proteins.  
3.1.1 Subcellular localisation of classical RASSFs 
 
RASSF1 is the best-studied RASSF protein among classical family members 
and its subcellular localisation is w ell documented. RASSF1 has eight isoforms 
(A-H) (Volodko et al., 2014); among these isoforms RASSF1A and RASSF1C 
are the most extensively studied members. RASSF1A is localised to the 
cytoplasm and cytoskeleton depending upon the cellular environment. It has 
been show n in dif ferent mammalian cell lines, including A549, LNCaP, HeLa 
and NIH-3T3, that both tagged or endogenous RASSF1A localises to 
cytoplasmic microtubules during interphase, to bipolar centrosomes associated 
w ith microtubules during prophase, and at metaphase and anaphase localise to 
spindle f ibers and spindle poles (Liu et al., 2003; Song et al., 2004). During 
early telophase localisation is to the midzone and at late telophase and during 
cytokinesis to the midbody (Liu et al., 2003; Song and Lim, 2004; Song et al., 
2004). Intriguingly, a later study in HeLa cells show ed that endogenous 
RASSF1A localises to the centrosome throughout the cell cycle (Guo et al., 
2007a) but the reason behind the dif ference in localisation is not very clear. It is 
also now  established that RASSF1A is a microtubule-associated protein as 
assessed by both yeast-tw o-hybrid and immunoprecipitation experiments and it 
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co-localises to tubulin as show n w ith immunofluorescence staining in several 
cell lines (Dallol et al., 2004; Vos et al., 2004) and associates w ith microtubule 
binding proteins (Dallol et al., 2007; Liu et al., 2005). Over-expression of 
RASSF1A resulted in both re-arrangement (Dallol et al., 2004) and preventing 
microtubules from depolymerisation (Dallol et al., 2004; Liu et al., 2003; Vos et 
al., 2004). More recently El-Kalla et al (2010) studied the importance of 
RASSF1A microtubule association and show ed that loss of RASSF1A 
microtubule association resulted in nuclear localisation of RASSF1A, loss of 
tubulin stability via the loss of tubulin acetylation and complete loss of tumour 
suppressor properties of RASSF1A. Furthermore, loss of RASSF1A microtubule 
localisation by a δMT mutant RASSF1A resulted in enhanced tumour promotion 
w hen expressed in mice (El-Kalla et al., 2010).  
Endogenous studies indicate that RASSF1C primarily localises to the nucleus 
(Kitagaw a et al., 2006; Song et al., 2004), binds to the apoptotic protein Daxx, 
before translocating to the cytoplasmic microtubules and regulating SAPK/JNK 
activation (Kitagaw a et al., 2006). Overexpressed RASSF1C w as localized 
primarily to the nucleus (Rong et al., 2004) and also associated w ith tubulin to 
provide a potential stabilization role for microtubules (Rong et al., 2004; Vos et 
al., 2004) similar to RASSF1A. Thus, subcellular localisation of RASSF1A and 
RASSF1C dif fer and their physiological functions seem to be antagonistic, at 
least in some contexts (see Introduction for a w ider comparison of RASSF1A 
and RASSF1C).  
Endogenous RASSF2 show ed nuclear localisation w ithin the both H417 and 
H720 lung cancer cell lines (Cooper et al., 2008). The same nuclear subcellular 
localisation for ectopic RASSF2 w as observed in COS-7, HeLa, HEK293 and 
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the breast tumour cell lines MCF7 and HTB19 (Cooper et al., 2008). 
Nonetheless, RASSF2 w as both cytoplasmic and nuclear in gastric cancer 
JRST cells w hen epitope tagged (Maruyama et al., 2008). RASSF2 regulates 
cell cycle and cell grow th in a nuclear localisation dependent manner (Kumari 
and Mahalingam, 2009) and it has a nucleo-cytoplasmic shuttling property 
(Kumari and Mahalingam, 2009). It has been also reported that in intestinal 
metaplasia RASSF2 localizes both to the cytoplasm and nucleus (Luo et al., 
2012). Finally in intraepithelial neoplasia, RASSF2 is dif fuse in cytoplasm and 
relocates to the nucleus to perform its functions (Guerrero-Setas et al., 2013). 
Therefore it is possible to describe RASSF2 as a shuttling protein that localises 
to both cytoplasm and nucleus but it seems to mediate its functions in the 
nucleus. 
RASSF3, the smallest member of RASSF family proteins, has not been 
extensively studied. There is one study show ing that GFP tagged RASSF3 
localizes to microtubules in vascular endothelial cells (Fujita et al., 2005). The 
subcellular localisation of RASSF4 has not been reported. 
RASSF5 (also know n as NORE1) has four isoforms (A -D). RASSF5A is 
reportedly centrosomally-localised w hen both endogenously expressed and 
GFP tagged in human lung epithelial cells (Moshnikova et al., 2006). In 
cancerous and normal A549 cell lines, overexpressed RASSF5A localises to 
the microtubules (Moshnikova et al., 2006). How ever, in Cos-7 cells, GFP-
RASSF5A w as present in both cytoplasm and nucleus w hereas GFP-RASSF5B 
w as localised only to the cytoplasm (Park et al., 2008). The same study also 
demonstrated that RASSF5A is a nucleo-cytoplasmic shuttling protein (Park et 
al., 2008). A further study indicated that RASSF5 is a nucleocytoplasmic 
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shuttling protein using a heterokaryon assay in HeLa cells (Kumari et al., 2010). 
Finally, there is evidence that RASSF5 and RASSF1A co-localise in the nucleus 
in Cos-7 cell lines (Donninger et al., 2014). There is no evidence for subcellular 
localisation of the shortest isoform, RASSF5C (also know n as NORE1B or 
RAPL).  
The literature describing the subcellular localisation of RASSF6 is limited. It has 
been show n in HeLa cells that FLAG-RASSF6 localises to both cytosol and the 
nucleus (Ikeda et al., 2007). In another report, GFP-RASSF6 localised to 
cytoplasm and to the basal portion of primary cilia in HK-2 cells (Withanage et 
al., 2012). More recently, RASSF6 w as detected in both the cytoplasm and 
nucleus (Huang et al., 2014). 
In summary, the subcellular localisation of classical RASSF family members is 
mainly observed in centrosomes, microtubules, cytoplasm and nucleus and in 
several cases w ith a nucleo-cytoplasmic shuttling property.  
3.1.2 Subcellular localisation of N-terminal RASSFs 
 
The literature concerning N-terminal RASSF members is much less extensive 
than for the classical family members and therefore these proteins w arrant 
further investigation. Evidence for the subcellular localisation of RASSF8 f irst 
came from Drosophila studies: endogenous RASSF8 co-localised w ith 
adherens junctions, especially w ith E-cadherin in w ing epithelial cells (Langton 
et al., 2009). Lock and colleagues continued localisation studies in human and 
show ed that endogenous RASSF8 w as present w ithin the nucleus and at the 
cell membrane, especially at sites of cell-cell contact in both parental A549 and 
H1792 lung cancer cells (Lock et al., 2010). This report supported Drosophila 
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data of RASSF8 co-localisation w ith E-cadherin (Langton et al., 2009). RASSF8 
immunostaining co-localised w ith the adherens junction components, β-catenin 
and E-cadherin, to regulate cell-cell adhesion (Lock et al., 2010).  
The only report concerning the subcellular localisation of RASSF9 (also know n 
as PCIP-1) show ed that w hen CHO and AtT-20 cells (f ibroblast and endocrine 
cell lines) w ere transfected w ith EGFP-RASSF9, RASSF9 associated w ith 
vesicles adjacent to the nucleus w hich appeared to be the recycling endosomes 
(Chen et al., 1998). These data have not been follow ed up and the subcellular 
localisation of endogenous RASSF9 remains to be elucidated.  
The latest member of the RASSF family to be identif ied, RASSF10, is co-
localised w ith tubulin at developing centrosomes during prophase and displays 
persistent localisation w ithin centrosomally radiating microtubule bundles until 
late telophase (Hill et al., 2011). The study also revealed putative nuclear 
localisation and export sequences on RASSF10, making it a potential nucleo-
cytoplasmic shuttling protein, similar to classical members, RASSF2 and 
RASSF5 (Hill et al., 2011; Richter et al., 2012). In KYSE150 cell lines, 
RASSF10 w as localised to the nucleus (Lu et al., 2014). Finally in SPCA-1 cells, 
RASSF10 localised at the cell membrane (Wang et al., 2014). 
In summary, there is less literature about the subcellular localisation of N-
terminal RASSF members. RASSF8 localised to junctions, RASSF9 may be 
nuclear and RASSF10 seemed to have a nucleo-cytoplasmic shuttling property, 
similar to classical members. 
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3.1.3 Subcellular localisation of RASSF7 
 
The f irst evidence show ing RASSF7 localisation came from Xenopus studies. 
Embryos injected either w ith an N-terminal GFP tagged RASSF7 or a C-
terminal HA tagged RASSF7 show ed co-localisation w ith centrosomes 
(Sherw ood et al., 2008). This w as show n by co-immunolabelling w ith the 
centrosomal protein, γ-tubulin.  
Subsequent w ork show ed that the localisation of human RASSF7 protein w as 
consistent w ith the Xenopus studies: RASSF7 co-localised w ith the centrosome 
(Recino et al., 2010). This w as show n for both endogenous and tagged 
RASSF7 in HeLa cells (Recino et al., 2010).  
3.1.4 Aims 
 
Although it has been show n that RASSF7 localises to the centrosome both in 
human and Xenopus, the mechanism underlying the subcellular localisation of 
RASSF7 remains elusive. This chapter w ill focus on:  
1. Investigating the domains responsible for centrosomal RASSF7 
localisation by using an N-terminal GFP-tag. 









3.2.1 Domain analysis of rassf7 and constructs 
 
To begin to understand the functional domains w ithin RASSF7, experiments 
focused on the domain that is responsible for centrosomal rassf7 localisation. 
Rassf7 is predicted to have an RA and a coiled-coil domain by the domain 
prediction programme, SMART (see Materials and Methods) (Figure 31A). In 
addition, there are tw o stretches of amino acids that are not predicted to form 
an identif iable domain by SMART, w hich have been called the A domain (region 
betw een the RA and the coiled-coil domains) and the B domain (C-terminal end 
of rassf7) (Figure 3.1A). Protein alignments w ere applied to reveal the similarity 
in domain architecture with human, mouse and Xenopus rassf7 proteins (Figure 
3.1B). RASSF7 amino acid sequences w ere obtained for the follow ing species; 
Homo sapiens (NP_003466, NP_001137465, NP_001137466; 3 splice 
variants), Mus musculus (NP_080162) and Xenopus laevis (NP_001086630, 
ABR21988). Amino acid sequences were obtained from the respective sources 
(See Materials and Methods), denoted here as NCBI accession numbers.  
A series of constructs w ere generated w ith site-directed mutagenesis, w hich 
coded for truncated versions of rassf7 fused to GFP (Figure 3.2) to study the 
role of rassf7 domains in rassf7 centrosomal localisation and RNA synthesised 
from these plasmids w as injected into tw o cell stage embryos. Successful 
injections w ere conf irmed by examining GFP expression in w hole amount stage 
10 embryos (Figure 3.3). The amount of centrosomal localisation show n by 
each truncated protein w as then analysed in cells from stage 10 embryos and is 





Human    1    MLLGLAAMELKVWVDGIQRVVCGVSEQTTCQEVVIALAQAIGQTGRFVLV 50 
Mouse         MVLELVAMELKVWVDGIQRVVCGVSEQTTCQEVVIALAQAIGQTGRFVLV 50 
Xenopus  1    -------MELKVWVDGVQRVVCGVSEQTSCQDVVIALAQAIGQTGRYVLI 43 
                     *********:***********:**:**************:**:                      
 
Human    1    QRLREKERQLLPQECPVGAQATCGQFASDVQFVLRRTGPSLAGRPSSDSC 100 
Mouse         QRLREKERQLLPQECPVGAQATCGQFANDVQFVLRRTGPSLSGRPSSDNC 100 
Xenopus  1    QTLRDKERQLLPHERPLEFLSKSGQYANDVHFILRRTGPSLAERPSSDTG 93 
              * **:*******:* *:   :..**:*.**:*:********: *****.  
  
Human    1    P-PPERCLIRASLPVKPRAAL-----GCEPRKTLT--------------- 129 
Mouse         P-PPERCPVRASLPPKPSAIP-----GREPRKALTFNL-----------R 133 
Xenopus  1    PVPPERTFVRSSLPLNTRTAGTEVTKSKEPKKSLTFNLGPIGSTDILSKH 143 
              * ****  :*:*** :. :       . **:*:**                
 
Human    1    -PEPAPSLSRPGPAAPVTPTPG--------CCTDLRGLELR--------- 161 
Mouse         CPKLVPSPSIPEPAALVGPIPD--------GFADLQDLELR--------- 166 
Xenopus  1    RQKQVNGTPVKDGSSPRPPSKEEIFKMVLRQQDQLKSLEMQNVSLGKDIQ 193 
                : . . .    ::   *              :*:.**::          
 
Human    1    ------------------------VQRNAEELGHEAFWEQELRREQARER 187 
Mouse         ------------------------IQRNTEELGHEAFWEQELQREQARER 192 
Xenopus  1    TWERGRAGRPMDQDEDEIAYLERLIQCNEAELGEEMFWEDELQRERAEEQ 243 
                                      :* *  ***.* ***:**:**:*.*: 
 
Human    1    EGQARLQALSAATAEHAARLQALDAQARALEAELQLAA---EAPGP-PSP 233 
Mouse         EGQARLQALSAATAEHAARLEALDAQACALEAELRLAA---EAPGP-PSA 238 
Xenopus  1    GRQEKMRKLRATMEEYTVKIQELTERTEALELEIQKETSKRLASGPSLTD 293 
                * ::: * *:  *::.::: *  :: *** *::  :    *.**  :  
 
Human    1     MASATERLHQDLAVQERQSAEVQGSLALVSRALEAAERALQAQAQELEEL 283 
Mouse          TASAAERLRQDLATQERHSLEMQGTLALVSQALEAAEHALQAQAQELEEL 288 
Xenopus  1     LEEMVIKMRKELETKIGQGRQLESNLSNVERACEEARRNLQARNQELDEV 343 
                 . . :::::* .:  :. :::..*: *.:* * *.: ***: ***:*: 
 
Human    1     NRELRQCNLQQFIQQTGAALPPPP-RPDRGP----PGTQGPLPPAREESL 328 
Mouse          NRELRQCNLQQFIQQTGAALPPPPPQLDRTI----PSTQDLLSPNRGE-L 333 
Xenopus  1     NKDLRQCNLQQFILQTGSTVTSAQLRPDEDPSLAEPHDVQWQNQQRNRGP 393 
               *::********** ***:::...  : *.      *         * .   
 
Human    1     LGAPS---ESHAGAQPRPRGGPHDAELL-EVAAAPAPEWCPLAAQPQAL 373 
Mouse          QGVPQ---SHILVSSLSP-----------EVPPMRQSSWR--------- 359 








Figure 3.1: RASSF7 domain architecture and protein alignments (A) Xenopus 
rassf7 domains and sequences. The RA and the coiled-coil domain are highlighted in 
green. (B) Protein alignments for human, mouse and Xenopus RASSF7s. Underlined 
residues indicate the RA and the coiled coil domains. Human and mouse have two 
separate predicted regions of coiled-coil, where Xenopus has one big predicted coiled-
coil region. * indicates positions which have a single, fully conserved residue, : 
indicates conservation between groups of strongly similar properties - scoring > 0.5 in 
the Gonnet PAM 250 matrix and . indicates conservation between groups of weakly 








Figure 3.2: GFP-rassf7 constructs. The series of constructs produced by site 
directed mutagenesis to allow expression of truncated versions of rassf7 fused to GFP. 
The RA and the coiled-coil domains are shown in green. The A and the B domains are 
shown in grey. The domain architecture of the following constructs: GFP-rassf7 (WT), 
GFP-rassf7 (RA+A+), GFP-rassf7 (RA+A+CC), GFP-rassf7 (RA), GFP-rassf7 
(A+CC+B), GFP-rassf7 (CC+B), GFP-rassf7 (A+CC), GFP-rassf7 (CC), GFP-rassf7 







Figure 3.3: Whole-mount images of stage 10 embryos expressing GFP-rassf7, 
GFP and truncated GFP-rassf7 proteins. Embryos were microinjected with RNA into 
the one cell at the two-cell stage, cultured until stage 10 and imaged as whole-mounts. 
GFP fluorescence is shown in green.GFP-rassf7 (RA+A+CC) and GFP-rassf7 (A+CC) 
showed more punctate GFP fluorescence when compared to other constructs and 




3.2.2 Analysis of the domains required for centrosomal localisation rassf7  
 
3.2.2.1 The coiled coil domain, but not the RA domain, is required for 
centrosomal rassf7 localisation 
 
The localisation of full-length rassf7 w as show n w ith GFP-rassf7 expressing 
cells, GFP-rassf7 co-localized w ith the centrosomal protein γ -tubulin (Figure 
3.4A) and w as used as a positive control. A GFP control, w hich did not show  
enrichment at the γ-tubulin spot w as used as a negative control. GFP-rassf7 
also show ed some nuclear localisation and sometimes some perinuclear or 
cortical enrichment. How ever, this staining is also seen in cells expressing the 
GFP control and so is not specif ic to the rassf7 protein. Data w ere quantif ied by 
intensity, size and integrated density (s ize x intensity) measurements (Figure 
3.4B). 
The domain analysis studies w ere initially performed w ith truncations at the N-
terminal end of rassf7. The GFP fusion protein w hich lacked the RA domain, 
GFP-rassf7 (A+CC+B), show ed a very similar pattern of localisation to full 
length GFP-rassf7, w ith clear localisation to γ-tubulin containing structures 
(Figure 3.4C). There w as no signif icant dif ference betw een GFP-rassf7 and 
GFP-rassf7 (A+CC+B) localisation in terms of size, intensity and integrated 
density of  the GFP-rassf7 at the γ-tubulin spot (Figure 3.5A, C and E).  
When both the A and the RA domain w ere removed, GFP-rassf7 (CC+B), a 
similar distribution w as observed. GFP-rassf7 (CC+B) w as able to localise to 
the centrosome w ith no signif icant dif ference to w ild type (Figure 3.4D). 
Quantif ication of size, intensity and integrated density of GFP-rassf7 at the γ-
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tubulin spot show ed that localisation did not change in GFP-rassf7 (CC+B) 
expressing cells. 
Further truncation of rassf7 to remove the coiled-coil domain as w ell as the RA 
and the A domains, GFP-rassf7 (B), resulted in a loss of the centrosomal 
localisation of rassf7 (Figure 3.4E) and a distribution resembling that of  the GFP 
control, data quantif ication w as consistent with confocal images (Figure 3.5A -F). 
The nuclear localisation, seen w ith the GFP control and full length GFP-rassf7, 
w as not lost and the ratio betw een centrosomal GFP and nuclear GFP w as 
reduced (appendix 4). This show s that the reduction in centrosomal GFP, seen 
w ith GFP-rassf7 (B), cannot be explained by a reduction in RASSF7 levels. 
These results suggest that the coiled coil domain is required for centrosomal 
rassf7 localisation w hereas the RA and the A domains are not required for 
centrosomal rassf7 localisation.  
The amount of γ-tubulin staining w as also measured follow ing expression of the 
GFP, GFP-rassf7, GFP-rassf7 (A+CC+B), GFP-rassf7 (CC+B) and GFP-rassf7 
(B) and there w as no signif icant dif ference betw een cells expressing positive 
control, negative control and three GFP-rassf7 domain constructs.  This show s 
that expression of these constructs did not lead to signif icant changes in γ -























Figure 3.4: The coiled-coil, but not the RA domain, is required for centrosomal 
rassf7 localisation. Embryos were microinjected with RNA at the two-cell stage, 
cultured until stage 10, fixed, sectioned and stained with a centrosomal marker (γ-
tubulin/red) and a nuclear marker (DAPI/blue). GFP fluorescence is shown in green. 
(A) GFP-rassf7 (green) co-localised with γ-tubulin (red) (arrows) as previously shown 
(Sherwood et al., 2008). (B) GFP negative control, GFP (green) and γ-tubulin (red, 
arrows). (C) GFP-rassf7 (A+CC+B) (green) co-localised with γ-tubulin (red). (D) GFP-
rassf7 (CC+B) (green) co-localised with γ-tubulin (red).  (E) GFP-rassf7 (B) (green) did 
not show significant co-localisation with γ-tubulin (red). Arrows highlight potential area 


































Figure 3.5: Quantification of the localisation of GFP-rassf7 domain constructs. 
Embryos were microinjected with RNA at the two-cell stage, cultured until stage 10, 
fixed, sectioned and images of the GFP fluorescence and γ-tubulin staining were 
collected by confocal microscopy. Example images are shown in the previous figure. 
The fluorescent area and intensity of the γ-tubulin staining and GFP was measured by 
using the LSM510 Image Browser software (ZEISS) and the integrated density was 
calculated by multiplying the area by the average intensity across the region of interest. 
(A) Intensity of GFP fluorescence at the γ-tubulin spot for the GFP-rassf7 fusion 
proteins and the positive and negative controls (GFP-rassf7 and GFP). Intensity of 
GFP-rassf7 (B) was similar to the negative control. (B) Intensity of γ-tubulin staining. 
Expression of truncated GFP-rassf7 proteins did not affect the intensity of the γ-tubulin 
staining. (C) Size of the GFP at the γ-tubulin spot. Size of GFP-rassf7 (B) was similar 
to negative control.  (D) Size of the γ-tubulin spot. Expression of truncated GFP-rassf7 
proteins did not affect the size of the γ-tubulin spot. (E) Integrated density of GFP 
fluorescence at the γ-tubulin spot for the GFP-rassf7 fusion proteins and the positive 
and negative controls (GFP-rassf7 and GFP). Integrated density of GFP-rassf7 (B) was 
similar to negative control (F) Integrated density of γ-tubulin. Expression of truncated 
GFP-rassf7 proteins did not affect the integrated density of the γ-tubulin staining. 
Based on at least three independent experiments, bars represent standard error and 
were calculated and plotted using GraphPad Prism 6. Statistical analysis was carried 
out using One-way Anova tests with Bonferroni post-test corrections. >100 cells were 







3.2.2.2 Removal of the B domain caused accumulation of rassf7 at the 
centrosomes and increased levels of γ-tubulin staining 
 
Having studied the N-terminal truncations, the next sets of truncations w ere 
performed from the C-terminal end of rassf7. Removal of  the B domain, GFP-
rassf7 (RA+A+CC), did not disrupt the ability of  the protein to localise at the 
centrosome (Figure 3.6A). In fact, there w as a striking increase in GFP signal 
that overlapped w ith the γ-tubulin spot (Figure 3.6A). Quantif ication revealed 
that there w as a greater than f ivefold increase in the amount of GFP (in size 
and integrated density but not in intensity) that overlapped w ith the γ -tubulin 
spot (Figure 3.7A, C and E). This effect w as so dramatic that it w as possible to 
observe GFP containing punctae in w hole amount embryos (Figure 3.3). 
In addition, cells expressing GFP-rassf7 (RA+A+CC) had a fourfold increase in 
the amount of γ-tubulin staining in comparison to controls (Figure 3.7B, D and 
F). This suggests that expression of this truncated version of rassf7 can affect 
centrosomal morphology. 
Removal of  the coiled-coil and the B domain, GFP-rassf7 (RA+A), caused a 
loss of co-localisation w ith γ-tubulin (Figure 3.6B), consistent w ith the coiled-coil 
domain being required for centrosomal rassf7 localisation. Quantif ication of the 
size, intensity and the integrated density of GFP-rassf7 at the γ-tubulin spot 
show ed the signif icant decrease in three measurements for GFP-rassf7 (RA+A) 
expressing cells (Figure 3.7A, C and E) w hereas there w as no signif icant 
change in γ-tubulin staining (Figure 3.7B, D and F).  
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The RA domain on its ow n, GFP-rassf7 (RA), also failed to co-localise w ith γ-
tubulin (Figure 3.6C) w hich suggests the RA domain is not suff icient for 
centrosomal rassf7 localisation. Follow ing expression of GFP-rassf7 (RA), there 






























Figure 3.6: Removal of the B domain led to accumulation of truncated rassf7 at γ-
tubulin spot and increased γ-tubulin staining. Embryos were microinjected with 
RNA at the two-cell stage, cultured until stage 10, fixed, sectioned and stained with a 
centrosomal marker (γ-tubulin/red) and a nuclear marker (DAPI/blue). GFP 
fluorescence is shown in green. (A) GFP-rassf7 (RA+A+CC) (green) co-localised with 
γ-tubulin (red). There appeared to be increased localisation and also enlargement of 
the γ-tubulin staining. (B) GFP-rassf7 (RA+A) did not show co-localisation with γ-
tubulin (red) (C) GFP-rassf7 (RA) (green) did not show co-localisation with γ-tubulin 























Figure 3.7: Quantification of the localisation of GFP-rassf7 domain constructs. 
Embryos were microinjected with RNA at the two-cell stage, cultured until stage 10, 
fixed, sectioned and images of the GFP fluorescence and γ-tubulin staining were 
collected by confocal microscopy. Example images are shown in the previous figure. 
The fluorescent area and intensity of the γ-tubulin staining and GFP was measured by 
using the LSM510 Image Browser software (ZEISS) and the integrated density was 
calculated by multiplying the area by the average intensity across the region of interest.  
(A) Intensity of GFP fluorescence at the γ-tubulin spot. GFP-rassf7 (RA+A+CC) 
showed a similar intensity to wild type with a non-significant increase whereas GFP-
rassf7 (RA+A) and GFP-rassf7 (RA) showed significant decrease (B) Intensity of the γ-
tubulin spot did not change among the constructs or controls. (C) Size of the GFP at 
the γ-tubulin spot. GFP-rassf7 (RA+A+CC) size was increased at least four fold. (D) 
Size of the γ-tubulin spot. In GFP-rassf7 (RA+A+CC) injected cells size of the γ-tubulin 
spot was significantly increased (more than fourfold). (E) Integrated density of GFP 
fluorescence at the γ-tubulin spot. GFP-rassf7 (RA+A+CC) showed an increased 
integrated density when compared to wild type. (F) Integrated density of the γ-tubulin 
spot. GFP-rassf7 (RA+A+CC) showed an increased integrated density when compared 
to wild type. Based on at least three independent experiments, bars represent standard 
error and were calculated and plotted using GraphPad Prism 6. Statistical analysis was 
carried out using One-way Anova tests with Bonferroni post-test corrections. >100 cells 







3.2.2.3 The coiled-coil domain is sufficient for centrosomal rassf7 
localisation 
The f inal set of  constructs investigated allow ed expression of the internal 
domains of rassf7. GFP-rassf7 (A+CC) lacks the N-terminal RA domain and the 
C-terminal B domain, but w as still able to co-localise w ith γ-tubulin (Figure 
3.8A). Similar to rassf7 w hich lacked just the B domain, there w as also greater 
than a f ive-fold increase in GFP that overlapped w ith the γ -tubulin and a four-
fold increase in γ-tubulin staining (Figure 3.9). 
The coiled-coil of  rassf7 on its ow n, GFP-rassf7 (CC), w as able to localise to 
centrosomes (Figure 3.8B) at a level comparable to full length GFP-rassf7 
(Figure 3.9). This suggests that the coiled-coil domain is suff icient for 
centrosomal rassf7 localisation, building on observations described above 
show ing the requirement of the coiled-coil domain for centrosomal rassf7 
localisation. Expression of GFP-rassf7 (CC) did not result in increased γ -tubulin 
staining (Figure 3.9B, D and F). This suggests that the combination of the 
coiled-coil and the A domain are required for aberrant accumulation at 
centrosomes of both rassf7 and γ-tubulin. The f inal truncated protein expressed 
w as GFP-rassf7 (A), w hich failed to co-localise w ith γ-tubulin (Figure 3.8C and 
Figure 3.9A, C and E) and did not have any effect on centrosomal morphology 
(Figure 3.9B, D and F). The results from all the constructs are summarised in 
















Figure 3.8: The coiled-coil domain is sufficient for the centrosomal localisation of 
rassf7. Embryos were microinjected with RNA at the two-cell stage, cultured until 
stage 10, fixed, sectioned and stained with a centrosomal marker (γ-tubulin/red) and a 
nuclear marker (DAPI/blue). GFP fluorescence is shown in green. (A) GFP-rassf7 
(A+CC) (green) co-localised with γ-tubulin (red). Accumulation at the centrosome and 
enlargement of γ-tubulin staining was also seen. (B) GFP-rassf7 (CC) (green) co-
localised with γ-tubulin (red). (C) GFP-rassf7 (A) (green) did not show co-localisation 

























Figure 3.9: Quantification of the localisation of GFP-rassf7 domain constructs. 
Embryos were microinjected with RNA at the two-cell stage, cultured until stage 10, 
fixed, sectioned and images of the GFP fluorescence and γ-tubulin staining were 
collected by confocal microscopy. Example images are shown in the previous figure. 
The fluorescent area and intensity of the γ-tubulin staining and GFP was measured by 
using the LSM510 Image Browser software (ZEISS) and the integrated density was 
calculated by multiplying the area by the average intensity across the region of interest. 
(A) Intensity of the GFP at the γ-tubulin spot. GFP-rassf7 (A) showed a significantly 
decreased intensity compared to wild type rassf7, GFP-rassf7 (CC) was similar to wild 
type rassf7 and GFP-rassf7 (A) was similar to the GFP negative control. (B) Intensity of 
the γ-tubulin spot did not change among the constructs or controls. (C) Size of the GFP 
at the γ-tubulin spot. GFP-rassf7 (A+CC) size was significantly increased, GFP-rassf7 
(CC) was similar to wild type rassf7 and GFP-rassf7 (A) was similar to the GFP 
negative control. (D) Size of the γ-tubulin spot. In GFP-rassf7 (A+CC) injected cells 
size of the γ-tubulin spot was significantly increased. (E) Integrated density of the GFP 
at the γ-tubulin spot. GFP-rassf7 (A+CC) showed a significantly increased integrated 
density compared to wild type rassf7, GFP-rassf7 (CC) was similar to wild type rassf7 
and GFP-rassf7 (A) was similar to the GFP negative control. (F) Integrated density of 
the γ-tubulin spot. GFP-rassf7 (A+CC) showed an increase in the integrated density of 
γ-tubulin when compared to the wild type rassf7. GFP-rassf7 (CC) and GFP-rassf7 (A) 
did not affect the integrated density of γ-tubulin. Based on at least three independent 
experiments, bars represent standard error and were calculated and plotted using 
GraphPad Prism 6. Statistical analysis was carried out using One-way Anova tests with 




Table 3.1: The ability of truncated rassf7 proteins to localise at the centrosome 
and promote increased γ-tubulin staining.  
GFP domain construct Centrosomal localization Increased γ-tubulin staining 
GFP-rassf7 (WT)   
GFP-rassf7 (RA+A+CC)   
GFP-rassf7 (RA+A)   
GFP-rassf7 (RA)   
GFP-rassf7 (A+CC+B)   
GFP-rassf7 (CC+B)   
GFP-rassf (A+CC)   
GFP-rassf7 (CC)   
GFP-rassf7 (A)   










3.2.2.4 Identification of hydrophobic residues critical for coiled-coil 
structure 
Having show n that the coiled-coil domain is necessary and suff icient for rassf7 
to localise to centrosomes; further investigations w ere performed.  To determine 
w hether the coiled-coil structure of rassf7 is required for centrosomal 
localisation, mutations designed to disrupt the helical nature of the coiled coil 
sequence w ere introduced and localisation of the mutants analysed.  
Coiled-coils are protein structural motifs that have been the subject of  intense 
research due to their predicted prevalence in proteins and interesting potential 
applications (Grigoryan and Keating, 2008). The name and structure of the 
coiled-coil domain w ere suggested for the f irst time in 1953 by Crick, af ter 
studying the structure of α-keratin (Crick, 1953). In fact, more than 5% open 
reading frames in eukaryotes are predicted to encode coiled-coils (Schnell et 
al., 2005). 
In a typical coiled-coil, bundles of α-helices are w rapped around each other to 
form a lef t-handed super helical structure to form bundles (Mason and Arndt, 
2004). Coiled-coils made of tw o, three or four helices are most commonly 
observed (Figure 3.10); how ever, coiled-coils that consist of  f ive or more helices 
also exist (Lupas and Gruber, 2005).  Characteristically, the amino acid side 
chains are packed in a ‘knobs-into-holes’ manner, as the helices are w rapped 
around each other (Crick, 1953). This requires the characteristic feature of all 
coiled-coils: each helix is encoded by a seven-residue repeat, know n as a 
heptad repeat (Grigoryan and Keating, 2008). The number of heptad repeats in 
each helix varies largely, f rom tw o to tw o hundred repeats. Each heptad repeat 
is denoted as a-b-c-d-e-f-g (Figure 3.10) (Mason and Arndt, 2004). 
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Figure 3.10: The heptad repeats of a coiled-coil. The coiled coils illustrated are a 
dimer, made up of two helices (a) and a tetramer, made up of four helices (b). The 
heptad repeats are denoted by the letters abcdefg, shown with blue and yellow circles. 
Blue circles are indicating the hydrophobic residues and yellow circles are indicating 
polar/charged residies. Adapted from (Grigoryan and Keating, 2008). 
 
Although the heptad repeats imply simplicity at the sequence level, coiled-coils 
have complex and diverse structures (Grigoryan and Keating, 2008).. 
Hydrophobic-polar patterning is w hat determines the orientation and specif icity 
of each coiled-coil. Therefore, each individual amino acid plays an important 
role in maintaining the structure and interactions of a coiled-coil. In general 
hydrophobic residues (e.g. leucine or valine) are found in positions a and d on 
the same side of the helix, and form the  interface betw een  tw o helices w ith a 
polar/charged residues (e.g. lysine or glutamate) found in positions e and g 
(Mason and Arndt, 2004).  
The dimerization of helices is largely facilitated by the non-polar nature of the a 
and d residues. This is evident by the fact that coiled-coils w ith a high 
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percentage of hydrophobic residues at positions a and d are more stable than 
coiled coils w ith a low er percentage (Mason and Arndt, 2004). Studies 
examining the important role of the a and d residues in the stability of  coiled 
coils have provided a better understanding of coiled coil structure; mutating 
these residues changes the dimerization interface and may even disrupt the 
coiled-coil structure completely. Indeed, a number of studies have mutated 
hydrophobic residues to investigate the role of coiled coil domain in the function 
or localisation of a protein of interest. One example is a study by Cheng et al. 
(2001), w ho introduced leucine-to-proline substitutions into coiled coil homology 
domain of the protein kinase c-Fes (Cheng et al., 2001). Wild type, single and 
double point mutant Fes proteins, tagged w ith GFP, w ere expressed in Rat-2 
f ibroblasts. The results show ed that one point mutation (L145P) caused a 
dramatic increase in the tyrosine kinase activity of Fes, w hile a dif ferent point 
mutation (L334P) had no effect. Of note, the combination of both mutations 
(L145P+L334P) caused a reduction in the kinase activity by almost 50%. This 
study emphasizes the importance of selecting appropriate mutations, since 
dif ferent point mutations have dif ferent eff ects on protein function and possibly 
localisation.  
Importantly, it needs to be taken under consideration that sometimes polar 
residues can be found at positions a and d; these polar residues confer 
specif icity, as hydrophobic interactions are often non-specif ic, although many 
times this compromises the stability of  the coiled coil (Mason and Arndt, 2004). 
In a large study by Tripet and colleagues, 20 dif ferent amino acid residues were 
substituted at position d of a model coiled coil protein to examine their ef fects 
on stability (Tripet et al., 2000). As expected, the results revealed that the 
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stability of  the coiled coil w as correlated w ith the hydrophobic ity of the side 
chain. Interestingly, the results show ed that, w hen proline w as incorporated at 
position d, the formation of coiled coil w as prevented. The same result w as also 
observed in a similar study, in w hich 20 dif ferent amino acid residues w ere 
substituted at position a of a model coiled coil protein (Wagschal et al., 1999). 
In conclusion, these results suggest that disruption of coiled coil conformation 
can be best achieved w hen hydrophobic residues at positions a and d are 
substituted w ith proline. Proline is a helix breaker because being an imino acid 
(not an amino acid) it disrupts the hydrogen bonding pattern in alpha helices. 
In this study the RASSF protein alignments of human, mouse and Xenopus 
w ere compared for identif ication of conserved hydrophobic leucine, isoleucine 
and valine residues (Figure 3.11) as these hydrophobic residues w ere mutated 
in the previous studies. Xenopus rassf7 (isoform ABR21988.1) w as marked w ith 
conserved hydrophobic residues w ithin the coiled-coil domain and fourteen 
conserved residues were shown (Figure 3.12). The conserved residues, w hich 
w ould disturb the coiled coil conformation to the greatest extent, w ere assessed 
using the The simple Modular Architecture Research Tool (SMART) prediction 
program and these residues were substituted for proline. This approach allow ed 
the identif ication of key residues and w as an alternative to trying to identify and 
mutate all residues in A and D positions, w hich may have been dif f icult due to a 
lack of structural studies on RASSF7. The mutants w ould help to further assess 






Human    1    MLLGLAAMELKVWVDGIQRVVCGVSEQTTCQEVVIALAQAIGQTGRFVLV 50 
Mouse         MVLELVAMELKVWVDGIQRVVCGVSEQTTCQEVVIALAQAIGQTGRFVLV 50 
Xenopus  1    -------MELKVWVDGVQRVVCGVSEQTSCQDVVIALAQAIGQTGRYVLI 43 
                     *********:***********:**:**************:**:                      
 
Human    1    QRLREKERQLLPQECPVGAQATCGQFASDVQFVLRRTGPSLAGRPSSDSC 100 
Mouse         QRLREKERQLLPQECPVGAQATCGQFANDVQFVLRRTGPSLSGRPSSDNC 100 
Xenopus  1    QTLRDKERQLLPHERPLEFLSKSGQYANDVHFILRRTGPSLAERPSSDTG 93 
              * **:*******:* *:   :..**:*.**:*:********: *****.  
  
Human    1    P-PPERCLIRASLPVKPRAAL-----GCEPRKTLT--------------- 129 
Mouse         P-PPERCPVRASLPPKPSAIP-----GREPRKALTFNL-----------R 133 
Xenopus  1    PVPPERTFVRSSLPLNTRTAGTEVTKSKEPKKSLTFNLGPIGSTDILSKH 143 
              * ****  :*:*** :. :       . **:*:**                
 
Human    1    -PEPAPSLSRPGPAAPVTPTPG--------CCTDLRGLELR--------- 161 
Mouse         CPKLVPSPSIPEPAALVGPIPD--------GFADLQDLELR--------- 166 
Xenopus  1    RQKQVNGTPVKDGSSPRPPSKEEIFKMVLRQQDQLKSLEMQNVSLGKDIQ 193 
                : . . .    ::   *              :*:.**::          
 
Human    1    ------------------------VQRNAEELGHEAFWEQELRREQARER 187 
Mouse         ------------------------IQRNTEELGHEAFWEQELQREQARER 192 
Xenopus  1    TWERGRAGRPMDQDEDEIAYLERLIQCNEAELGEEMFWEDELQRERAEEQ 243 
                                      :* *  ***.* ***:**:**:*.*: 
 
Human    1    EGQARLQALSAATAEHAARLQALDAQARALEAELQLAA---EAPGP-PSP 233 
Mouse         EGQARLQALSAATAEHAARLEALDAQACALEAELRLAA---EAPGP-PSA 238 
Xenopus  1    GRQEKMRKLRATMEEYTVKIQELTERTEALELEIQKETSKRLASGPSLTD 293 
                * ::: * *:  *::.::: *  :: *** *::  :    *.**  :  
 
Human    1     MASATERLHQDLAVQERQSAEVQGSLALVSRALEAAERALQAQAQELEEL 283 
Mouse          TASAAERLRQDLATQERHSLEMQGTLALVSQALEAAEHALQAQAQELEEL 288 
Xenopus  1     LEEMVIKMRKELETKIGQGRQLESNLSNVERACEEARRNLQARNQELDEV 343 
                 . . :::::* .:  :. :::..*: *.:* * *.: ***: ***:*: 
 
Human    1     NRELRQCNLQQFIQQTGAALPPPP-RPDRGP----PGTQGPLPPAREESL 328 
Mouse          NRELRQCNLQQFIQQTGAALPPPPPQLDRTI----PSTQDLLSPNRGE-L 333 
Xenopus  1     NKDLRQCNLQQFILQTGSTVTSAQLRPDEDPSLAEPHDVQWQNQQRNRGP 393 
               *::********** ***:::...  : *.      *         * .   
 
Human    1     LGAPS---ESHAGAQPRPRGGPHDAELL-EVAAAPAPEWCPLAAQPQAL 373 
Mouse          QGVPQ---SHILVSSLSP-----------EVPPMRQSSWR--------- 359 
Xenopus  1     MDSPPRPSSNHLMGHPRNLQNPMVSGLSPEVLSSREASWT--------- 433 
 
Figure 3.11: Conserved hydrophobic (leucine, isoleucine and valine) residues of 
RASSF7 coiled coil domain in human, mouse and Xenopus. The proposed coiled-
coil domain of Xenopus rassf7 is underlined. Conserved residues are highlighted. 
Yellow highlighted residues indicate conservation in human, mouse and Xenopus and 
green highlighted residues are conserved in human and mouse but are different in 
Xenopus. 
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3.2.2.5 Point mutations in the coiled-coil domain reduced the centrosomal 
localisation of GFP-rassf7 
Once identif ied, hydrophobic amino acids w ere substituted individually for the 
helix disrupting amino acid proline. As discussed previously, studies have 
show n that proline disrupts the coiled-coil conformation w hen introduced at a 
and d positions. The simple Modular Architecture Research Tool (SMART) w as 
used to predict the effects of each mutation on the coiled-coil structure. 
Mutations predicted to disturb the coiled-coil structure to a signif icant extent, 
w ere selected to further assessment of the requirement of the coiled-coil 
domain for localisation. Three point mutations (leucine 235 to proline, leucine 
235 and isoleucine 263 to proline, leucine 235, isoleucine 263 and leucine 350 
to proline) (Figure 3.13A) w ere made w hich replace hydrophobic amino acids 
(leucine or isoleucine) w ith prolines according to their predicted effect on coiled-
coil structure. These are predicted to disrupt the three dimensional structure of 
the coiled-coil according to SMART prediction (Figure 3.13). The single point 
mutation predicted not to affect signif icantly the structure of the coiled-coil 
(Figure 3.11 GFP-rassf7 (RA+A+CC’+B)), also did not af fect the centrosomal 
localisation of GFP-rassf7 (Figure 3.14A + Figure 3.15). The double point 
mutation predicted to disrupt the structure of the coiled-coil (Figure 3.13 GFP-
rassf7 (RA+A+CC’’+B)), had only a small measurable effect on the centrosomal 
localisation of GFP-rassf7 (Figure 3.14B + Figure 3.15). The triple mutation, 
w hich w as predicted to cause almost complete loss of the coiled-coil structure 
(Figure 3.13 GFP-rassf7 (RA+A+CC’’’+B)), show ed signif icantly less 
centrosomal localisation than w ild type rassf7 (Figure 3.14C + Figure 3.15), 
consistent w ith the coiled-coil domain being required for the localisation of 
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rassf7. Statistical analysis show ed that the effect of  triple mutation w as 
signif icant (Figure 3.13). In conclusion, point mutations in the coiled-coil, GFP-
rassf7 (RA+A+CC’’’+B), predicted to disrupt the coiled-coil conformation 
signif icantly, reduced the centrosomal rassf7 localisation, w hich supports the 



























Figure 3.12: Identification of conserved hydrophobic residues in rassf7 coiled-
coil domain in Xenopus. Conserved hydrophobic residues in the coiled-coil domain 
of rassf7 (Xenopus isoform ABR21988.1) are highlighted in yellow. The underlined 
residues indicate the coiled-coil domain. Due to lack of structural studies on rassf7 
coiled-coil, exact positions of the a and d residues were not clear. Therefore mutations 
were based on SMART predictions of the most important conserved hydrophobic 



























Figure 3.13: The predicted domain architecture of the coiled-coil domain point 
mutations. Constructs were made that contained mutations in the coiled coil region. 
Three mutations were made using site directed mutagenesis; GFP-rassf7 
(RA+A+CC’+B) with one point mutation (leucine 235 to proline), GFP-rassf7 
(RA+A+CC’’+B) with two point mutations (leucine 235 and isoleucine 263 to proline) 
and GFP-rassf7 (RA+A+CC’’’+B) with three point mutations (leucine 235, isoleucine 














Figure 3.14: Mutations in the coiled coil domain reduced the centrosomal 
localisation of GFP-rassf7. Embryos were microinjected with RNA at the two-cell 
stage, cultured until (stage 10), fixed, sectioned and stained with a centrosome marker 
(γ-tubulin /red) and a nuclear marker (DAPI/blue). GFP fluorescence is shown in green.  
(A) GFP-rassf7 (RA+A+CC’+B) (green) co-localised with γ-tubulin (red). (B) GFP-
rassf7 (RA+A+CC’’+B) (green) co-localised with γ-tubulin (red). (C) GFP-rassf7 
(RA+A+CC’’’+B) (green) showed decreased co-localisation with γ-tubulin (red). In 

























Figure 3.15: Quantification of the localisation of point mutations on the coiled-
coil domain. Embryos were microinjected with RNA at the two-cell stage, cultured until 
stage 10, fixed, sectioned and images of the GFP fluorescence and γ-tubulin staining 
were collected by confocal microscopy. Example images are shown in the previous 
figure. The fluorescent area and intensity of the γ-tubulin staining and GFP was 
measured by using the LSM510 Image Browser software (ZEISS) and the integrated 
density was calculated by multiplying the area by the average intensity across the 
region of interest. A) Intensity of the GFP fluorescence at the γ-tubulin spot was 
significantly decreased but not lost in GFP-rassf7 (RA+A+CC’’’+B) injected cells. 
(B)Intensity of γ-tubulin. Expression of truncated GFP-rassf7 proteins did not affect the 
intensity of the γ-tubulin staining. (C) Size of the GFP fluorescence at the γ-tubulin 
spot.  (D) Size of the γ-tubulin spot was not affected from the injections. E) Integrated 
density of the GFP fluorescence at the γ-tubulin spot. GFP-rassf7 (RA+A+CC’’’+B) 
showed reduced centrosomal localisation when compared to the wild type protein. (F) 
Integrated density of the γ-tubulin spot. Mutations did not affect the integrated density 
of the γ-tubulin staining. Based on at least three independent experiments, bars 
represent standard error and were calculated and plotted using GraphPad Prism 6. 
Statistical analysis was carried out using One-way Anova tests with Bonferroni post-








3.2.3 Identification of Potential Phosphorylation sites on rassf7 
Further investigations focused on identif ication of potential phosphorylation sites 
w ithin RASSF7 in order to understand the effects of potential phosphorylation 
sites on centrosomal rassf7 localisation. As discussed in Chapter 1, most 
centrosomal proteins have their localisation and/ function regulated through 
phosphorylation. Mutating potential phosphorylation sites (based on the 
hypothesis that predicted phosphorylation sites are phosphorylated in rassf7) 
w ould provide a f irst step in indicating if  phosphorylation is important for correct 
rassf7 localisation. 
Human, mouse and Xenopus RASSF7 amino acid sequences w ere screened 
w ith a post-translational modif ication prediction site, ELM (see Materials and 
Methods) to identify predicted phosphorylation sites, especially  sites that may 
be modif ied by kinases implicated in regulating cell division/mitosis. Four 
interesting groups of potential phosphorylation sites w ere predicted by ELM at 
f irst glance: PKA, PLK, CDK1 and PIKK (Figure 3.16). A predicted PLK 
phosphorylation site w as seen in each of the three species, w ith dif ferences in 
sequence position but all w ere located w ithin the B domains, w hich made it a 
possible candidate to mutate. Absence of this predicted phosphorylation site 
could be responsible for the accumulation seen w hen the B domain GFP-rassf7 
(RA+A+CC) is not present (Figure 3.6A). The other three predicted 
phosphorylation sites w ere not seen in the three species therefore experiments 
focused on the predicted phosphorylation site, PLK,  Plk as a mitotic kinase, 
potentially has a role related to RASSF7’s mitotic function. 
Another group of potential sites to search for w ere Aurora A kinase sites, given 
RASSF7’s role in mitosis and its centrosomal localisation.  RASSF7 exhibits 
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strong parallels w ith Aurora A in its prominent overexpression in cancers and its 
role at the centrosome and MT dynamics in mitosis, thus raising the question of 
w hether Aurora A phosphorylates and interacts and/or regulates RASSF7 
localization. How ever, no obvious Aurora A phosphorylation sites w ere 
predicted w ith ELM. Thus, to identify potential Aurora A kinase phosphorylation 
sites, the broad Aurora A phosphorylation consensus, K/R-X-T/S (w here X is 
any amino acid) (Alexander et al., 2011; Kettenbach et al., 2011) w as used to 
select and identify candidate motifs. Furthermore, RASSF1A, w hich has also 
been show n to play a signif icant role on MTs in mitosis , is phosphorylated and 
regulated by Aurora A (Rong et al., 2007). In addition, RASSF1A is 
phosphorylated by additional kinases (PKA and PKC) at the same site as 
Aurora A (Richter et al., 2010). Thus, predicted phosphorylation sites identif ied 
(particularly for PKA) w ere also screened for Aurora A’s consensus 
phosphorylation sequence (Figure 3.16, presented in red). Four motifs 
apparently satisf ied the consensus on RASSF7. Of these, tw o motifs (R-R-T-G, 
R-P-S-S-D) exhibited very high conservation betw een three species, w hile the 
other tw o (R-A/S-S-L, K/R-R-T/A/S-L) w ere not conserved.  
Because of the know n importance of phosphorylation by mitotic kinases, 
experiments w ere focused on mutating the predicted PLK phosphorylation site 






















Figure 3.16: Predicted phosphorylation sites on RASSF7. Human, mouse and 
Xenopus RASSF7 proteins were aligned via CLUSTAL. Potential protein kinase A 
(PKA), polo-like kinase (Plk), cyclin-dependant kinase 1 (Cdk1) and 
Phosphatidylinositol 3-kinase-related kinase (PIKK) phosphorylation sites were 
predicted with ELM. Overlaps in predicted phosphorylation sites are highlighted in grey. 
Four highly conserved, potential Aurora A phosphorylation sites (highlighted by red 
lines) were identified by scanning predicted PKA phosphorylation sites for similarity 
with the broad Aurora A phosphorylation consensus, K/R-X-T/S (where X is any amino 
acid). In addition, amino acid residues of RASSF7 corresponding to the identified 
phosphorylated Ser/Thr motif on RASSF1A (via alignment) are represented in red. The 
serine/threonine residues that were used for alanine and aspartic acid substitution are 













3.2.3.1 Mutating the potential PLK site on rassf7 did not change the 
centrosomal localisation of rassf7 
In order to investigate the importance of phosphorylation in rassf7 centrosomal 
localisation, the predicted PLK phosphorylation site w as mutated. The amino 
acids that are phosphorylated include serine, threonine and tyrosine because 
they contain a -OH group substitutable by a phosphate group.  Serine 374 
(Figure 3.16) w ithin the PLK site w as mutated using site-directed mutagenesis 
in tw o alternative forms; a serine to alanine (S374-A) substitution (alanine 
contains an inert alkyl side-group) that is a non-phosphorylatable residue and a 
serine to aspartic acid (S374-D) substitution (aspartic acid retains a negatively 
charged carboxy side group), w hich mimics phosphorylation of serine (see 
Materials and Methods). Tw o substitutions; GFP-rassf7 (S374-A) and GFP-
rassf7 (S374-D) w ere applied to further study the centrosomal localisation of 
rassf7. 
GFP-rassf7 (S374-A) and GFP-rassf7 (S374-D) expressing cells show ed a 
similar localisation of rassf7 to the centrosome as the w ild type (Figure 3.17A 
and B). Preventing phosphorylation of the predicted PLK site via an alanine 
substitution and mimicking the phosphorylation by an aspartic acid substitution 
appeared to have no effect on centrosomal rassf7 localisation (Figure 3.18A, C 
and E) and no effect on γ-tubulin staining (Figure 3.18B, D and F).  
This result suggests that phosphorylation of the predicted PLK site w ithin rassf7 











Figure 3.17: Mutating the predicted PLK site does not change the centrosomal 
rassf7 localisation. Embryos were microinjected with RNA at the two-cell stage, 
cultured until (stage 10), fixed, sectioned and stained with a centrosome marker (γ-
tubulin /red) and a nuclear marker (DAPI/blue). GFP fluorescence is shown in green.   
(A) GFP-rassf7 (S374-A) (green) co-localised with γ-tubulin (red). (B) GFP-rassf7 
(S374-D) (green) co-localised with γ-tubulin (red). Arrows highlight the potential area 




























Figure 3.18: Quantification of the localisation of mutated predicted PLK site on 
rassf7. Embryos were microinjected with RNA at the two-cell stage, cultured until 
stage 10, fixed, sectioned and images of the GFP fluorescence and γ-tubulin staining 
were collected by confocal microscopy. Example images are shown in the previous 
figure. The fluorescent area and intensity of the γ-tubulin staining and GFP was 
measured by using the LSM510 Image Browser software (ZEISS). (A) Intensity of the 
GFP at the γ-tubulin spot. (B) Intensity of the γ-tubulin spot. (C) Size of the GFP at the 
γ-tubulin spot. (D) Size of the γ-tubulin spot. No significant changes were observed. 
Based on at least three independent experiments, bars represent standard error and 
were calculated and plotted using GraphPad Prism 6. Statistical analysis was carried 
out using One-way Anova tests with Bonferroni post-test corrections. >100 cells were 











3.2.3.2 Mutating the potential Aurora A phosphorylation sites on rassf7 
did not change centrosomal localisation of rassf7 
Having studied the effect of  mutating the predicted PLK phosphorylation site on 
rassf7 centrosomal localisation, the effects of Aurora A’s consensus 
phosphorylation sites w ere then examined. Of the potential Aurora A 
phosphorylation sites identif ied as described above, the RSSL motif , matching 
best w ith a more stringent predicted Aurora A phosphorylation consensus, K/R-
X-S/T-ϕ (w here X and ϕ represent any amino acid and hydrophobic residue, 
respectively) (Alexander et al., 2011; Dephoure et al., 2008; Kettenbach et al., 
2011) w as selected for substitution w ith alanine and aspartic acid. Serine 104 
and 105 w ere coding for one predicted Aurora a phosphorylation s ite (Figure 
3.16) so mutation of single predicted Aurora A phosphorylation site w as applied 
by substitution of tw o serine residues to alanine (S/104,105-A) and to aspartic 
acid (S/104,105-D). See f igure 3.16 (boxes) for the serine residues that are 
used for substitution.  
GFP-rassf7 (S/104,105-A) expressing cells show ed a similar localisation of 
rassf7 to the centrosome as the w ild type (Figure 3.19A). Preventing the 
phosphorylation of one predicted Aurora A phosphorylation site by alanine 
substitution appeared to have no effect on centrosomal rassf7 localisation 
(Figure 3.20A, C and E) and no effect on γ -tubulin staining (Figure 3.20B, D and 
F). 
GFP-rassf7 (S/104,105-D) expressing cells also show ed a similar localisation of 
rassf7 to the centrosome as the w ild type (Figure 3.19B). Mimicking the 
phosphorylation of one predicted Aurora A phosphorylation site by an aspartic 
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acid substitution did not af fect the centrosomal localisation of rassf7 (Figure 
3.20A, C and E) and did not af fect γ-tubulin staining (Figure 3.20B, D and F). 
No change w as observed in centrosomal localisation of rassf7 and γ -tubulin 
staining w ith mutating one predicted Aurora A phosphorylation site either w ith 
alanine or aspartic acid substitution. In addition, the three most conserved 
motifs (RRTG, RPSSD, RSSL) w ere also selected for combined mutation to 
give a mutation of three dif ferent predicted Aurora A phosphorylation sites (triple 
mutant; a total of  f ive Ser/Thr residues: T80, S89, 90,104,105 w ere substituted 
and annotated as S/T5-A and S/T5-D in Figure 3.19). 
Remarkably, GFP-rassf7 (S/T5-A) and GFP-rassf7 (S/T5-D) triple mutants 
yielded similar results to single mutants. They w ere both able to co-localise w ith 
γ-tubulin (Figure 3.19C and D) w ith no signif icant dif ference than w ild type 
rassf7 levels (Figure 3.20A, C and E). Mutating the triple predicted Aurora A 
phosphorylation sites also did not change the γ -tubulin staining (Figure 3.20B, 
D and F). 
This result suggests that, similar to predicted PLK site, phosphorylation of the 
predicted Aurora A sites w ithin rassf7 does not play a direct role in centrosomal 




















Figure 3.19: Mutating the predicted PKA sites did not change the centrosomal 
rassf7 localisation. Embryos were microinjected with RNA at the two-cell stage, 
cultured until (stage 10), fixed, sectioned and stained with a centrosome marker (γ-
tubulin /red) and a nuclear marker (DAPI/blue). GFP fluorescence is shown in green.   
A) GFP-rassf7 (S104,105-A) (green) co-localised with γ-tubulin (red). (B) GFP-rassf7 
(S104,105-D) (green) co-localised with γ-tubulin (red). (C) GFP-rassf7 (S/T5-A) (green) 
co-localised with γ-tubulin (red). (D) GFP-rassf7 (S/T5-D) (green) co-localised with γ-























Figure 3.20: Quantification of the localisation of mutated predicted PKA sites on 
rassf7. Embryos were microinjected with RNA at the two-cell stage, cultured until 
stage 10, fixed, sectioned and images of the GFP fluorescence and γ-tubulin staining 
were collected by confocal microscopy. Example images are shown in the previous 
figure. The fluorescent area and intensity of the γ-tubulin staining and GFP was 
measured by using the LSM510 Image Browser software (ZEISS). (A) Intensity of the 
GFP at the γ-tubulin spot. (B) Intensity of the γ-tubulin spot. (C) Size of the GFP at the 
γ-tubulin spot. (D) Size of the γ-tubulin spot. No significant changes were observed. 
Based on at least three independent experiments, bars represent standard error and 
were calculated and plotted using GraphPad Prism 6. Statistical analysis was carried 
out using One-way Anova tests with Bonferroni post-test corrections. >100 cells were 














In the present chapter, the domain responsible for centrosomal RASSF7 
localisation has been investigated in Xenopus laevis. The key f indings are that 
the coiled-coil domain is suff icient and required for centrosomal rassf7 
localisation. In contrast, the RA domain does not seem to be responsible for 
centrosomal localisation of rassf7. Constructs w hich lacked the B domain, but 
contained the A domain and the coiled-coil domain, show ed aberrant 
accumulation at the centrosomes and resulted in an abnormal increase of γ -
tubulin staining at centrosomal punctae. Finally , mutating the predicted PLK and 
Aurora A phosphorylation sites did not have any signif icant effects on 
centrosomal rassf7 localisation. 
3.3.1 The coiled-coil domain is key in driving centrosomal rassf7 
localisation 
Data presented here show s that the coiled-coil domain is key in driving the 
localisation of rassf7 to the centrosome. Previous proteomic characterisation of 
centrosomes found that a high percentage of centrosomal proteins contain a 
coiled-coil (Andersen et al., 2003) and many centrosome proteins w ith coiled-
coils have been studied. These include, pericentrin (Doxsey et al., 1994), Ninein 
(BoucksonCastaing et al., 1996), Hice1 (Wu et al., 2008), TASS (Gergely et al., 
2000a; Gergely et al., 2000b) centriolin (Gromley et al., 2003), Cep135 
(Gromley et al., 2003), C-Nap1 (Fry et al., 1998a) and Pix1/2 (Hames et al., 
2008). Previous studies have also show n that coiled coil domains can mediate 
centrosome localisation. For example, TACC proteins have a C-terminal coiled-
coil domain w hich is required for interactions w ith the centrosomes (Gergely et 
al., 2000a). Therefore, show ing that the coiled-coil of  rassf7 is suff icient and 
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required for centrosomal localisation, it supports the idea that coiled-coils play a 
key role in mediating centrosome localisation of the proteins.  
A coiled-coil is a protein-protein interaction domain and it may be regulating 
centrosomal localization of RASSF7 by interacting w ith mitotic regulatory 
proteins. For example, Pascreau et al have identif ied a centrosomal localization 
signal w hich localizes cyclin A to the centrosome independent of Cdk binding, 
and contributes to targeting and recognition of centrosomal Cdk substrates 
(Pascreau et al., 2010). Therefore, searching for motifs w ithin the RASSF7 
coiled-coil region that may play a role in centrosome localization came next: f irst 
a single point mutation, predicted to disrupt the coiled-coil domain w as 
introduced to rassf7. The centrosomal rassf7 localisation did not change w ith 
the single point mutation. A previous study show ed that a single mutation is not 
suff icient to effect the localisation: the localisation of HIP1 w ith a single point 
mutation in its coiled-coil domain w as similar to the localisation of the w ild type 
HIP1 (Fontaine et al., 2012). Importantly, w hen tw o or more mutations w ere 
introduced into the coiled-coil domain of HIP1, protein aggregates w ere 
observed in a proportion of cells and HIP1 lost its normal localisation pattern 
(Fontaine et al., 2012). Similarly, w hen more than tw o mutations w ere 
introduced to rassf7, the centrosomal localisation w as signif icantly reduced. It 





3.3.2 The RA domain and the A domain did not appear essential for 
centrosomal localisation of rassf7 
The other domains of rassf7 did not appear necessary for its centrosomal 
localisation. These included the RA domain, making it likely that the role of this 
domain is to interact w ith effector molecules, potentially recruiting them to the 
centrosome w here they may regulate mitosis. RASSF7 has been show n to bind 
NRas (Takahashi et al., 2011), HRas and KRas via the RA domain (Chan et al., 
2013) in pull dow n experiments w ith tagged proteins, although it remains to be 
conf irmed that RASSF7 is binding endogenous Ras family members. Recent 
proteomic studies have show n that RASSF7 can interact w ith a number of other 
cellular proteins, including ASPP and PP1 family members (Hauri et al., 2013). 
dRASSF8, the Drosophila homologue of RASSF7 and RASSF8, can also bind 
dASPP; although dRASSF8 protein localises at epithelial junctions rather than 
the centrosomes (Langton et al., 2009). Future w ork is needed to establish 
w hether the RA and A domains, either in concert or independently, bring these 







3.3.3 Removal of the B domain led to accumulation of rassf7 at the 
centrosomes and increased levels of γ-tubulin staining 
 
Removing the B domain of rassf7 had a striking effect on its localisation, w ith a 
far greater amount of rassf7 co-localising w ith γ-tubulin. There are a number of 
possible models to explain this result. The B domain might act as an auto-
inhibitory domain that binds to the coiled coil of  rassf7 in a regulated w ay and 
w hile in a closed conformation blocks the coiled coil f rom binding centrosomal 
proteins. Removing the B domain could then cause unregulated accumulation 
of rassf7 at the centrosome. This w ill be investigated w ith the functional studies 
of the rassf7 B domain in next chapter.  
Another possible explanation for the increased RASSF7 localization to the 
centrosome w hen the B domain w as removed can be caused by a mechanism 
such as ubiquitination in the B domain. Ubiquitins regulate protein degradation 
via the proteasome. Takahashi et al., suggested a ubiquitin proteasome 
pathw ay for RASSF7 by show ing a reduction in RASSF7 expression in cells 
w hich are treated by a proteasome inhibitor (Takahashi et al., 2011). Zhao et al 
show ed the accumulation of parkin (a protein linked to Parkinson disease) to 
the centrosome w hen cells w ere treated w ith a proteasome inhibitor (Zhao et 
al., 2003). If  there is such a ubiquitination mechanism in the B domain; it may 
be possible that loss of the B domain prevents ubiquitination. Therefore excess 
RASSF7 does not become targeted to the proteasome and instead 
accumulates at the centrosome. Thus no RASSF7 is available for transpor t to 
the nucleus.  This could be tested by measuring the ubiquitination in the GFP-
RASSF7 domain construct lacking a B domain to determine w hether the 
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increased RASSF7 centrosomal accumulation phenotype occurs or not. 
Examining protein levels of RASSF7 w ould also be informative. 
A related model is that the B domain acts to control the turnover of rassf7 at 
centrosomes by an unknow n mechanism. Consistent w ith this proposal, there 
are predicted phosphorylation sites for a number of mitotic kinases in the B 
domain that could potentially regulate rassf7 turnover. Phosphorylation can alter 
the structure, function, interaction and subcellular localisation of proteins and it 
is vital for regulating the cell cycle (Cohen, 2000). ELM identif ied potential 
phosphorylation sites w ithin the RASSF7 protein and the predicted PLK 
phosphorylation site w as f irst chosen for mutation. Although this site is not 
conserved betw een species, its presence in human, Xenopus and mouse 
suggests that it may have an important role. The PLKs are a group of 
serine/threonine kinases localised to the centrosome w hich play an important 
role in spindle assembly, cytokinesis and centrosome separation (Nigg, 1998). 
RASSF7 knockdow n causes severe defects in spindle formation (Recino et al., 
2010; Sherw ood et al., 2008) and associations of PLKs w ith the centrosome led 
to interest in this predicted phosphorylation site. Biochemical and genetic 
analysis has show n the importance of PLKs in regulating centrosome behaviour 
(Lee et al., 1998). Moreover, overexpression of PLKs in tumour cell lines 
causes early centrosome maturation resulting in mitotic defects and leads to 
apoptosis (Takai et al., 2005). The authors further suggest that overexpression 
of PLK causes early centrosome maturation, increase in centrosome size 
leading to chromosome instability (Takai et al., 2005). How ever, mutating the 
predicted PLK phosphorylation site in rassf7 w ith either an alanine or aspartic 
acid mutation did not af fect the ability of  rassf7 to localise to the centrosome. 
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Signif icantly, mutating the predicted PLK site in the B domain did not result in a 
similar phenotype (accumulation of rassf7 at the centrosome and increased γ-
tubulin staining) to truncating the entire B domain.  
Another potentially important phosphorylation site to mutate w as the PKA 
phosphorylation site. Interestingly, PKA has also been show n to associate w ith 
the centrosome and MTs, w hose kinase activity is thought to regulate several 
aspects of mitosis (Matyakhina et al., 2002; Searle and Sanchez, 2004) and 
indeed, PKA-phosphorylation w as seen to negatively regulate RASSF1A 
(Richter et al., 2010). Thus, it can be speculated that PKA itself  might 
phosphorylate RASSF7 to regulate its localization and/or function. Furthermore, 
the consensus for PKA phosphorylation highly resembles that of  Aurora A, 
conf irming that Aurora A phosphorylation sites might overlay those of PKA  
(Kettenbach et al., 2011; Neuberger et al., 2007). Thus, upon identif ication of 
potential Aurora A phosphorylation sites (w ithin predicted PKA phosphorylation 
sites), mutations w ere introduced to the sites to observe their possible effects 
on centrosomal rassf7 localisation. Intriguingly, neither single nor triple mutation 
of the potential Aurora A phosphorylation sites had any effect on the 
centrosomal rassf7 localisation. Thus, it appears that predicted Aurora A 
phosphorylation at these motifs does not regulate RASSF7 localization. 
How ever, both the PLK and Aurora mutation studies should be considered as 
preliminary as the sites studied are only predicted sites and localisation w as the 
only aspect of RASSF7 function that w as investigated. Future w ork is required 




In conclusion, the coiled-coil of  Xenopus rassf7 is responsible for driving its 
centrosomal localisation. The RA domain and the A domain did not seem to 
have any role in this process. The removal of  the B domain caused an 
accumulation of GFP at the centrosomes and an enlargement of centrosomes 
that w ill be investigated in more detail w ithin the next chapter. Finally, mutation 
of the predicted phosphorylation sites on rassf7 did not af fect the centrosomal 


















4 Truncated rassf7 causes centrosome and mitotic 
defects and ultimately cell death 
4.1 Introduction 
Having show ed in the previous chapter that C-terminal truncation of rassf7 
causes an accumulation of GFP at the centrosomes and enlargement of 
centrosomes; this chapter w ill focus on the possible causes/consequences of 
these f indings. 
4.1.1 RASSF7 and cancer 
The expression of RASSF7 w as show n to be increased in a number of tumour 
types (Friess et al., 2003; Li et al., 2013c; Logsdon et al., 2003; Low e et al., 
2007; Tan et al., 2009), but it is not clear if  RASSF7 can promote tumour 
formation. The previous w ork on RASSF7 show ed that overexpression of w ild 
type RASSF7, carried out for localisation and rescue experiments, did not have 
a clear effect on HeLa cells or Xenopus embryos (Recino et al., 2010; 
Sherw ood et al., 2008). In the previous chapter (Chapter 3) it has been show n 
that the w ild type full length GFP-rassf7 did not have any strong effect on 
centrosomes or on the localisation pattern of the protein but w hen truncated, 
GFP-rassf7 (RA+A+CC), caused an accumulation of GFP at the centrosomes 
and centrosome enlargements (see Chapter 3 results).  
As discussed in the main introduction, centrosome amplif ications/abnormalities 
are linked to mitotic defects and they w ere also show n to be a biomarker of 
cancer cells (see Chapter 1). Furthermore, enlarged centrosome phenotype 
w as show n in some particular cell types, such as breast cancer (Guo et al., 
2007b) and bladder cancer (Jiang et al., 2003). Therefore, investigating the 
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effects of the C-terminal truncation w ill be informative to explore role of RASSF7 
in cancer. 
 
4.1.2 An auto-inhibitory model for the C-terminal B domain 
Although it has been show n in the previous chapter that C-terminal truncation 
causes accumulation of GFP at the centrosomes, the key question is w hy 
truncation causes accumulation? One possible explanation for this f inding could 
be an auto-inhibitory role for the B domain. The C-terminal B domain could be 
an auto-inhibitory domain that interacts w ith another domain/domains of the 
protein and stabilizes its localisation w ithin the cell.  
Auto-inhibitory domains are regions of proteins that negatively regulate the 
function of other domains via intra-molecular interactions (Pufall and Graves, 
2002) (Figure 4.1). Plk-4 tandem polo box domain (PB1) is a good example for 
auto inhibitory domains those regulate protein function/activation (Klebba et al., 
2015). Regarding to f indings reported in this thesis, an autoinhibitory role w ill be 





Figure 4.1: Autoinhibition as a regulatory mechanism. An autoinhibitory domain 
modulates the activity of a second, separable domain (centre). Autoinhibition can be 
counteracted and reinforced by modification (left) or by association with a second 
molecule, partner protein (right). Autoinhibition is often identified experimentally by 
deletion of the autoinhibitory domain. Proteolysis is also a regulatory strategy in vivo 
(lower). Figure adapted from (Pufall and Graves, 2002).  
 
4.1.3 Aims  
This chapter w ill investigate if  GFP-rassf7 (RA+A+CC) causes mitotic defects 
and its role/link, if  there is any, in/w ith cancer cells and w ill test an auto-
inhibitory role for the B domain w ith the aims listed below : 
1) Establish if  truncated rassf7 causes mitotic defects. 
2) Investigate the mechanism of w hy accumulation occurs. 
3) Find out if  similar truncations occur in human tumours. 
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4.2 Results 
4.2.1 GFP-rassf7 (RA+A+CC) promoted amplification of the Ƴ-tubulin spot 
To begin to investigate the aberrant centrosomal morphology observed in cells 
expressing C-terminally truncated rassf7 in more detail, an analysis of the 
number of Ƴ-tubulin spot per cell w as carried out. This w ould show  if  C-terminal 
truncation w ould cause supernumerary centrosomes, w hich is common in 
cancer cells. 
Cells expressing GFP or w ild type GFP-rassf7 had one or tw o Ƴ-tubulin spots 
depending on their cell cycle stage (Figure 4.2A and B). How ever, in cells 
expressing GFP-rassf7 (RA+A+CC) there w ere often three or more Ƴ-tubulin 
spots (Figure 4.2C). Quantif ication of centrosome number (Ƴ -tubulin spot) 
show ed that unlike controls, GFP-rassf7 (RA+A+CC) injected cells frequently 
have more than tw o Ƴ-tubulin spot (Figure 4.3). In summary, C-terminal 
truncation of rassf7 caused an increased number of Ƴ-tubulin spot as w ell as an 
increase in the size of the Ƴ-tubulin spot, suggesting an increase in the number 





Figure 4.2: Expression of GFP-rassf7 (RA+A+CC) caused increased numbers of 
γ-tubulin spot. Embryos were microinjected with RNA at the two-cell stage, cultured 
until stage 10, fixed, sectioned and stained with a centrosomal marker (γ-tubulin/red) 
and a nuclear marker (DAPI/blue). GFP fluorescence is shown in green. (A) GFP 
(green) and γ-tubulin (red). (B) GFP-rassf7 (green) and γ-tubulin (red). (C) GFP-rassf7 
(RA+A+CC) (green) and γ-tubulin (red). Cells expressing GFP-rassf7 (RA+A+CC) 


















Figure 4.3: Quantification of centrosome numbers. Embryos were microinjected 
with RNA at the two-cell stage, cultured until stage 10, fixed, sectioned and images of 
the GFP fluorescence and γ-tubulin staining were collected by confocal microscopy. 
Centrosome number for GFP, GFP-rassf7 and GFP-rassf7 (RA+C+CC) injected cells 
were counted. Unlike controls, GFP-rassf7 (RA+A+CC) injected cells frequently have 
more than two γ-tubulin spot. Based on at least three independent experiments.>100 










4.2.2 GFP-rassf7 (RA+A+CC) endorsed increased number of mitotic cells 
Given the apparent abnormalities in the centrosomes (increased size and 
number of Ƴ-tubulin spot), the functional consequences of these defects w ere 
then investigated by analysing the proportion of cells in mitosis. This w as 
achieved by staining for Phospho-H3 (Figure 4.4). GFP-rassf7 (RA+A+CC) 
(Figure 4.4C) expressing cells had more Phospho-H3 positive cells than GFP 
(Figure 4.4A) and GFP-rassf7 (Figure 4.4B) injected cells (Figure 4.5). 
Therefore, it is possible to hypothesise that the centrosomal abnormalities 
caused by expression of GFP-rassf7 (RA+A+CC) lead to a delay in progression 



















Figure 4.4: GFP-rassf7 (RA+A+CC) injected cells accumulate in mitosis. Embryos 
were microinjected with RNA at the two-cell stage, cultured until stage 10, fixed, 
sectioned and stained with a mitosis marker (Phospho-H3/red) and a nuclear marker 
(DAPI/blue). GFP fluorescence is shown in green. (A) GFP (green) injected cells were 
stained for Phospho-H3 (red). (B) GFP-rassf7 (green) injected cells were stained for 
Phospho-H3 (red). (C) GFP-rassf7 (RA+A+CC) (green) injected cells were stained for 
Phospho-H3 (red). The number of Phospho-H3 positive cells increased when 
compared to GFP and GFP-rassf7. In panels A-C arrows highlight example nuclear 
















Figure 4.5: Quantification of Phospho-H3 positive cells. Embryos were 
microinjected with RNA at the two-cell stage, cultured until stage 10, fixed, sectioned 
and images of the GFP fluorescence and phospho-H3 staining were collected by 
confocal microscopy. The percentage of GFP positive cells that are Phospho-H3 
positive was calculated. Based on at least three independent experiments, bars 
represent standard error and were calculated and plotted using GraphPad Prism 6. 
Statistical analysis was carried out using One-way Anova tests with Bonferroni post-










4.2.3 GFP-rassf7 (RA+A+CC) injected embryos showed increased embryo 
death and lost the centrosomal localisation at later stages in development 
Having show n that GFP-rassf7 (RA+A+CC) caused centrosomal defects, 
follow ing experiments focused on investigating the long-term consequences of 
expressing this construct. GFP-rassf7 (RA+A+CC) injected embryos w ere 
cultured and rates of embryo death monitored. Uninjected, GFP injected and 
GFP-rassf7 injected embryos show ed some death during development (Figure 
4.6A). How ever, the rate of embryo death w as signif icantly increased in 
embryos injected w ith GFP-rassf7 (RA+A+CC) (Figure 4.6A). 
Some stage 30 embryos, expressing GFP-rassf7 (RA+A+CC) did how ever 
survive (Figure 4.6B), allow ing the study of the subcellular localisation of w ild 
type rassf7 and C-terminally truncated rassf7 at this stage. GFP and GFP-
rassf7 in stage 30 embryos show ed similar subcellular distributions to stage 10, 
w ith cytoplasmic and centrosomal localisation respectively (Figure 4.7A and B). 
How ever, unexpectedly GFP-rassf7 (RA+A+CC) did not co-localise w ith Ƴ-
tubulin in stage 30 embryos (Figure 4.7C). Where the GFP-rassf7 (RA+A+CC) 
w as expressed, the cells did not appear to have clear Ƴ-tubulin spot. This led 
the question of w hether there w as increased programmed cell death, 















Figure 4.6: GFP-rassf7 injected embryos at tadpole stages. Embryos were 
microinjected with RNA at the two-cell stage, cultured until tadpole stages (stage 30), 
fixed, sectioned and stained with a centrosomal marker (γ-tubulin/red) and a nuclear 
marker (DAPI/blue). GFP fluorescence is shown in green. (A) Embryo survival for 
uninjected, GFP injected, GFP-rassf7 injected and GFP-rassf7 (RA+A+CC) injected 
embryos. Based on at least three independent experiments, >60 embryos were 




























Figure 4.7: Stage 30 embryos lost the centrosomal localisation of GFP-rassf7 
(RA+A+CC). Embryos were microinjected with RNA at the two-cell stage, cultured until 
stage 30, fixed, sectioned and images of the GFP fluorescence and γ-tubulin staining 
were collected by confocal microscopy (A) GFP (green) expressing cells stained with γ-
tubulin (red) from stage 30 embryos. (B) GFP-rassf7 (green) expressing cells stained 
with γ-tubulin (red) from stage 30 embryos. (C) GFP-rassf7 (RA+A+CC) (green) 
expressing cells stained with γ-tubulin (red) at stage 30. Unlike the situation at stage 
10, the GFP-rassf7 (RA+A+CC) fluorescence (green) did not co-localise with γ-tubulin 






4.2.4 GFP-rassf7 (RA+A+CC) injected cells showed cell death at stage 30  
To determine w hether the loss of centrosomal localisation in GFP-rassf7 
(RA+A+CC) expressing cells w as due to the programmed cell death, cells w ere 
stained for the apoptosis marker, active caspase-3 (Figure 4.8). GFP (Figure 
4.8A) and GFP-rassf7 (Figure 4.8B) expressing control cells show ed low  levels 
of active caspase-3 staining. In contrast, a high percentage of GFP-rassf7 
(RA+A+CC) (Figure 4.8C) expressing cells w ere positive for active caspase-3 
(Figure 4.9). These data suggest that early centrosome defects may lead to 




















Figure 4.8: GFP-rassf7 injected cells undergo increased rates of apoptosis. 
Embryos were microinjected with RNA at the two-cell stage, cultured until tadpole 
stages (stage 30), fixed, sectioned and stained with an apoptosis marker (Active 
caspase-3/red) and a nuclear marker (DAPI/blue). GFP fluorescence is shown in 
green. (A) GFP injected cells (green) were stained with an antibody against active 
caspase-3 (red). (B) GFP-rassf7 injected cells (green) were stained with an antibody 
against active caspase-3 (red). (C) GFP-rassf7 (RA+A+CC) injected cells (green) were 
stained an antibody against active caspase-3 (red). GFP-rassf7 (RA+A+CC) 
expressing cells showed increased levels of active caspase-3 (red) positive nuclei 















Figure 4.9: Quantification of active caspase positive cells. Embryos were 
microinjected with RNA at the two-cell stage, cultured until stage 30, fixed, sectioned 
and images of the GFP fluorescence and active caspase-3 staining were collected by 
confocal microscopy.  The % percentage of GFP positive cells which were active 
caspase-3 positive was calculated. Based on at least three independent experiments, 
bars represent standard error and were calculated and plotted using GraphPad Prism 
6. Statistical analysis was carried out using One-way Anova tests with Bonferroni post-






4.2.5 Does the B domain have an auto-inhibitory role? 
The accumulation of GFP at the centrosomes and enlargement of the 
centrosomes w ere observed in GFP-rassf7 (RA+A+CC) injected cells (see 
chapter 3) and led to the question: w hy does removing the B domain cause this 
effect? One possible explanation for this f inding could be an auto-inhibitory role 
for the B domain (see chapter 4 introduction).  
To test this hypothesis, injection of GFP-rassf7 (B) and GFP-rassf7 (RA+A+CC) 
w as carried out at the same time. If  the C-terminal B domain is an auto-
inhibitory domain, rescue of the phenotype (accumulation of GFP at the 
centrosome and enlargement of centrosomes) would be expected (Figure 4.10).  
Figure 4.11 show s the centrosomal localisation of the rescue experiments. 
When GFP-rassf7 (B) and GFP-rassf7 (RA+A+CC) w ere injected together, 
some of the GFP expressing cells show ed similar GFP expression and γ-tubulin 
staining to the w ild type w hereas some other cells still show ed GFP 
accumulation and enlargement of γ-tubulin (Figure 4.11C). Quantif ication of the 
results indicated that GFP-rassf7 (RA+A+CC) + GFP-rassf7 (B) show ed 
reduced GFP accumulation and less enlarged centrosomes compared to w ild 
type GFP-rassf7 (RA+A+CC) (Figure 4.12).  
This indicates that addition of the GFP-rassf7 (B) partially rescues the effect of  
GFP-rassf7 (RA+A+CC) and this is consistent w ith the auto-inhibitory model for 














Figure 4.10: Schematic diagram of predicted auto-inhibitory role for the C-
terminal B domain. (A) In the presence of the B domain, autoinhibition occurs and 
centrosomal localisation of rassf7 is regulated. (B) In the absence of the B domain, 





























Figure 4.11: Effects of the rescue experiment on the centrosomal localisation of 
rassf7. Embryos were microinjected with RNA at the two-cell stage, cultured until 
stage 10, fixed, sectioned and images of the GFP fluorescence and γ-tubulin staining 
were collected by confocal microscopy.(A) GFP-rassf7 (B) expressing cells (green) did 
not show co-localisation with γ-tubulin (red) (arrows). (B) GFP-rassf7 (RA+A+CC) 
(green) co-localised with γ-tubulin (red) (arrows) and also showed accumulation of 
GFP at the centrosomes and an enlargement of centrosomes (see chapter 3). (C) 
When GFP-rassf7 (B) was expressed with GFP-rassf7 (RA+A+CC), cells showed co-
localisation with γ-tubulin (red) (arrows). Some cells were similar to GFP-rassf7 
(RA+A+CC), while others were similar to the wild type GFP-rassf7. Arrows highlight 





































Figure 4.12: Quantification of the effects of the rescue experiment on 
centrosomal localisation of rassf7. Embryos were microinjected with RNA at the 
two-cell stage, cultured until stage 10, fixed, sectioned and images of the GFP 
fluorescence and γ-tubulin staining were collected by confocal microscopy. Example 
images are shown in the previous figure. The fluorescent area and intensity of the γ-
tubulin staining and GFP was measured by using the LSM510 Image Browser software 
(ZEISS) and the integrated density was calculated by multiplying the area by the 
average intensity across the region of interest. (A) The intensity of GFP signal for GFP-
rassf7 (RA+A+CC) + (B) was similar to full length GFP-rassf7 protein. (B) The intensity 
of γ-tubulin did not change after expressing the constructs. (C, D, E, F) The size of the 
GFP, size of the γ-tubulin spot, integrated density of GFP and integrated density of the 
γ-tubulin spot was significantly increased in GFP-rassf7 (RA+A+CC)+(B) expressing 
cells when compared to GFP-rassf7, but showed a significant decrease compared to 
GFP-rassf7 (RA+A+CC). Based on at least three independent experiments, bars 
represent standard error and were calculated and plotted using GraphPad Prism 6. 
Statistical analysis was carried out using One-way Anova tests with Bonferroni post-












4.2.6 Analysis of RASSF7 mutations in human cancers  
Truncated rass7, w hich lacks its C-terminal B domain, can drive centrosomal 
abnormalities (enlarged and increased numbers of Ƴ -tubulin spot), something 
that is of ten seen in cancer cells. This led to the question if  there are any 
mutations of RASSF7 in human cancer samples similar to C-terminal truncation. 
To establish if  similar truncations might occur, a database of mutations in 
human cancers has been searched.  
The cBioPortal database w as used to search sequence data from eighty 
dif ferent cancer studies for alterations in RASSF7 (Figure 4.13). RASSF7 w as 
found to be amplif ied in a number of tumours, consistent w ith previous reports 
of increased RASSF7 expression (see introduction to the chapter). Tw enty -
three cancers, w hich had mutations in RASSF7, w ere also identif ied (Figure 
4.14). The mutations w ere mainly missense mutations, but there w ere tw o 
nonsense mutations and one deletion that w ould be predicted to truncate 
RASSF7 (Figure 4.14). One of the nonsense mutations and the deletion w ere 
predicted to produce protein that w ould be truncated in or near the RA domain 
(Figure 4.14A and B). My data suggests that these are unlikely to localise to the 
centrosome and may be hypomorphs. The nonsense mutation, f rom a renal 
clear cell carcinoma, w hich is at R285 w ould be predicted to be truncated at the 
end of the coiled coil (Figure 4.14C). This resembles GFP-rassf7 (RA+A+CC) 
(Figure 3.2), and raises the possibility that in this cancer truncated RASSF7 













Figure 4.13: RASSF7 alterations in human cancer samples. Alterations in RASSF7 
were identified in cancer studies using the cBioPortal for cancer genomics website. 
There are various alterations in the RASSF7 gene including, mutations (shown in 
green), deletions (shown in blue) and amplifications (shown in red). Multiple alterations 












Figure 4.14: RASSF7 mutations in human cancers (red: nonsense mutations or 
deletions, green: missense mutations). Three nonsense mutations were applied to 
human RASSF7 protein sequence and domain architectures were predicted using 
SMART. The predicted domain architecture of RASSF7 for the three nonsense 
mutations represented as A, B and C. Mutation A, R285* Mutation B, S97*. Mutation C, 













In the current chapter, the effects of the C-terminal truncation on rassf7 function 
have been investigated. Experiments focused on the effect of  the C-terminal 
truncation and data show ed that C-terminal truncation of rassf7 causes 
supernumerary γ-tubulin spot, consistent w ith supernumerary centrosomes, 
increased number of mitotic cells and cell death later on development. The 
proposed auto-inhibitory role for the C terminal B domain w as tested by a 
rescue approach and the data show ed that adding GFP-rassf7 (B) as w ell as 
the GFP-rassf7 (RA+A+CC) partially rescues the accumulation of GFP at the 
centrosomes and the enlargement of centrosomes. Finally, a similar truncation 
has been identif ied in a human tumour samples. This data proposes that 
RASSF7 might act as an oncogene in a small subset of tumours w hen 
truncated C-terminally. 
 
4.3.1 The C-terminal truncation, centrosomal amplifications, increased 
mitotic levels and cell death  
In this current chapter expressing a tagged full length rassf7 did not drive 
alterations in centrosome size, number, mitotic cells or cell death. This suggests 
that increased levels of w ild type RASSF7 w hen expressed in w ild type cells 
may not act in an oncogenic role, although RASSF7 can also protect against 
stress induced cell death, an aspect that I have not investigated here 
(Takahashi et al., 2011). In contrast to the w ild type protein, expression of 
truncated rassf7, w hich lacked the B domain, caused elevated amounts of γ -
tubulin staining at γ-tubulin spot and an increased number of γ -tubulin spot per 
cell. This phenotype resemble the enlargement and amplif ication of 
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centrosomes that can occur in cancer cells (Godinho and Pellman, 2014; 
Godinho et al., 2014; Nigg, 2006) and recent evidence suggests that 
centrosome amplif ication can drive cellular invasion (Godinho et al., 2014). 
How ever, the mechanism/mechanisms that drive the centrosome amplif ications 
still remain elusive. One possibility could be that the GFP-rassf7 (RA+A+CC) 
expressing cells may have errors during the centrosome cycle. The results 
reported in this thesis referred to centrosomes and centrosomal amplif ications 
by looking at γ-tubulin spot, how ever other centrosomal markers are needed for 
further conf irmation and understanding of the mechanism causing the defects 
discussed above. For this purpose, a centriole marker antibody (centrin) that is 
predicted to w ork in Xenopus, w as tried but didn’t w ork. Future w ork w ill need to 
look at other centrosomal markers. Furthermore, it w ould be interesting to see 
the GFP-rassf7 (RA+A+CC) expressing cells’ centrosomes w ith electron 
microscopy. This w ould help to identify if  the C-terminal truncation causes 
centrosome structural defects.  
In GFP-rassf7 (RA+A+CC) expressing cells increased levels of mitosis w ere 
detected by Phospho-H3 staining, this is consistent w ith the f inding that extra 
centrosomes prolong mitosis in human cells (Yang et al., 2008). Later in 
development GFP-rassf7 (RA+A+CC) expressing cells did not appear to have a 
clear γ-tubulin spot, how ever the cells show ed increased programmed cell 
death. This could be associated w ith the apparent loss of γ -tubulin spot or it 
may be possible that the cells undergo apoptosis and therefore lose their γ -




4.3.2 An auto-inhibitory role for the C-terminal B domain 
As seen in the chapter 3 the coiled coil domain w as suff icient and required for 
centrosomal localisation of rassf7, w hereas an accumulation of rassf7 at the 
centrosome and an enlargement of centrosomes w as seen w hen the B domain 
w as removed. This raises the possibility that the B domain might act as an auto-
inhibitory domain and stabilizes centrosomal localisation of rassf7. Auto-
inhibitory domains are regions of proteins that negatively regulate the function 
of other domains via molecular interactions (see chapter introduction and Figure 
4.1).   
The results and the model proposed here suggested that removing the B 
domain could cause unregulated accumulation of rassf7 at the centrosome. 
Therefore, adding the B domain back to rassf7 might rescue the effects. Results 
show ed that the rescue w as partial.  The partial rescue seen in the results might 
be due to lack of modif ications or interactions w hen the autoinhibitory domain is 
added separately. A variety of protein-protein interaction assays can 
demonstrate intermolecular binding of an inhibitory domain to the targeted 
functional domain. As a future w ork, one assay to demonstrate auto-inhibitory 
role w ould be the FRET (Förster Resonance Energy Transfer) (Shrestha et al., 
2015; Tyagi and Lemke, 2015). Well-def ined structural domains of a protein 
retain their folded state as a protein fragment and can function in isolation from 
other regions. A simpler idea is that a full structure of w ild type RASSF7 w ould 
show  if  it is folded like the proposed model. Thus, biochemical and structural 
approaches should be applied to test an auto-inhibitory function, along w ith an 
investigation of regulatory pathw ays that causes auto-inhibition. Another future 
direction for the rescue experiment w ould be to tag the B domain w ith another 
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tag (for example w ith an HA tag) to determine how  its position and if  there is 
any interaction w ith other domains. In summary, to conf irm an autoinhibitory 
role for the B domain further experiments are required including Western 
Blotting. Western blotting w ould be a f irst step and w ould show  if  expression of 
the tw o protein fragments is altering their stability. The loss of phenotype could 
also be caused by a reduction in truncated rassf7 protein levels. Although 
Western Blotting w as tried, it w as not successful af ter several tries and due to 
time limit and requirement of many injections Western Blotting could not be 
processed any further. 
 
4.3.3 The C-terminal truncation and cancer 
The data presented in this chapter suggested that C-terminally truncated rassf7, 
GFP-rassf7 (RA+A+CC), could act as an oncogene. Interestingly, a mutation 
w as found in RASSF7 from a renal clear cell carcinoma that w ould produce a 
similar truncation to GFP-rassf7 (RA+A+CC). My data suggests that the protein 
produced follow ing this mutation could drive centrosome defects, w hich w ould 
be consistent w ith RASSF7 acting as an oncogene in this tumour. This 
oncogenic role w ould require the cancer cells to also have defects in apoptosis 
as the truncated protein also promoted cell death that could counter a role in 
promoting tumour formation. Another possibility is that other changes in tumour 
cells could promote more w ild type RASSF7 to centrosomes, w hich then causes 
centrosome defects and promote tumour formation. 
I have currently found one tumour w ith this type of mutation, f rom a database 
containing sequences from 80 studies and over 20,000 patient samples, 
suggesting that it may only be a small subset if  tumours w here RASSF7 
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functions in this w ay. How ever, as sequences from more and more tumours 
become available it w ill be interesting to see w hether additional tumours w ith C-
terminal RASSF7 truncations are discovered.  
4.3.4 Conclusion 
This chapter show ed that the C-terminal truncation of rassf7 in Xenopus causes 
an amplif ication of the number of centrosome (γ-tubulin spot) and increased 
number of mitotic cells. These cells lost the centrosomal localisation and w ent 
through apoptosis later in development. Lastly, a database of tumour 
sequences identif ied a mutation in RASSF7, w hich w ould cause a similar C-
terminal truncation of the protein suggesting that truncated RASSF7 could act 
















5 Evidence for junctional rassf7 localisation 
5.1 Introduction 
Determining the subcellular localisation of a protein is a key step tow ards 
understanding the cellular function of that protein. How ever, the same protein 
can have dif ferent subcellular localisations w ithin the cell and therefore could be 
involved in various dif ferent processes. Also, proteins may have dif ferent 
subcellular localisations w ithin dif ferent species if  their function is not 
evolutionary conserved. This chapter w ill focus on the possibility of  rassf7 
localisation in dif ferent cellular compartments, especially at the cellular junctions 
of epithelial cells. 
5.1.1 Introduction to junctional complexes 
The junctional complexes in epithelial and endothelial cells helps to create a 
tissue homeostasis (sometimes referred as ‘barrier function’) that is very 
important for the formation of tissue and organs (Farquhar and Palade, 1963). 
Epithelial cells organise into tissues that compartmentalise and line our bodies, 
providing the primary barrier against chemical, physical and pathogenic insults 
(Wang et al., 2012). How ever, rather than being strictly impermeable barriers, 
these tissues are specialised structures that must also be capable of f inely 
regulating vectorial transport of  nutrients, w aste and ions (Martin-Belmonte and 
Perez-Moreno, 2012). As epithelial cells constitute a large percentage of the 
cells in the human body, and as they are constantly exposed to damaging 
stimuli, epithelial tumours, or carcinomas, constitute approximately 90% of all 
human cancers.  
A common feature of carcinoma is the loss of epithelial architecture and 
associated functions (Martin-Belmonte and Perez-Moreno, 2012). Epithelial 
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tissues have an apical plasma membrane, w hich faces the central lumen, and a 
basal plasma membrane, w hich interacts with the underlying extracellular matrix  
(ECM) (Figure 5.1). As they face very dif ferent environments, the apical and 
baso-lateral plasma membranes require specif ic properties and this is achieved 
through asymmetric lipid and protein compositions (Martin-Belmonte and Perez-
Moreno, 2012). Individual epithelial cells are joined together by various junction 
proteins. The apical junction complex def ines the boundary betw een the apical 
and basal plasma membrane domains and consists of tight junctions, also 
know n as the zonula occludens, and adherens junctions, or the zonula 




Figure 5.1: A simplified 2D schematic of an epithelium. Epithelia have a polarised 
structure with specialised apical and basal plasma membranes, which are composed of 
distinct lipids and proteins. The apical surface faces the central lumen and the basal 
side interacts with the underlying extracellular matrix (ECM). They are separated by the 





The tight junctions restrict the movement of f luids and solutes as small as ions 
(Aijaz et al., 2006; Farquhar and Palade, 1963). Tight junctions are composed 
of over forty proteins including the transmembrane proteins occludin and 
claudins along w ith peripheral membrane-associated proteins zonula occludens 
(ZO)-1, 2 and 3 w hich link the transmembrane tight junction proteins to the 
cytoskeleton (Aijaz et al., 2006; Matter and Balda, 2003). The contribution of 
tight junction proteins to barrier function is w ell established and modulation of 
expression of tight junction molecules resulted in key changes in tight junction 
barrier function leading to the successful metastasis of a number of dif ferent 
cancer types (Martin and Jiang, 2009), w hereas their contribution to cell cycle is 
only beginning to be understood. How ever there is an increasing amount of 
studies show ing the involvement of junctional proteins in cell cycle regulation 
(Chow  et al., 2004; Huang et al., 2007; Kaplan et al., 2004; Phillips et al., 2008; 
Runkle et al., 2011).  
 
5.1.2 Different cellular localisation of RASSF protein 
As discussed in previous chapters (chapter 1 and 3), RASSF family members 
can act as shuttling proteins (such as RASSF2 and RASSF5), translocate 
betw een many dif ferent cellular compartments and have dif ferent biological 
roles. RASSF family mostly have tumour suppressor properties and they are 
involved in regulation of  cell cycle and microtubules (Clark et al., 2012; 
Donninger et al., 2007; Richter et al., 2009; Volodko et al., 2014).  
Among the N-terminal RASSF members, RASSF8 is show n to co-localise w ith 
adherens junctions both in Drosophila and Human (Langton et al., 2009; Lock 
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et al., 2010). Intriguingly, Drosophila has one homologue, dmRASSF7/RASSF8, 
w hich is very closely related to vertebrate RASSF7 and RASSF8 (Sherw ood et 
al., 2010). Therefore, it is possible to speculate that RASSF7 might have a 
junctional localisation, but this has not seen previously in our laboratory.  
 
5.1.3 Aims 
Although it is now  w ell established that RASSF7 localises to the centrosomes 
and required for completing mitosis (Recino et al., 2010; Sherw ood et al., 2008), 
it may also have junctional localisation. This chapter w ill focus on: 
1. Establish if  rassf7 localises at the junctions in Xenopus embryos. 
2. If  it localises, investigate the responsible domain for the junctional rassf7 
localisation. 





























5.2.1 Investigating junctional rassf7 localisation 
While studying the localisation of rassf7 in Xenopus embryos, a striking GFP-
rassf7 localisation at the junctions in the outer layer of the embryo w as 
observed, w hich raised the possibility that rassf7 may localise to the junctions. 
In order to investigate this possibility, stage 10 embryos w ere examined for co-
localisation w ith junctional marker, ZO-1. 
5.2.1.1 Investigating junctional rassf7 localisation in stage 10 embryos 
To establish w hether rassf7 localises to the junctions, embryos w ere injected 
w ith GFP and GFP-rassf7. The vitelline membranes of embryos at stage 10 
w ere removed (see Materials and Methods, vitelline membrane tends to give 
non-specific background staining). After sectioning, sections w ere stained w ith 
the tight junction marker, ZO-1 to establish any co-localisation w ith GFP-rassf7 
(Figure 5.2). In Xenopus the outer cells are polarised epithelial cells, therefore I 
looked in the outer cells, w hich w ere positive for ZO-1.  
It w as dif f icult to interpret the data from early stage embryos. Although it looked 
like GFP-rassf7 may show  some co-localisation w ith ZO-1 in some embryos 
(Figure 5.2A), the dif ference betw een negative control (GFP) expressing cells 
(Figure 5.2B) at the junctions w as not alw ays clear. How ever, clear centrosome 
staining in outer and inner cells w as seen as previously. 
Quantif ication of the data w as also dif f icult as the ZO-1 staining w as clear only 
in a few  junctions. Therefore, w ith no clear evidence of junctional rassf7 




Figure 5.2: Junctional localisation of  rassf7 at stage 10 embryos. Embryos were 
microinjected with RNA at the two-cell stage, cultured until stage 10, fixed, sectioned 
and stained with a tight junction marker (ZO-1/red) and a nuclear marker (DAPI/blue). 
GFP fluorescence is shown in green. (A) GFP (green) expressing cells did not seem to 
strongly co-localise with ZO-1 (red) (B) GFP-rassf7 (green) expressing cells may have 
a slightly stronger co-localisation with ZO-1 (red) compared to GFP expressing cells 











5.2.1.2 Evidence for junctional rassf7 localisation at stage 30 embryos 
Having seen no obvious co-localisation w ith ZO-1 at stage 10, embryos w ere 
grow n until stage 30, w hen they have a clearer outer layer for junctional 
staining. GFP and GFP-rassf7 expressing cells at stage 30 w ere stained w ith 
ZO-1 (Figure 5.3).  
GFP-rassf7 expressing cells at stage 30 show ed clear co-localisation w ith ZO-1 
staining (Figure 5.3A). A GFP control, w hich show ed some enrichment at the 
junctions but w as much less than the full length GFP-rassf7, w as used as a 
negative control (Figure 5.3B). This data provides the f irst evidence for rassf7 
localisation at the tight junctions. In outer cells, GFP-rassf7 localised to 
junctions, w hereas in inner cells, w hich do not have tight junctions, GFP-rassf7 













Figure 5.3: Junctional localisation of rassf7 at stage 30 embryos. Embryos were 
microinjected with RNA at the two-cell stage, cultured until tadpole stages (stage 30), 
fixed, sectioned and stained with a tight junction marker (ZO-1/red) and a nuclear 
marker (DAPI/blue). GFP fluorescence is shown in green. (A) GFP (green) expressing 
cells showed less co-localisation with ZO-1 (red), when compared to wild type GFP-
rassf7. (B) GFP-rassf7 (green) expressing cells showed clear co-localisation with ZO-1 












5.2.2 Analysis of the domains required for tight junctional rassf7 
localisation 
To identify the domains responsible for junctional rassf7 localisation, the GFP-
domain constructs described previously w ere used to make the RNA injected to 
embryos and grow n until stage 30 to study rassf7 localisation at the junctions. 
 
5.2.2.1 The RA and A domains are not required or sufficient for tight 
junctional rassf7 localisation, but the coiled coil domain is sufficient and 
required 
The GFP fusion protein that lacked the RA domain, GFP-rassf7 (A+CC+B), 
show ed a very similar pattern of junctional localisation to full length GFP-rassf7 
w ith clear co-localisation w ith ZO-1 (Figure 5.4A), w hereas the GFP domain 
construct, w hich only had the RA domain, GFP-rassf7 (RA) did not co-localise 
w ith the junctions (Figure 5.4B). This suggests that the RA domain is not 
required or suff icient for junctional rassf7 localisation.   
When both the RA and the A domains w ere removed, GFP-rassf7 (CC+B), a 
similar junctional localisation pattern w as observed and GFP-rassf7 (CC+B) 
w as able to co-localise w ith ZO-1 (Figure 5.4C). Thus, removing the A domain 
as w ell as the RA did not seem to affect rassf7 localisation at the junctions. 
Further analysis of rassf7 domains w as consistent w ith the idea that the RA and 
the A domains w ere not required or suff icient for junctional rassf7 localisation: 
neither GFP-rassf7 (RA+A) nor GFP-rassf7 (A) showed co-localisation w ith ZO-
1 (Figure 5.5A and C). How ever, GFP-rassf7 (CC) co-localised w ith ZO-1 
(Figure 5.5B) indicating that the coiled coil domain is suff icient and required for  





Figure 5.4: The RA and the A domains are not required for tight junctional rassf7 
localisation. Embryos were microinjected with RNA at the two-cell stage, cultured until 
tadpole stages (stage 30), fixed, sectioned and stained with a tight junction marker 
(ZO-1/red) and a nuclear marker (DAPI/blue). GFP fluorescence is shown in green. (A) 
GFP-rassf7 (A+CC+B) (green) expressing cells co-localised with ZO-1 (red) (B) GFP-
rassf7 (RA) (green) expressing cells did not co-localise with ZO-1 (red). (C) GFP-rassf7 
(CC+B) (green) expressing cells showed co-localisation with ZO-1 (red). Arrows 





















Figure 5.5: The coiled coil domain is sufficient for tight junctional rassf7 
localisation. Embryos were microinjected with RNA at the two-cell stage, cultured until 
tadpole stages (stage 30), fixed, sectioned and stained with a tight junction marker 
(ZO-1/red) and a nuclear marker (DAPI/blue). GFP fluorescence is shown in green. (A) 
GFP-rassf7 (RA+A) (green) cells showed less co-localisation with ZO-1 (red), when 
compared to wild type rassf7. (B) GFP-rassf7 (CC) (green) showed co-localisation with 
ZO-1 (red). (C) GFP-rassf7 (A) (green) did not co-localise with ZO-1 (red). Arrows 









5.2.2.2 The B domain may contribute to the tight junctional rassf7 
localisation, as well as the coiled coil domain 
The last set of  truncations show ed that the B domain may be involved in the 
junctional rassf7 localisation. The GFP fusion protein, GFP-rassf7 (B), w hich 
only has the B domain, also show ed co-localisation w ith ZO-1 (Figure 5.6A). 
Removing the B domain, GFP-RASSF7 (RA+A+CC) did not cause any obvious 
amplif ication of the junctions and there w as no specif ic localisation of rassf7. 
Mostly cytoplasmic distribution of GFP-rassf7 (RA+A+CC) bulks w as observed 
at stage 30 embryos (Figure 5.6B) and because of the non-specif ic distribution, 
it w as dif f icult to study co-localisation at the junctions. Therefore, quantif ication 
w as limited to the measurement of the f luorescence intensity at the ZO-1 spot. 
The size and therefore the integrated density of GFP at the ZO-1 spot or of  the 
ZO-1 spot could not be measured due to the limitations. 
The effect of  GFP-rassf7 (A+CC) w as very similar to GFP-rassf7 (RA+A+CC) 
(Figure 5.6C).  
The quantif ication of the localisation of GFP-rassf7 domain constructs w as 
consistent w ith the confocal images (Figure 5.7). 
Domain analysis suggests that the RA and the A domains are not required for 
junctional rassf7 localisation w hereas the coiled coil and the B domains are 
sufficient to drive the junctional rassf7 localisation. Additionally, removal of  the B 
domain did not cause any obvious junctional amplif ication as seen w ith the 









Figure 5.6: The B domain is also sufficient to drive junctional rassf7 localisation. 
Embryos were microinjected with RNA at the two-cell stage, cultured until tadpole 
stages (stage 30), fixed, sectioned and stained with a tight junction marker (ZO-1/red) 
and a nuclear marker (DAPI/blue). GFP fluorescence is shown in green. (A) GFP-
rassf7 (B) (green) showed co-localisation with ZO-1 (red). (B) GFP-rassf7 (RA+A+CC) 
(green) did not co-localise with ZO-1 (red). (C) GFP-rassf7 (A+CC) (red) did not co-






Figure 5.7: Quantification of the localisation of GFP-rassf7 domain constructs at 
stage 30. Embryos were microinjected with RNA at the two-cell stage, cultured until 
stage 30, fixed, sectioned and images of the GFP fluorescence and ZO-1 staining were 
collected by confocal microscopy. Example images are shown in the previous figures . 
The fluorescent intensity of the ZO-1 staining and GFP was measured by using the 
LSM510 Image Browser software (ZEISS). (A) Intensity of GFP fluorescence at the 
junctions for the GFP-rassf7 fusion proteins and the positive and negative controls 
(GFP-rassf7 and GFP). (B) Intensity of ZO-1 spot. Expression of truncated GFP-rassf7 
proteins did not affect the intensity of the ZO-1 staining. Based on at least three 
independent experiments, bars represent standard error and were calculated and 
plotted using GraphPad Prism 6. Statistical analysis was carried out using One-way 
Anova tests with Bonferroni post-test corrections. >50 cells were measured in total. 
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5.2.3 Sub-cloning of human RASSF7 to establish junctional RASSF7 
localisation in mammalian cell lines 
In order to establish if  RASSF7 is junctional and to study the effects of RASSF7 
domains on its localisation in mammalian cell lines, the human RASSF7 w as 
sub-cloned into a viral vector (pAd5cmv-GFP-RASSF7) for adenoviral 
transduction of the mammalian cell lines (see materials and methods) as 
viruses are easy to drive expression by infecting epithelial cells such as MDCKII 
w hich, are hard to transfect. This w ould help to establish if  RASSF7 localises to 
junctions as w ell as the centrosomes in human epithelial cell lines. It w ould also 
make it possible to see if  the C-terminal truncation of RASSF7 causes the same 
effect (enlargement of centrosomes, increased centrosome numbers, increased 
mitotic cells and cell death) on mammalian cells as w ell as the Xenopus. 
Firstly the full-length GFP-RASSF7 and the C-terminally truncated GFP-
RASSF7 (RA+A+CC) w ere sub-cloned into the viral vector. The sub-cloning 
process w as successful, the transfection of HEK293 cells show ed GFP 
expression when transfected w ith pAd5cmv-GFP-RASSF7 and pAd5cmv-GFP-
RASSF7 (RA+A+CC) (Figure 5.8). How ever upon several repeats w ith dif ferent 
DNA concentrations of RASSF7, the production of virus was not successful, the 
plaque formation that is necessary for virus production did not occur. Chris 
Bryant’s (University of Bath, PhD student) plasmid (pAd5cmv+EGFPBRAF) that 
has been successfully sub-cloned into same viral vector and produced virus 
previously, w as transfected to the cells and this plasmid produced the plaque 
and the virus, w hereas cells transfected w ith pAd5cmv-GFP-RASSF7 and 
















Figure 5.8: HEK293 cells expressing sub-cloned plasmids. HEK293 cells were 
maintained between passages 30 and 40 at 37° in DMEM supplemented with FBS. 
Cells were passaged twice weekly at a dilution of 1/12. (A) pAd5cmv+GFP-RASSF7 

















5.2.4 Endogenous RASSF7 staining of MDCKII cells to establish junctional 
RASSF7 localisation  
Having failed to produce adenovirus for viral transfection of human cell lines, 
experiments focused on staining MDCKII cells for endogenous RASSF7 to 
establish if  it localises to tight junctions in mammalian epithelial cells.  
MDCKII cells w ere initially stained w ith RASSF7, ZO-1 and γ-tubulin antibodies 
individually to establish the best f ixation protocol for the cells and the 
antibodies. Cells w ere f ixed in MeOH (Figure 5.9A) and PFA (Figure 5.9B), 
MeoH gave the better antibody staining, especially for the γ -tubulin antibody. To 
establish if  RASSF7 show s co-localisation w ith γ-tubulin and ZO-1 cells w ere 
f ixed in MeOH; double stained w ith RASSF7 and γ -tubulin (Figure 5.10A) and 
w ith RASSF7 and ZO-1 antibodies (Figure 5.10B).  
As it is w ell know n from Xenopus (Sherw ood et al., 2008) and Human (HeLa 
cells) (Recino et al., 2010) studies that RASSF7 localises to centrosome, co-
localisation w ith γ-tubulin in MDCKII cells w as expected. How ever, RASSF7 did 
not show  co-localisation w ith γ-tubulin (Figure 5.10A). The double staining w ith 
ZO-1 and RASSF7 also did not indicate any co-localisations (Figure 5.10B).  
Endogenous RASSF7 staining show ed that RASSF7 is not junctional or 
centrosomal in MDCKII cells. There w as not any co-localisation betw een 
RASSF7 and γ-tubulin (Figure 5.10A) and betw een RASSF7 and ZO-1 (Figure 
5.10B). This suggests the antibody that stained HeLa cells did not w ork in 
MDCKII cells, perhaps due to species dif ference. Therefore it remains to be 
established if  RASSF7 localises to junctions in mammalian cells.  
To further investigate the rassf7 localisation pattern, the plasmids that w ere 
generated for the virus production (pAd5cmv+GFP-RASSF7 and 
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pAd5cmv+GFP-RASSF7 (RA+A+CC)) w ere used to transfect the MDCKII cells 
to look for the exogenous (GFP-RASSF7) localisation. How ever, the 
transfection of the MDCKII cells w as not successful upon several trials w ith 















Figure 5.9: MDCKII cells with RASSF7, γ-tubulin and ZO-1 antibody stainings. 
MDCKII cells were plated at a density of 2x105cells/ml on 8-well µ-slides. Cells were 
fixed and permeabilised in ice-cold methanol at -20°C or in PFA at room temperature 
and rinsed in PBS. Non-specific binding sites were blocked in normal goat serum and 
cells incubated with primary and then secondary. Nuclei were counterstained with 
DAPI and slides were imaged using a Zeiss LSM510META laser-scanning confocal 
microscope. Confocal images are presented as overhead composite projections of 
multiple 1µM Z-slices through the MDCKII monolayer. All images were processed 
using ImageJ software. Images from different experimental conditions were processed 
in an identical fashion. Presented images are representative of three independent 
experiments (A) MDCKII cells fixed in MeOH and stained with RASSF7, γ-tubulin and 
ZO-1 antibodies individually. (B) MDCKII cells fixed in PFA and stained with RASSF7, 
γ-tubulin and ZO-1 antibodies individually. Lower panels show the merge images with 











Figure 5.10: MDCKII cells with double staining. MDCKII cells were plated at a 
density of 2x105cells/ml on 8-well µ-slides. Cells were fixed and permeabilised in ice-
cold methanol at -20°C rinsed in PBS. Non-specific binding sites were blocked in 
normal goat serum and cells incubated with primary and then secondary. Nuclei were 
counterstained with DAPI and slides were imaged using a Zeiss LSM510META laser-
scanning confocal microscope. Confocal images are presented as overhead composite 
projections of multiple 1µM Z-slices through the MDCKII monolayer. All images were 
processed using ImageJ software. Images from different experimental conditions were 
processed in an identical fashion. Presented images are representative of three 
independent experiments. (A) MDCKII cells double stained with RASSF and γ-tubulin 
antibodies (B) MDCKII cells double stained with RASSF7 and ZO-1 antibodies. A 
nuclear marker (DAPI) is used for the nuclear staining (blue). No co-localisation 








In the present chapter, the junctional localisation of RASSF7 has been 
investigated in both Xenopus laevis and mammalian cell lines. This data 
indicates the f irst evidence for RASSF7 at the junctions and show s that in 
Xenopus the coiled coil and the B domains are suff icient to drive the junctional 
localisation on their ow n w hereas the RA and A domain do not seem to affect 
the junctional rassf7 localisation. Localisation in mammalian cells needs further 
investigation.  
 
5.3.1 GFP-rassf7 shows co-localisation with ZO-1 at stage 30 embryos 
Data presented in this chapter show ed that GFP-rassf7 co-localises w ith ZO-1 
in outer cells of stage 30 Xenopus embryos, w hich provides the f irst evidence 
for junctional rassf7 localisation. The striking junctional GFP-rassf7 localisation 
w as initially observed in GFP-rassf7 expressing stage 30 embryos w hile 
studying the effect of  GFP-rassf7 (RA+A+CC) at later stage. This localisation 
w as tested w ith negative control (GFP) to see if  the GFP w as going to junctions 
instead of rassf7 but as discussed in the results and show n by the confocal 
images as w ell as the intensity measurements, this junctional localisation w as 
specif ic to rassf7.  
Previous studies show ed the involvement of junctional proteins in cell cycle 
regulation and their link w ith centrosomes and microtubules (Huang et al., 2007; 
Kaplan et al., 2004; Phillips et al., 2008; Runkle et al., 2011). For instance, a 
recent study show ed that the junctional protein, occludin localises to the 
centrosomes and modif ies mitotic entry (Runkle et al., 2011). Although this is 
the f irst and only study show ing the centrosomal localisation of occludin; 
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another study show s that occludin regulates the cell division in retinal pigment 
epithelial cells (Phillips et al., 2008).  Beta-catenin is an adherens junction 
protein that also localises to the centrosome (Huang et al., 2007) and regulates 
centrosomal separation in a Nek-2 dependent manner (Bahmanyar et al., 
2008). Therefore, it is possible that centrosomal proteins may also have a role 
at the epithelial junctions.  
Recent proteomic studies have show n that RASSF7 can interact w ith a number 
of cellular proteins, including ASPP and PP1 family members (Hauri et al., 
2013). The Drosophila homologue of RASSF7 and RASSF8, also localises to 
the epithelial junctions and can also bind to dASPP (Langton et al., 2009). My 
data suggests that rassf7 localises to the tight junctions in Xenopus and the 
future w ork w ould need to establish the role of rassf7 at the junctions and if  it 
involves ASPP and PP1. 
 
5.3.2 The coiled coil and the B domains are sufficient on their own to drive 
junctional rassf7 localisation 
The coiled coil (GFP-rassf7 CC)) and the B domains (GFP-rassf7 (B)) drove the 
junctional rassf7 localisation w hen expressed individually. A coiled coil is a 
protein-protein interaction domain and it may be regulating RASSF7’s junctional 
localisation by interacting w ith the junctional complex. For example, the tight 
junction protein, occludin, discussed above, contains a coiled coil domain, 
w hichcan act to organize the functional elements of the epithelial tight junction 
(Walter et al., 2009). Occludin and the adherens junctions protein, α-catenin, 
also interacts w ith another junctional protein ZO-1 via their coiled coil domains 
(Muller et al., 2005). Cingulin is another example of a junctional protein w ith a 
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coiled coil domain that interacts to ZO-1 via this domain (Cordenonsi et al., 
1999). Thus, it is not surprising that the coiled coil of  rassf7 drives the junctional 
localisation and as seen in chapter3 it also drives the centrosomal localisation 
of rassf7.  
Intriguingly, the B domain w as also able to drive the junctional rassf7 
localisation on its ow n (GFP-rassf7 (B)). From the domain prediction 
programmes, the B domain did not come up as any know n domains; it w as an 
unknow n protein region. Therefore, it is not possible to give/f ind example 
proteins that localises to junctions via this domain. How ever, phosphorylation 
prediction programmes revealed potential phosphorylation sites w ithin the B 
domain (chapter 3). It may be possible that the phosphorylation of the B domain 
may mediate its localisation at the junctions, as it is w ell-know n phosphorylation 
can mediate/control intracellular localisation of proteins (Diaz-Moreno et al., 
2009; Esmenjaud-Mailhat et al., 2007). It w ould be interesting to see if  mutating 
the phosphorylation site w ithin the B domain w ould affect the junctional rassf7 
localisation. Future w ork w ill need a blast search of the B domain, to see if  any 
other proteins have similar domains. 
Altering the other tw o domains of rassf7 did not af fect the junctional localisation; 
upon removal of  the RA, the A and the both domains, junctional localisation still 
observed. As discussed in the chapter 3, future w ork w ill need to establish any 
possible interaction mechanisms (such as binding partners, see f inal 






5.3.3 Sub-cloning of human RASSF7 to establish junctional RASSF7 
localisation in human cell lines 
Junctional localisation is observed in in later s tage Xenopus embryos. The next 
section aimed to analyse the junctional localisation of rassf7 in human cell lines. 
How ever, although the sub-cloning process w as successful, the virus 
production failed. This may be due to the RASSF7 plasmid used for sub-cloning 
w as blocking the virus formation. Virus production has been tested w ith a 
positive control; under the same experimental conditions and it w as successful. 
Future w ork w ill need to try an alternative system to express RASSF7 in human 
cell lines.  
5.3.4 Endogenous RASSF7 staining in MDCKII cells 
Staining MDCKII cells by using a RASSF7 antibody did not show  any co-
localisation w ith γ-tubulin and ZO-1 antibodies. It may be possible that RASSF7 
has a dif ferent localisation pattern in MDCKII cells although this w as 
unexpected especially as it has been show n in dif ferent species that RASSF7 
localises to the centrosomes (Recino et al., 2010; Sherw ood et al., 2008). Thus, 
it raised the possibility that the antibody might have not w orked in this cell line, 
as RASSF7 antibody w as a human antibody and MDCKII cells are canine in 
origin. Future w ork w ould be staining the other epithelial human cell lines (such 
as Caco2) w ith the RASSF7 antibody to establish junctional localisation or to 
raise an antibody against canine RASSF7.  
The next experiments aimed to transfect the MDCKII cells w ith the plasmids 
that are generated for the virus production, pAd5cmv+GFP-RASSF7 and 
pAd5cmv+GFP-RASSF7 (RA+A+CC), how ever transfections w ere not 
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successful. Future w ork w ill need to repeat the transfections using the HeLa 
cells, although they don’t have tight junctions and this w ouldn’t establish the 
junctional rassf7 localisation, it w ould be interesting to see if  the centrosome 
defects w ould occur in the GFP-RASSF7 (RA+A+CC) expressing HeLa cells. 
Due to time limitations, RASSF7 localisation studies in human cells and further 




In the current chapter, Xenopus rassf7 is show n to co-localise w ith the tight 
junctional marker ZO-1. These data reveal the f irst evidence for junctional 
rassf7 localisationin Xenopus Domain analysis studies show ed that the coiled 
coil and the B domains w ere suff icient to drive the junctional rassf7 localisation 
on their ow n, w hereas the RA and the A domains did not af fect the localisation 
pattern of rassf7 at the junctions. Establishment of junctional rassf7 localisation 
in human cell lines could not be completed due to failure in virus production and 











6 Final Discussion 
RASSF7 is a key regulator of mitosis and possible oncogene, but the molecular 
basis of its function remains to be elucidated. The current project aimed to 
understand the molecular basis of RASSF7 function w ith emphasis on the 
RASSF7 domains driving its localisation.  
6.1 Main Conclusions 
The key f indings from this thesis demonstrated that:  
 The coiled coil domain is suff icient and required for centrosomal rassf7 
localisation.  
 The RA domain of rassf7 does not appear to play a key role in mediating 
its centrosomal localisation.  
 Removing the B domain of rassf7 caused it to accumulate at the γ -tubulin 
spot and cause accumulation of abnormally high levels of γ -tubulin.  
 Expression of C-terminally truncated rassf7 also increased the number of 
γ-tubulin spot per cell, elevated the number of cells in mitosis and 
ultimately resulted in cell and embryo death.  
 Analysis of sequences from human tumours identif ied a similar truncated 
version of RASSF7 from a clear renal cell carcinoma, suggesting that 
RASSF7 may promote centrosome defects and act as an oncogene in a 
small subset of tumours w ith such mutations. 
 Localisation studies provided the f irst evidence for RASSF7 at the 
junctions and show s that in Xenopus the coiled coil and the B domains 
are suff icient to drive junctional localisation on their ow n. 
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6.2 Understanding the coiled coil driven localisation 
Although it has been show n in the chapter 3 and 5 that rassf7 localises to the 
centrosomes and tight junctions via its coiled coil domain, due to the lack of 
structural studies and interaction partners, the mechanism behind the coiled coil 
driven rassf7 localisation remains elusive.  
Previous proteomic characterisation of centrosomes found that a high 
percentage of centrosomal proteins contain a coiled coil (Andersen et al., 2003) 
and many centrosome proteins w ith coiled coils have been studied, how ever it 
is not clear for many  centrosomal proteins if  they localise to the centrosome via 
their coiled coil domains and if  so how  is this localisation driven by the coiled 
coil.  Recently, structural studies of SAS-6 shed light on how  coiled coils can 
drive localisation of centrosomal proteins, and provided a major advance in our 
molecular understanding of centriole assembly (Cottee et al., 2011; Kitagaw a et 
al., 2011; van Breugel et al., 2011). SAS-6 is a centrosomal coiled coil protein 
and required for centriole duplication (Avidor-Reiss and Gopalakrishnan, 2013; 
Hirono, 2014; Leidel et al., 2005; Strnad et al., 2007) and the dimerization of 
SAS-6 coiled coil domain is required for its interaction w ith other centriole 
proteins (SAS-5), thus regulating centriole assembly (Qiao et al., 2012). These 
studies demonstrated that dimerization/oligomerization of coiled coil domains is 
necessary for other regulatory domains to interact w ith centriole proteins. In 
terms of RASSF7, the results represented in this thesis, propose a direct role 
for rassf7’s coiled coil to interact w ith centrosome proteins as the GFP domain 
construct that had only the coiled coil domain of rassf7, GFP-rassf7 (CC), 
show ed  clear co-localisation w ith γ-tubulin (see chapter 3). How ever, the 
structure of RASSF7 and the binding partners has not been solved/identif ied. 
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Therefore, the exact mechanism of the rassf7 coiled coil domain driven 
localisation remains to be established. Future w ork w ould need to study the 
rassf7 structure and interaction/binding partners.  
 
6.3 Identifying RASSF7 interaction partners are crucial to 
understand RASSF7 function 
The identif ication of RASSF7 binding partners is required to fully explain the 
molecular mechanisms of RASSF7 function. RASSF7 could interact w ith other 
centrosomal proteins by direct or indirect binding to localise to centrosomes, 
and also to function in mitosis. RASSF7 interaction partners at the tight 
junctions w ould also explain the new  junctional localisation pattern that w as 
show n in chapter 5.  
Potential binding partners for human RASSF7 have been identif ied via a 
number of large-scale yeast tw o-hybrid studies. Proteins w ith a possible 
interaction w ith RASSF7 include CHMP1B (charged multivesicular body protein 
1B), w hich is associated w ith endosomal membrane trafficking and forms part of  
CHMP protein-interaction netw ork, homologous to the yeast ESCRT III. This 
complex is a group of proteins involved in the formation of multivescular bodies 
and degradation of internalized transmembrane receptor proteins (Tsang et al., 
2006). Secondly, RASSF7 interacts w ith a centrosome associated protein 
DISC1 (disrupted in schizophrenia 1), associated w ith schizophrenia (Morris et 
al., 2003). DISC1 interacts w ith cytoskeletal and centrosome proteins and co-
localises w ith the centrosomal complex (Morris et al., 2003). DISC1 interaction 
is a good example to explain the centrosomal localisation of RASSF7 as DISC1 
is show n to be required for recruiting other centrosomal proteins to the 
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centrosome (Fukuda et al., 2010; Kamiya et al., 2008) and is also show n to 
interact w ith microtubules (Morris et al., 2003). Lastly an interaction partner from 
yeast tw o-hybrid studies w as TSC1 (tuberous sclerosis protein 1) gene product, 
hamartin, a peripheral membrane protein potentially involved in vesicular 
transport and docking (Yasui et al., 2007).  
In addition to yeast tw o hybrid studies, a recent proteomic study has show n that 
RASSF7 can interact w ith a number of other cellular proteins, including ASPP 
and PP1 family members (Hauri et al., 2013). The analysis of ASPP2 and 
ASPP1, and the PP1G catalytic subunit interactions resulted in an netw ork 
w hich includes RASSF7 and all three PP1 catalytic subunits (PP1A, B and G) 
and multiple regulatory subunits (Hauri et al., 2013). Both ASPP1 and ASPP2 
can interact w ith three PP1 catalytic subunits, the coiled coil proteins CC85B 
and CC85C and RASSF7, RASSF8 and RASSF9; interaction data ref ined the 
ASPP/RASSF/PP1 sub netw ork (Hauri et al., 2013). ASPP1 and ASSP2 do not 
interact w ith each other; therefore authors suggested a mutually exclusive 
ASPP/RASSF/PP1 complex (Hauri et al., 2013). ASPP localises to the junctions 
(Langton et al., 2009; Lock et al., 2010) and ASPP knock out mouse loses its 
junctions (Sullivan and Lu, 2007). dRASSF8, the Drosophila homologue of 
RASSF7 and RASSF8, can also bind dASPP and dRASSF8 protein localises at 
epithelial junctions (Langton et al., 2009). This ASPP/RASSF/PP1 complex can 
explain the f indings from Drosophila and also a junctional role for RASSF7 as 
suggested by this study.  
Another recent study show ed that ASPP1 and ASPP2 interact w ith C-Nap1 
(centrosome linker protein 1) and PP1 and regulates centrosome assembly 
(Zhang et al., 2015). RASSF7 might be involved in this interaction, how ever it is 
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crucial to verify these RASSF7 protein-protein interactions by 
immunoprecipitation, mass spectrometry and Western blotting techniques. 
Once this is done, it w ill be interesting to test if  the constitutively active/inactive 
forms of the binding partners, w hich are capable of attenuating or reversing the 
mitotic aberrations observed in RASSF7 def icient cells and/or to see if  these 
inactive forms are able to drive centrosomal localization, if  there is any 
centrosomal amplif ication w hen interaction is blocked. Another approach w ould 
be to overexpress or knockdow n of interaction partners to see if  these w ould 
change RASSF7 localisation.  Finally, it w ould also improve our understanding 
of rassf7 junctional localisation and w hat functions the protein has at the 
junctions. 
 
6.4 RASSF7 and cancer 
Although gene and protein studies have identif ied a correlation betw een 
abundant expression of RASSF7 and cancer progression (Friess et al., 2003; 
Logsdon et al., 2003; Low e et al., 2007; Mutter et al., 2001; Tan et al., 2009) , 
the lack of molecular and functional data has led to incomplete understanding of 
w hat role, if  any, RASSF7 could have in cancer progression.  
The results reported in this thesis, especially the existence of the C-terminal 
truncation of RASSF7 in a human cancer, as w ell as the previous w ork from 
Recino et al., (2010) and the w ork of Takashi and colleagues (2011) suggest an 
association of elevated RASSF7 levels w ith tumourigenesis. In addition, the 
new  localisation pattern of rassf7 that w as seen at tight junctions may suggest a 
new  role for the protein, w hich could be related w ith cancer as the tight junction 
has a vital role in maintaining cell to cell integrity and that the loss of cohesion 
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of the structure can lead to invasion and thus metastasis of cancer cells  (Martin 
and Jiang, 2009). Unlike other RASSF proteins w ith tumour suppressor 
properties, RASSF7 could exert an anti-apoptotic function and increased levels 
could be responsible for incorrect completion of mitosis if  w ork from this thesis 
and previous studies are combined. 
As a future w ork, the production of RASSF7 transgenic mice overexpressing 
RASSF7 could elucidate w hether RASSF7 w ild type or mutants have the ability 
to promote cancer. How ever, overexpressing RASSF7 on its ow n is not likely to 
be enough to promote tumour formation in a mouse model, established 
oncogenes may also need to be expressed.  
In summary, more investigation is needed on the molecular basis of RASSF7 
including its binding partners as w ell as the mouse knockout system to improve 
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Appendix 3: Table of the example quantif ications that w ere shown in appendix 1 
and 2. 
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1 6.67 71 473.57 6.17 82 505.94 0 5 0 7.12 119 847.28 
2 4.88 123 600.24 4.88 127 619.76 1.98 70 138.6 7.13 43 306.59 
3 4.28 122 522.16 4.28 125 535 0.63 30 18.9 8.1 115 931.5 
4 2.63 115 302.45 2.63 123 323.49 0 5 0 2.26 23 51.98 
5 3.16 109 344.44 3.21 112 359.52 0 7 0 1.98 21 41.58 
6 4.78 93 444.54 4.63 112 518.56 0 8 0 6.98 42 293.16 
7 3.28 92 301.76 3.33 113 376.29 1.16 32 37.12 6.49 53 343.97 
8 2.88 70 201.6 2.86 72 205.92 0 72 0 5.07 121 613.47 
9 3.56 85 302.6 3.57 109 389.13 1.02 54 55.08 1.82 52 94.64 
10 3.57 72 257.04 3.67 98 359.66 0 6 0 5.28 88 464.64 
11 4.64 132 612.48 4.57 128 584.96 0 23 0 3.01 34 102.34 
12 2.21 138 304.98 2.45 112 274.4 0 36 0 6.97 123 857.31 
13 1.16 43 49.88 0.97 35 33.95 0 35 0 5.47 125 683.75 
14 2.72 80 217.6 3.9 95 370.5 0 6 0 6.2 95 589 
15 4.23 116 490.68 4.16 112 465.92 0 17 0 5.06 112 566.72 
16 4.85 105 509.25 4.22 117 493.74 0 5 0 5.46 98 535.08 
17 5.75 119 684.25 5.36 123 659.28 0 15 0 4.88 111 541.68 
18 4.89 117 572.13 4.96 127 629.92 0 13 0 3.62 95 343.9 
19 5.06 121 612.26 5.43 132 716.76 0 17 0 4.35 117 508.95 
20 1.16 82 95.12 1.08 91 98.28 0.252 24 13.14 5.118 83.52 458.8179 
21 1.2 79 94.8 1.16 89 103.24       
22 1.67 71 118.57 3.67 138 506.46       
23 2.79 94 262.26 2.92 123 359.16       
24 5.84 125 730 6.01 136 817.36       
25 2.63 76 199.88 3.78 119 449.82       
26 1.82 95 172.9 4.74 123 583.02       
27 2.36 89 210.04 5.14 133 683.62       
28 2.41 102 245.82 3.07 119 365.33       
29 3.02 98 295.96 5.08 138 701.04       









Appendix 4: Ratio of GFP intensity at the Ƴ-tubulin foci vs GFP intensity in 
the nuclei. The ratio of intensity for GFP at the Ƴ-tubulin foci vs GFP intensity 
at the nuclei w as calculated for each construct. Constructs w hich show ed 
reduced centrosomal staining had reduced Ƴ-tubulin to nuclei ratio. Constructs 
w ith increased centrosomal localisation show ed increased Ƴ -tubulin to nuclei 
ratio. The change in ratio show s that the changes in localisation seen w ith the 
constructs cannot be explained by changes in protein expression levels of the 
constructs. Based on at least three independent experiments and n>100 cells. 
 
 
